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Adiponectin is well known as an insulin-sensitising hormone secreted exclusively from 
adipose tissue. Paradoxically, adiponectin is increased during calorie restriction (CR) 
when typical adipose depots are reduced in volume. Interestingly, bone marrow adipose 
tissue (BMAT) increases in volume during CR and has been shown to be a major source 
of circulating adiponectin in this context. CR itself exerts diverse metabolic and skeletal 
effects: one hypothesis is that increased BMAT contributes to bone loss during CR, 
whereas many of the metabolic benefits of CR are similar to those ascribed to 
adiponectin.  However, it remains unknown what causes BMAT to increase during CR; if 
BMAT contributes to circulating adiponectin in other conditions; and if BMAT and/or 
adiponectin influence skeletal or metabolic adaptations to CR. The goal of my PhD 
research was to address these critical gaps in knowledge. 
 
My first hypothesis was that BMAT is also a source of adiponectin following treatment 
with thiazolidinediones, a class of anti-diabetic drugs that increase both BMAT and 
adiponectin. To address this, mice resistant to BMAT expansion were treated with 
rosiglitazone, a well-studied thiazolidinedione, to investigate the ability of BMAT to 
secrete adiponectin in other conditions of BMAT expansion and hyperadiponectinaemia. 
These mice were less resistant to BMAT expansion in response to rosiglitazone 
compared to CR, which limited the ability to draw strong conclusions; however, there 
were some indications that BMAT is an important source of adiponectin in this context, 
and the data provide other insights about how BMAT compares to other adipose 
subtypes. 
 
To begin investigating the roles of BMAT and adiponectin during CR, wild-type (WT) 
male and female mice were placed on varying durations of CR or ad libitum control diet. 
The increases in BMAT were then assessed and compared to changes in skeletal 
architecture, adiponectin and glucose tolerance. I found that BMAT expansion depends 
not only on CR duration, but also varies by skeletal site and between the sexes. BMAT in 
tibiae and femurs increased with 6-week CR in both sexes, but only female femurs 
showed increased BMAT after 2-week CR. BMAT expansion generally coincided with 
bone loss in femurs but occurred after bone loss in tibiae; notably, bone loss occurred in 
humeri despite a lack of BMAT in these bones. Together, these findings show that BMAT 




In terms of metabolic and endocrine effects, adiponectin was maximally increased after 3 
to 4 weeks of CR, approximately coinciding with the increases in BMAT and adiponectin 
expression within bone. However, improvements in glucose tolerance occurred after 
only 1 week of CR, especially in male mice, preceding BMAT expansion and 
hyperadiponectinaemia. Strikingly, I found that females resist many of the metabolic 
benefits of CR: unlike males, during CR females did not lose fat mass and had only mild 
improvements in glucose tolerance. Collectively, it was not clear from these findings if 
BMAT expansion or adiponectin are playing a role in the metabolic benefits of CR. 
 
For this reason, adiponectin knockout mice (KO) and WT controls were subjected to CR 
to investigate if adiponectin contributes to CR-induced improvements in glucose 
homeostasis. Male KO mice performed better in glucose tolerance tests than WT mice, a 
finding going directly against my hypothesis. This indicates that adiponectin may be 
playing an unexpected role during CR, in which it impairs glucose tolerance. One 
possibility is that this relates to adiponectin’s role in stimulating fat oxidation; however, 
further work is required to elucidate the underlying mechanism. 
 
Together, these studies reveal several new discoveries. Firstly, CR-induced BMAT 
expansion is dependent on CR duration and is both sex- and skeletal-site-specific. 
Secondly, BMAT expansion is not required for CR-induced bone loss in humeri, but may 
contribute to bone loss in femurs and tibiae. Thirdly, female mice resist fat loss and 
improvements in glucose tolerance during CR, an unexpected finding that warrants 
further study. Fourthly, CR-induced improvements in glucose tolerance precede BMAT 
expansion and hyperadiponectinaemia, suggesting that the latter are not drivers of the 
former. Finally, lack of adiponectin is associated with improved glucose tolerance during 
CR, suggesting that the function of adiponectin during CR is distinct to its reported roles 
in obesity and insulin-resistant states. The latter indicate that adiponectin may impact 
the therapeutic benefits of CR and may provide insights toward the evolutionary 






Fat tissue was historically thought of as an inert store of energy. Research over the past 4 
decades has shown that fat tissue actually releases a wide variety of hormones in the 
blood and plays an important role in biological processes. One such hormone released 
from fat is called adiponectin. Adiponectin is secreted exclusively from fat tissue but 
shows a surprising relationship with fat. As body fat increases, the amount of 
adiponectin in the blood decreases. Conversely as fat decreases, adiponectin increases. 
One such time this occurs is during calorie restriction (CR), when daily calorie intake in 
reduced but malnutrition is avoided. It is known that during CR the majority of fat tissue 
decreases in mass in order to provide energy but the fat tissue in the bone marrow 
increases. Additionally, it is known that during CR the fat found in the bones acts as a 
major secretory source of adiponectin. Therefore, the first hypothesis in this thesis is 
further examining the role of bone marrow fat in secreting adiponectin during CR and 
other conditions of simultaneously increased adiponectin and bone marrow fat. We used 
mice resistant to increased bone marrow fat and treated them with a drug known to 
increase bone marrow fat and adiponectin. The mice did not sufficiently resist the 
increases in bone marrow fat and so it was difficult to draw robust conclusions in this 
regard but there was some evidence that BMAT is an important source of circulating 
adiponectin in contexts supplementary to CR. 
Adiponectin has been shown to improve the response to glucose by limiting the extent to 
which it increases blood sugar levels. CR has also been shown to exert this effect and so 
the second hypothesis tested by this thesis is that adiponectin is responsible for some of 
the metabolic effects of CR. To begin investigating this we exposed male and female mice 
to varying durations of CR and examined the durational increases in adiponectin and 
bone marrow fat. I found that the increases in bone marrow fat were highly dependent 
on the type of bone analysed and the sex of the mouse. Bone loss was not associated with 
increased bone marrow fat indicating that bone marrow fat increases were not required 
for bone loss caused by CR. Increases in adiponectin over the different durations of CR 
roughly coincided with the increases in bone marrow fat and the increase in bone 
production of adiponectin. However, improvements in response to glucose occurred 
very rapidly indicating that increased adiponectin nor bone marrow fat is required for 
this to happen. 
Finally, we produced mice that were unable to make adiponectin and gave them a CR 
diet. If adiponectin is providing some of the benefits of CR we hypothesised that these 
mice would not respond to CR as well as mice able to produce the hormone. We found 
the opposite, male mice without adiponectin had a better response to glucose indicating 
that adiponectin may be playing an unexpected role during CR. 
 
 
Overall this thesis shows that increased bone marrow fat increases in response to CR are 
dependent on duration of CR; sex; and the location examined in the skeleton. Secondly, 
many differences exist between males and females in their response to CR.  Thirdly, the 
role of adiponectin during CR may be more complex than presented in previous research 
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1.1.1. The Discovery of the adipocyte-derived hormone adiponectin 
Adiponectin is an adipocyte-derived hormone that has been reported to exert beneficial 
effects on cardiometabolic function, as well as various other health benefits. It was first 
discovered in 1995 and was initially called adipocyte complement-related protein of 
30kDa (Acrp30) given its structural similarity to complement factor C1q1. It was 
identified via an enrichment of adipocyte-specific genes in a subtractive cDNA library1. 
Northern blot analysis showed that this protein was exclusively expressed in adipocytes 
and expression was increased 100-fold upon adipocyte differentiation1. Further 
experimentation showed that adiponectin was detectable in the extracellular media of 
cultured adipocytes and in mouse serum, indicating that adipocytes secrete adiponectin 
into the circulation. In addition, it was found that adiponectin secretion was increased in 
vitro following insulin treatment1. Adiponectin was also independently discovered in 
1996 by mRNA differential display, whereby the adiponectin cDNA was identified and 
named Adipoq. This study too showed that adiponectin is exclusively expressed in 
adipocytes, but importantly also observed that adiponectin expression is drastically 
reduced in the fat pads of obese mice compared to normal weight controls2. A human 
homologue of adiponectin was identified in 1996 using a cDNA library from human 
adipocytes; it was named adipose most abundant gene transcript 1 (apM1) given the fact 
it was the most abundant transcript present3. More work on human adiponectin using 
gelatin affinity chromatography revealed that, like mice, human plasma contains high 
levels of circulating adiponectin4. Once adiponectin had been successfully isolated work 
began to determine the structure of the protein. 
1.1.2. Structure and multimerisation of adiponectin 
Adiponectin consists of a globular domain and a collagenous domain and is structurally 
similar to collagen X2. This structure is highly conserved with the amino acid sequence 
sharing 80% homology across all species so far studied5. Additionally, many post-
translational modifications are present on the collagenous domain including lysine 
glycosylation sites which have shown to be vitally important in conferring functionality 
to adiponectin action in vitro5. 
Throughout the early work on adiponectin it was repeatedly observed that secreted 
adiponectin was present at different molecular weights, representing different protein 
complexes, in both rodents1 and humans4. Further work to classify these complexes 
showed that adiponectin exists in a variety of multimeric states, the commonest being 
trimers, hexamers and high-molecular-weight multimers6,7, in addition to the 
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proteolytically cleaved globular adiponectin monomer8,9. Fluorescent labelling has been 
used to show that the multimeric state of adiponectin complexes is determined pre-
secretion and, once in the circulation, there is no multimer interconversion. Labelled 
adiponectin concentrations in the circulation decreased over time, indicating 
degradation in the plasma and the importance of secretion in maintaining and 
influencing adiponectin concentrations in the blood10. Whilst adiponectin has been 
shown to exhibit a physiological effect, changes in circulating adiponectin concentrations 
are also associated with a variety of pathologies. 
1.1.3. Adiponectin as a biomarker of metabolic dysfunction 
The major correlative factor with circulating adiponectin is adiposity. It is well 
established that hypoadiponectinaemia (<4µg/ml) is associated with high body mass 
index (BMI) and large adipocyte area in subcutaneous and visceral depots11-14. Patients 
with obesity show an inverse correlation between circulating adiponectin and visceral 
fat area (measured by computed tomography scans) but not BMI or subcutaneous fat 
area15. Notably, these low concentrations of adiponectin can be reversed by reducing 
visceral fat area16,17 indicating an important role for visceral fat in 
hypoadiponectinaemia. Hypoadiponectinaemia also correlates with the onset of type 2 
diabetes and insulin resistance, and circulating adiponectin in is lower in obese type 2 
diabetics than age- and BMI-matched non-diabetic obese patients17. Higher adiponectin 
levels are also associated with a reduced risk of developing type 2 diabetes18. 
Adiponectin has also been shown to be associated with various atherosclerotic diseases. 
Myocardial infarction patients are more likely to display hypoadiponectinaemia19 and 
the degree of this can be used to predict the severity of coronary artery atherscerlosis20. 
When looking at cardiac parameters a slightly unexpected pattern exists, with 
adiponectin concentrations raised in patients with chronic heart failure and further 
increased as heart failure worsens21,22. One hypothesis for this paradoxical relationship 
is the development of adiponectin resistance, with downregulation of AdipoR1 
transcripts downregulated in skeletal muscle biopsies of chronic heart failure paients23. 
Another risk factor in cardiovascular disease development is chronic kidney disease 
(CKD); in a similar fashion to chronic heart disease, there is some evidence that 
adiponectin circulates at normal levels in patients with CKD24. Additionally, high 
adiponectin was a predictor for CKD but only in male patients25. Despite these 
associations with CKD, hypertension is negatively correlated with circulating 
adiponectin, and hypoadiponectinaemia is a risk factor for hypertensive disease26,27. 
Finally, adiponectin has been shown to negatively correlate with bone mineral density28 
which will be discussed further in later sections.  
Together, these observations support the conclusion that decreased circulating 
adiponectin is generally associated with increased cardiometabolic risk, although, as in 
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the case of CKD in males, increased adiponectin is not always associated with beneficial 
health outcomes. 
1.1.4. Cellular secretion of adiponectin and extracellular adiponectin 
receptors 
As previously mentioned, adiponectin is secreted from adipocytes into the extracellular 
media in vitro and into the circulation in vivo. The method of secretion is thought to be 
via a peri-nuclear compartment related to the Golgi body. This adiponectin-containing 
membrane compartment is trafficked to the extracellular membrane for release, a 
process that is distinct to the secretion of leptin, another prominent adipose-tissue-
secreted hormone29. 
Once in the circulation, adiponectin is able to bind to two receptors named adiponectin 
receptor 1 (AdipoR1) and 2 (AdipoR2). Both receptors are structurally analogous, with 
an intracellular N-terminus and extracellular C-terminus and are located on different 
chromosomes (AdipoR1 on chromosome 1 in humans and in mice; AdipoR2 on 
chromosome 12 in humans and chromosome 6 in mice). Double knockout of both 
AdipoR1 and AdipoR2 in mice has shown that these receptors mediate the majority of 
adiponectin signalling in vivo30. Adiponectin has also been shown to associate with T-
cadherin receptor in cardiac tissue, with loss of interaction between adiponectin and 
cardiomyocytes in T-cadherin knockout mice31. The downstream effects of activation of 
these receptors are detailed below. 
 
1.1.5. Multimer-specific signalling of adiponectin 
As described above, adiponectin exists in the circulation in a variety of multimeric 
complexes, typically these are globular adiponectin monomers, low molecular weight 
trimers (LMW), medium molecular weight hexamers (MMW) and high molecular weight 
multimers (HMW)6. There is evidence that differing molecular weight complexes have 
distinct signalling effects and may be an important aspect of adiponectin specificity. 
HMW has been described as a more active form of adiponectin32 based on findings that 
the ratio of HMW adiponectin to total adiponectin is a strongly correlated with insulin 
sensitivity33, however there is also research to show that total HMW adiponectin is more 
important than ratio34. Regardless, it is known that HMW adiponectin has potent insulin 
sensitizing effects and these effects are likely mediated through signalling by HMW 
adiponectin in the liver35. 
Conversely, globular adiponectin has been shown to signal to a large extent on the 
skeletal muscle to increase activate AMPK resulting in increased fatty acid oxidation and 
insulin sensitivity36. LMW adiponectin is able to cross the blood brain barrier where it 




1.1.6. Action of adiponectin in the central nervous system 
 
Adiponectin signalling in the central nervous system (CNS) is a relatively recent area of 
study for the signalling effects of the hormone. This may be because the concentration of 
adiponectin is found in the cerebrospinal fluid (CSF) at a 1000-fold lower concentration 
compared to the serum38. Despite this, adiponectin has been shown to have effects on a 
multitude of brain parhways with a variety of outcomes. 
It has been shown that administration of adiponectin by intracerebroventricular (ICV) 
injection directly into the CSF causes a reduction in food intake in rats39. Additionally, 
this effect was shown to be specific to AdipoR1 mediated signalling by knockdown of 
each adiponectin receptor39. Furthermore, ICV administration of adiponectin has been 
shown to decreases body weight in obese mice with an associated increased in energy 
expenditure40. Adiponectin has also been shown to play a role in stroke response, 
cerebral artery occlusion was performed on adiponectin knockout and wild-type mice. 
This study showed that adiponectin knockout mice had larger infarct sizes as well as 
more severe neurological harm41. Finally, a potential negative role for adiponectin in the 
CNS was shown in patients suffering from Alzheimer's disease. Adiponectin 
concentrations in the plasma were higher in patients with mild cognitive impairment 
and patients with Alzheimer's disease compared to healthy controls42. This correlation 
was also observed between CSF adiponectin concentrations and mildly cognitively 
impaired patients but not in patients with Alzheimer's disease42.  
The above studies show a potentially important role for adiponectin in the CNS both in 
terms of feeding behaviour and metabolism but also in neurological pathologies. Whilst 
the central effects of adiponectin are not the focus of this thesis and do not appear in the 
following hypotheses, it is worth staying mindful of the central effects caused by 
adiponectin signalling. 
 
1.1.7. Action of adiponectin action in skeletal muscle 
 
Studies of adiponectin signalling in the skeletal muscle have been primarily focussed on 
its insulin-sensitising and anti-diabetic effects, given skeletal muscle’s important role in 
these physiological responses43. In vitro research has shown that adiponectin is able to 
increase glucose uptake in cultured rat skeletal myocytes44 and this was further 
confirmed in in vivo models which also implicated a role for AMPK activation in 
downstream signalling36,45. Further mechanistic research on the insulin-sensitising 
effects of adiponectin showed that adiponectin signalling induces glucose transporter 
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type 4 (GLUT4) translocation to the plasma membrane of myocytes44. Adiponectin 
knockout mice have been used to investigate the role of adiponectin in peripheral 
glucose homeostasis, and whilst these mice have only a mild insulin resistance, when fed 
a high-fat diet the knockout mice develop more-severe metabolic dysfunction than wild-
type controls46,47. 
Adiponectin is also able to influence lipid homeostasis in the muscle, where it has been 
shown to act, again, through AMPK activation to increase fatty acid oxidation45,48. This 
increase of fatty acid oxidation in the muscle has also been linked with weight loss in 
response to adiponectin signalling8. In addition to fatty acid oxidation, adiponectin has 
been implicated in mitochondrial biogenesis, with insulin-resistant individuals showing 
a strong positive correlation between circulating adiponectin and mitochondrial DNA 
content in the muscle49. It was also shown that mice lacking adiponectin have lower 
mitochondrial number and lower mitochondrial enzymatic activity in their skeletal 
muscle49. In vitro experimentation revealed that adiponectin treatment of primary 
myocytes induces mitochondrial biogenesis and increases fatty acid oxidation49. The 
mechanism of action of adiponectin-mediated increases in mitochondrial biogenesis is 
through a suppression of Mitogen-Activated Protein Kinase Phosphatase-1 (MAPK1) in 
skeletal muscle50. 
Peroxisome proliferator-activated receptor γ coactivator 1 alpha (PGC1α) is a further 
protein linked to both adiponectin signalling and mitochondrial biogenesis. PGC1α is 
commonly regarded as a master inducer of mitochondrial biogenesis and respiration51. A 
link between adiponectin signalling has been shown by suppression of adipoqR1 causing 
a decrease in PGC1α expression, further resulting in a decrease in mitochondrial content 
of primary cultured myocytes52. 
1.1.8. Action of adiponectin in the liver 
Hepatocytes have been shown to express both adipoR1 and adipoR2 on their plasma 
membranes53 and treatment of cultured hepatocytes with adiponectin causes them to be 
more sensitive to insulin-mediated reductions in glucose production, even at sub-
physiological concentrations of insulin54. When adiponectin is injected intraperitoneally 
it is able to lower the blood glucose concentrations in both healthy and diabetic mice54. 
Despite this action, supra-physiological levels of injected adiponectin do not cause 
hypoglycaemia 54. When compared to the effects of insulin injection, adiponectin is able 
to lower blood glucose even when the ability of insulin to stimulate glucose uptake is 
removed55. Therefore, it could be suggested that adiponectin acts in the liver to inhibit 
glucose production, rather than increasing glucose uptake56. This was confirmed by 
combining adiponectin infusion with hyperinsulinaemic euglycaemic clamps: 
adiponectin caused a 65% reduction in glucose production and a down regulation of 
hepatic gluconeogenic enzymes, indicating that adiponectin reduces hepatic glucose 
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production57. Additionally, cultured hepatocytes treated with adiponectin show greatly 
reduced glucose production and secretion into the culture medium58. 
Presently, the majority of research regarding adiponectin has focus on states of obesity 
or insulin resistance. Yet little research has been performed on adiponectin in organisms 
of relatively improved metabolic health such as calorie restriction where the role of 
adiponectin is largely unknown. 
 
1.2. Caloric restriction 
1.2.1. Human examples of calorie restriction 
The above findings demonstrate the extensive study of adiponectin, particularly in the 
context of diabetes and obesity. Yet adiponectin is greatly increased in conditions of 
caloric restriction (CR). CR is the dietary regimen of reducing daily calories and, when 
used as a method for improving health, also involves avoiding any form of associated 
malnutrition. Historical examples of this occurring in the human population are rare 
given the high likelihood of malnutrition occurring during calorie scarcity; however, 
some examples do exist. For example, Okinawa is a small cluster of Japanese Islands in 
the East China Sea whose occupants historically have eaten a low-calorie but nutrient-
rich diet. The dietary calorie intake of the Okinawan population compared to the 
mainland Japanese is reported to be 83%59. Studies on the Okinawans have shown that 
they have increases in both their maximal and average life span, and a lower incidence of 
coronary heart disease as well as a variety of cancers including colon, breast and 
prostate60. It is important to note that this effect was only observed in Okinawans born 
before World War Two, because after this the diet of the islanders changed dramatically 
to more closely resemble that of mainland Japan. This also caused a convergence in life 
expectancy between Okinawa and mainland Japan, with the latter even overtaking 
Okinawa in life expectancy61. Together, this supports this concept that CR in humans can 
increase life expectancy and decrease the incidence of chronic diseases. 
An example of a smaller but more controlled human CR is the Biosphere 2 simulation. 
Biosphere 2 did not begin as a calorie restriction experiment but was an attempt to 
simulate conditions of extra-terrestrial habitation. A 3.15 acre closed system biosphere 
was constructed in Arizona with 8 participants living inside without external influence 
for 2 years62,63. The participants were solely responsible for growing enough food to 
sustain themselves over the 2-year experiment and, prior to commencement, daily 
calorie intake was predicted to be ~2500kcal per person per day. Due to crop cultivation 
issues actual calorie intake during the first 6 months of the experiment was 1784kcal per 
person per day, rising to ~2000 kcal for the remainder of the study64. Whilst this 
represented a large decrease in calorie intake, the food that was grown was high in 
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nutrients, preventing any form of malnutrition. All participants displayed weight loss 
over this period, with males and females displaying a 21% and 14% reduction in body 
weight, respectively64, which was caused by a decrease in body fat65. In addition to the 
weight loss, many physiological and biochemical changes were observed in the 
participants, including significant decreases in cholesterol (both LDL and HDL) and 
triglycerides. Upon exit of Biosphere 2 and resumption of a normal diet these 
parameters generally returned to pre-experiment levels, indicating these changes are a 
result of the Biosphere 2 environment and likely due to the calorie restriction66.  
Whilst suggestive, the Biosphere 2 study was not designed to directly test the effects of 
CR in humans and there was a pressing need for a clinically control trial into the effects 
of CR in humans. The CALERIE (Comprehensive Assessment of Long-term Effects of 
Reducing Intake of Energy) study is a cross-centre study aimed at examining the effects 
of caloric restriction on humans in a controlled manner.  The experiment commenced in 
May 2007 with the recruitment of 220 healthy volunteers across three sites in the USA. 
Participants were randomly assigned to either a calorie restriction or ad-libitum diet in a 
2:1 ratio. Volunteers on the calorie restriction diet underwent a 25% reduction in daily 
calories, with behavioural and dietary modifications in order to maximise adherence to 
the long-term diet67. Large effects were observed by this 2 year calorie restriction: 
participants in the calorie-restricted group were significantly lighter than the ad-lib diet 
group, with loss of both fat-free mass and fat mass68. Subcutaneous and visceral adipose 
depots were each reduced, along with a reduction in ectopic lipid in the liver and soleus 
muscle68. Blood biochemistry was also significantly altered: circulating fatty acids were 
increased by calorie restriction whilst insulin sensitivity was increased and fasting blood 
glucose reduced69. 
These examples show CR as a powerful tool for improving human health and potentially 
longevity. Large changes are observed in body weight, particularly accounted for by fat 
mass, as well as a wide variety of metabolic benefits including improvements in insulin 
and glucose tolerance and reductions in hepatic lipid accumulation. 
1.2.2. Suitability of animal models of calorie restriction 
The recent interest in the health benefits of CR in humans is based largely on studies in 
animal models. Much of the early caloric restriction experimentation on animals 
focussed on the ability of caloric restriction to extend lifespan. This is now a well-
established effect in a diverse range of organisms from single celled species such as 
yeast70, through simple multicellular organisms such as nematode worms and flies and 
onto rodents71,72 and, potentially, primates73,74. Some ambiguity remains around the 
effects of calorie restriction on primates given the time taken to perform these 
experiments and the difficulty at the time in sourcing primates resulting in animals that 
had previously been used in other experiments. Despite these potentially confounding 
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issues, there is now evidence that calorie restriction has caused a decrease in all-cause 
mortality in rhesus monkeys75. Additionally there were substantial reductions in the 
incidence of cancer, insulin resistance and diabetes75.  
Currently, mice and rats are some of the most widely used organisms to examine the 
effects of caloric restriction. They appear to be a good model of mimicking the effects of 
caloric restriction in humans. This is evidenced by the analogous effects of calorie 
restriction in both humans and rodents. 
1.2.3. Mechanism of metabolic effects 
The metabolic adaption to calorie restriction is well established. In the fed state ingested 
glucose is absorbed by the liver and skeletal muscle; the latter occurs in direct response 
to increased concentrations of blood insulin. In the liver and muscle, glucose is readily 
converted to glycogen, gluconeogenesis is also supressed in the liver76.  This acts to 
remove excess glucose from the blood and store it as glycogen for use in times of energy 
scarcity76.  In the following hours post-feed, the concentrations of blood glucose start to 
decrease as does the concentration of insulin, concurrently the concentration of 
glucagon rises76. Glucagon acts to stimulate the breakdown of glycogen in the liver to 
glucose and inhibits hepatic glycogen and fatty acid synthesis resulting in a large 
increase in the glucose secretion from the liver76. As glucose scarcity continues, the 
skeletal muscle becomes more reliant on fatty acids for their energy requirements whilst 
the resulting glycerol is transported to the liver, further driving gluconeogenesis76. 
Proteolysis is also utilised to provide more products for use in gluconeogenesis. During 
prolonged starvation, ketone bodies synthesised from fatty acids become a major energy 
source, able to pass the blood brain barrier, they alleviate the need for glucose in the 
brain and help reduce the amount of proteolysis occurring, preserving essential muscle 
required for survival76. Once these fatty acids reserves are exhausted only protein 
remains for energy eventually leading to heart, liver or kidney failure and death76,77. 
One of the earliest hypotheses for how CR imparts its effects focused on the body size of 
rats following calorie restriction, showing that reduction in growth corresponded to an 
increase in life span72,78. Further work to better characterise this effect showed that loss 
of fat was an important factor in the beneficial effects of caloric restriction79. A reduction 
in energy expenditure could explain these effects on body morphometry and has also 
been proposed as a mechanism of caloric restriction’s effects80. However, the research 
has shown mixed results with some showing that chronic calorie restriction does not 
influence relative metabolic rate and therefore is not a causal factor in the effects of 
calorie restriction81,82. Interestingly, others show that metabolic rate is decreased by 
CR83. 
It has been suggested that the effects of caloric restriction occur in two phases: first the 
animal adapts to the reduction in calories, followed by a second phase that lasts the 
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remainder of the animal’s lifespan. The metabolic rate of rats is decreased by transient 
calorie restriction and  the metabolic rate returns to basal levels within a few weeks as 
the rats adapt to the diet82. During this adaptive period animals exhibit rapid weight loss, 
specifically for fat mass84. This follows the reduction in blood glucose stimulating the 
breakdown of glycogen by the release of glucagon from the pancreas85. Glycogen 
supplies are rapidly depleted and so the animal resorts to fat oxidation to provide 
energy, including the synthesis of ketone bodies to help meet the organism’s energy 
needs. This pattern of adaption results in a large decrease in blood glucose initially, 
followed by a rise to maintain a steady concentration, albeit lower than ad-libitum fed 
levels86. These chronically reduced blood glucose concentrations cause less insulin to be 
released by the β cells in the pancreas which in turn increases insulin sensitivity of the 
animals87. 
The neuroendocrinology of animals during caloric restriction is greatly altered and has 
been proposed as a mechanism of action for some of the effects of this dietary 
intervention. Glucocorticoids have been shown to be largely elevated during calorie 
restriction88,89 but neuronal adaptation has also been shown to occur during chronic 
calorie restriction with reductions in glucocorticoid receptors acting as negative 
feedback to limit excessive glucocorticoid activity90.Therefore, this may not represent a 
mechanism of action through which calorie restriction greatly acts.  
Insulin-like growth factor 1 (IGF-1) is a liver-derived hormone downstream of growth 
hormone (GH) signalling. It acts in a multitude of tissues to stimulate growth and 
proliferation whilst also inhibiting cell death91. During calorie restriction IGF-1 is greatly 
reduced92 in the circulation and this reduction has been shown to influence longevity93-
95. In addition, IGF-1 has been shown to induce hypoglycaemia when infused into rats96 
and to recover growth rate of diabetic rats97. For these reasons, IGF-1 has also been 
suggested to be an important regulator of the effects of caloric restriction. Yet despite 
these findings, data in humans have shown that protein restriction may be a more 
important determinant on plasma IGF-1 concentrations than more general calorie 
restriction, especially considering it has been shown that CR does not reduce IGF-1 in 
humans98. 
1.2.4. Adiponectin and caloric restriction 
Given that adiponectin is exclusively secreted from adipocytes, and that calorie 
restriction causes a decrease in body mass caused by a decrease in fat mass, it would 
seem likely that during calorie restriction concentrations of circulating adiponectin 
would be reduced; however, this is not the case. During caloric restriction 
concentrations of adiponectin greatly increase99-101 and, conversely, during obesity, 
adiponectin concentrations are reduced3,102,103. Many of the metabolic effects of 
adiponectin (discussed above) are similar to effects of caloric restriction, yet little work 
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has been done to investigate if adiponectin contributes to the benefits of caloric 
restriction.  
The role of adiponectin as a hormone acting in starvation in opposition to insulin has 
also been widely discussed. Briefly, adiponectin’s ability to increase fatty acid oxidation 
and insulin sensitivity while also decreasing energy expenditure and gluconeogenesis 
and this is postulated to act to minimise the anabolic effects of insulin signalling during 
CR. This is compounded by the evolutionary basis for adiponectin being unlikely due to a 
need for reacting to obesity, type 2 diabetes and other outcomes of our sedentary 
western lifestyles, but more likely as a method of surviving starvation, a far more likely 
encountered pathology during human evolution104-106. Independently it has been shown 
that adiponectin plays a role in energy expenditure with adiponectin deficient mice 
showing decreased food intake and increased energy expenditure37.  
Direct evidence for adiponectin’s beneficial role in calorie restriction come from studies 
of myocardial infarction. Caloric restriction has been shown to provide a 
cardioprotective effect when rats are injured by cardiac reperfusion injury107 and this 
effect is abrogated in transgenic mice with  reduced circulating adiponectin108. Also a CR 
study in Adipoq KO mice, showing that the KOs have impaired response to CR-mediated 
improvement in hind limb ischaemia109. So, there seems to be a role for adiponectin in 
the cardiovascular benefits of CR. 
In obesity, decreased circulating adiponectin is mirrored by decreased expression and 
secretion from WAT, yet in CR, increased circulating adiponectin can occur despite no 
increase in adiponectin expression in WAT110. Other secretory sites of adiponectin aside 
from the traditional WAT have therefore been investigated and the influence of bone 
marrow adipose tissue on circulating adiponectin is introduced below. 
1.3. Bone marrow adipose tissue 
1.3.1. Basic physiology 
The presence of adipose tissue within the bone marrow cavity has been known 
scientifically since the late 19th century111. Yet, the physiological and clinical significance 
of this adipose depot has been relatively ignored until recently. An important early 
observation in bone marrow adipose tissue (BMAT) research was histogenic differences 
between the BMAT and the haematopoetic red marrow cells112. Further ultrastructural 
analyses suggested that BMAT and white adipose tissue (WAT) do not share a common 
progenitor cell type113. BMAT is typically found at the periphery of the skeleton114 and 
begins to increase from distal regions, such as the toes, after birth115. BMAT continues to 
accumulate through life, first increasing in distal sites and moving into the proximal 
skeleton116. This pattern is apparent in rodents, with the tail representing the most distal 
skeletal site and location of earliest BMAT development117. As BMAT develops, two 
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distinct types of adipocytes can be observed histologically: in the distal regions of the 
bones BMAT adipocytes appear tightly packed and resemble WAT. This depot of 
adipocytes is termed constitutive BMAT (cBMAT) given that it is present in the skeleton 
from shortly after birth116,118. On the other hand, BMAT adipocytes present in the 
proximal regions of long bones and in the axial skeleton present in a more 
heterogeneous environment. These are single adipocytes interspersed within the 
haematopoietic red marrow cells; they possess a far greater plasticity in response to 
exogenous stimuli and so are referred to as regulated BMAT (rBMAT)118. Variation 
between cBMAT and rBMAT is not limited to the microenvironment of these cells. For 
example, cBMAT adipocytes have been shown to be larger than rBMAT cells in diameter 
and therefore volume118. In addition, differences in fatty acid composition also exist with 
distal regions of bones containing higher levels of unsaturated fatty acids compared to 
more central or proximal regions118,119. The mass of BMAT in adults is approximated to 
be 2.48kg in males and 1.8kg in females120, therefore, for an average 73kg male BMAT 
represents approximately 3.4% of total body mass and 3% in a 60kg female120. This 
relateees to around 8 – 10% of the total fat mass of an individual. As discussed below, 
BMAT increases during states of energy deficit, such as CR or anorexia nervosa. 
Therefore, during these conditions BMAT can comprise an even greater percentage of 
total fat mass121. 
1.3.2. Clinical and molecular influencers of BMAT volume 
One of the most robust indicators for increased BMAT volume is age. It has been shown 
that BMAT first appears in the toes around birth115 and continues to grow from the most 
distal regions to more proximal until 20 to 25 years of age116. BMAT accumulation in the 
axial skeleton then continues with advanced age, accelerating particularly in women 
post-menopausally122. 
An area underscoring the strong clinical relevance of BMAT is the association between 
elevated BMAT volume and increased risk of bone loss and osteoporosis123,124. BMAT 
accumulation has been associated with the loss of a wide variety of calcified bone 
parameters125-127. However, whilst this is a well-established correlation, evidence 
suggests that increased BMAT volume is not always required for reductions in bone 
integrity128,129. 
Like WAT, the transcription factor PPARgamma is a key regulator of BMAT formation. 
Thiazolidinediones (TZDs) are a class of pharmacological PPARγ agonists that have been 
shown to cause large increases in BMAT volume130 whilst also providing anti-diabetic 
effects131. Despite the strong antidiabetic effects of these drugs their use was widely 
discontinued given the side effect of increased bone fracture risk132. 
The most important modulator of BMAT, in the context of this thesis, is caloric 
restriction. Despite the loss of WAT during calorie restriction, as discussed above, BMAT 
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volume increases in times of energy scarcity. This counter-intuitive phenomenon has 
been observed in a wide variety of organisms including mice133, deer134 and moose135. In 
addition to calorie restriction, BMAT has also been shown to increase in more 
pathological contexts of energy deficit, such as during anorexia nervosa in humans136,137.  
Several mechanisms have been proposed to contribute to BMAT accumulation during 
CR. One notable candidate is the adipokine leptin. The ob/ob mouse, lacking leptin, and 
the db/db mouse, lacking the leptin receptor, both show increased BMAT138,139, whilst 
leptin treatment abrogates this effect140. However, more recent research has shown that 
hypoleptinaemia is not required for BMAT expansion and is more associated with 
increased glucocorticoids129.  
Growth hormone (GH) has been proposed to play an important role in BMAT expansion 
given that mice with spontaneous mutations in GH signalling have low GH 
concentrations as well as high BMAT volumes141. Additionally, mice with high GH 
concentrations have relatively little BMAT142. However, GH may not be the major 
determinant, as humans with anorexia nervosa have high concentrations of GH yet large 
amounts of BMAT. A proposed reason for this is that patients with anorexia have 
developed a resistance to the signalling of GH as, despite having high GH, they show low 
levels of IGF-1143. As mentioned above, CR is known to decrease IGF-1 in animal models 
so it may be that decreased IGF-1 contributes to expansion of BMAT during CR, although 
this remains to be formally tested.  
There is not a large amount of research regarding temporal relationship between CR and 
BMAT expansion. It has recently been shown that short term fasting causes an increase 
in vertebral BMAT but not femoral BMAT144. However, this temporal relationship 
remains ignored, highlighting the need for further research to help identify potential 
causes and consequences of BMAT expansion during CR. 
 
1.3.3. BMAT endocrinology and metabolic influence 
The ability of WAT to act as an endocrine organ is now well established and specific 
adipokines are numerous, including the satiety hormone, leptin145,146; the antidiabetic 
hormone, adipsin147; and, as previously mentioned, adiponectin. Despite the 
endocrinology of WAT being well studied, the endocrinology of BMAT is far less well 
characterised.  
In vitro study of adipocytes differentiated from bone marrow mesenchymal stem cells 
has shown leptin expression and secretion148-150, however differentiated and cultured 
bone marrow adipocytes may not faithfully represent the true nature of these cells in 
vivo. An in vivo example of leptin expression from BMAT comes from a microarray 
analysis of isolated mouse bone marrow adipocytes showing enriched levels of Lep 
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transcript151. In addition to this, Lep transcripts have also been detected in the distal 
BMAT of rabbits where, as in WAT, they are downregulated during CR129. 
Given the above observations, a logical hypothesis was that BMAT may be contributing 
to the calorie restriction induced hyperadiponectinaemia. Notably, this effect is not 
solely limited to calorie restriction: BMAT increases and hyperadiponectinaemia are 
concordant in conditions such as aging151,152, animal models of type 1 diabetes153,154, 
anorexia nervosa136,155 and TZD treatment156,157. However, whether BMAT also 
contributes to hyperadiponectinaemia in these or other conditions remains unknown. 
Similarly, it is unclear whether, by producing adiponectin, BMAT contributes to the 
systemic metabolic effects of CR. 
Empirical evidence for BMAT secretion of adiponectin during calorie restriction is based 
on studies in transgenic Ocn-Wnt10b mice. These mice have increased bone formation 
resulting from the transgenic expression of the signalling molecule, Wnt10b, from the 
human osteocalcin promoter; this results in osteoblast-specific Wnt10b 
overexpression158. Wnt10b is known to stimulate osteoblastogenesis and inhibit 
adipogenesis159, and therefore they were tested as a model that may be BMAT-deficient. 
Consistent with this, these Ocn-Wnt10b mice display a higher bone mass and, whilst the 
volume of BMAT is the same on a normal chow diet, when placed on a CR diet the WT 
mice show the expected increase in BMAT but this increase is significantly blunted in the 
Onc-Wnt10b mice121. In addition to the effect on BMAT volume, Ocn-Wnt10b mice also 
have significantly lower concentrations of adiponectin in the circulation, including total 
levels and the levels of the specific multimers121. This occurs despite no changes in 
adiponectin production from WAT. Together, this indicates that increases in BMAT are 
required for the hyperadiponectinaemia induced by CR.  
 
1.4. Hypothesises and aims 
 
Given the preceding information, I propose the following hypothesis: 
BMAT is an important secretory source of adiponectin during CR as well as other 
condition of BMAT expansion and hyperadiponectinaemia. Furthermore, this secreted 
adiponectin is at least partly responsible for the metabolic adaptions induced by CR. I 
will test this hypothesis through the following sub-hypotheses and aims: 
 
1. BMAT will contribute to hyperadiponectinaemia not only during CR but also in 
response to TZD treatment, another context in which both BMAT and circulating 
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adiponectin are increased. I will address this hypothesis by pursuing the 
following aims: 
a. Determine if Ocn-Wnt10b mice also resist TZD-induced BMAT 
expansion. 
b. Determine if Ocn-Wnt10b mice resist TZD-induced 
hyperadiponectinaemia, compared to wild-type controls. 
I hypothesise that mice resistant to BMAT expansion will show blunted 
hyperadiponectinaemia in response to TZD treatment, compared to wild type 
controls. 
 
2. CR-induced BMAT expansion is dependent on the duration of CR and is 
associated with endocrine, skeletal and metabolic effects of CR. I will address 
this hypothesis by pursuing the following aims:  
a. Determine the time frame over which BMAT expansion occurs in 
response to CR. 
b. Determine the time frame over which hyperadiponectinaemia occurs in 
response to CR. 
c. Determine the time frame over which beneficial metabolic adaptions 
occur in response to CR, including decreased fat mass and improved 
glucose tolerance. 
d. Compare these time frames to evaluate if changes in BMAT and 
hyperadiponectinaemia are associated with the metabolic adaptions. 
I hypothesise that changes in BMAT will precede or occur simultaneously with the onset 
of hyperadiponectinaemia, and that hyperadiponectinaemia will precede or occur 
simultaneously to the metabolic adaptions to caloric restriction. 
3. Adiponectin contributes to the metabolic effects of CR. I will address this 
hypothesis by pursuing the following aims:  
a. Generate a transgenic adiponectin knock-out mouse line and compare 
how this mouse responds to CR vs wild type mice across a variety of 
metabolic parameters. 





2. Materials and methods 
2.1. Animal husbandry 
2.1.1. General husbandry 
2.1.1.1. Ocn-Wnt10b mice 
The study was approved by the University Committee on Use and Care of Animals and 
mice were cared for by the Unit for Laboratory Animal Medicine at the University of 
Michigan. These mice were generated, bred and culled prior to commencement of this 
PhD project. Ocn-Wnt10b mice overexpress the Wnt10b specifically in osteoblasts 
resulting in increased bone mineral density, bone volume fraction and trabecular 
number. This effect is caused by an increased number of osteoblasts per bone surface.158 
A consequence of this increase in bone is that there is significantly less BMAT volume in 
the medullary cavity of the bones making it a useful tool for studying BMAT expansion in 
vivo121. At the time these mice were used no other models specifically resistant to BMAT 
expansion existed. Now, multiple research groups are developing rodent models which 
lack BMAT and these will be discussed in subsequent chapters. 
2.1.1.2. C57BL/6NCrl mice and adiponectin knock-out mice 
The studies at The University of Edinburgh were approved by the local named veterinary 
surgeons in line with establishment, project and personal licences issued by the UK 
Home Office. Mice were housed in communal housing rooms with a 12-hour light-dark 
cycle between 7am and 7pm and at an ambient temperature of 25°C. 
2.1.2. Transgenic line generation 
2.1.2.1. Ocn-Wnt10b mice 
Ocn-Wnt10b mice were generated at the University of Michigan prior to commencement 
of this PhD project as previously reported158. In summary, the human osteocalcin 
promoter from pBS(K-) vector was excised using HindIII and Xhol. This DNA was ligated 
into pCRII vector containing mouse cDNA for Wnt10b at the HindIII/Sal1 site; this was 
followed by a rabbit β‐globin intron/poly A tail sequence. The transgenic construct 
containing the Ocn-Wnt10b region was digested using HindIII, XholI, purified, and 
microinjected into fertilised C57BL/6J mice eggs. Successful transgene integration was 
screened for by PCR using transgene specific primers. One founder male was selected for 
moderately increased BMD and was bred with wild-type C57BL/6J females to generate 
line designated 488 from which experimental mice were bred. 
2.1.2.2. C57BL/6NCrl mice 
These mice were acquired from breeding stocks maintained by the Bioresearch and 
Veterinary Services at The University of Edinburgh. 
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2.1.2.3. Adiponectin knock-out mice 
Transgenic Adipoqtm1a(KOMP)Wtsi sperm was purchased from The Knockout Mouse Project 
KOMP Repository.  This sperm was used the fertilise wild-type C57BL/6N (Charles River 
Laboratory, acquired from local BVS stock) mouse eggs by in vitro fertilisation. 
Recombinant Tet-Cre recombinase was also injected into the egg causing recombination 
at the LoxP sites thereby excising exon 3 of the Adipoq gene at the single-cell stage. This 
converted the Adipoqtm1a(KOMP)Wtsi allele to the Adipoqtm1b(KOMP)Wtsi allele (Figure 2.1). 
Subsequent heterozygous pups were bred with other heterozygotes to generate pups 
homozygous for the Adipoqtm1b(KOMP)Wtsi allele (KO) or control mice homozygous for the 
wild-type allele (WT); these two genotypes were used as the experimental mice. 
 
Figure 2.1 – Conversion of tm1a to tm1b allele. Sperm containing the tm1a allele was 
purchased and used to fertilise wild type eggs. During the IVF process, recombinant Cre 
recombinase was also injected causing conversion to the tm1b allele by excision of exon 
3 of the Adipoq gene. Grey boxes are exons (numbered above); FRT, flippase recognition 
target; lacZ, open reading frame for b-galactosidase reporter gene; loxP, recombination 
site for Cre recombinase; neo, open reading frame for neomycin resistance gene. Figure 
from www.komp.org. 
 
2.1.3. Rosiglitazone treatment 
The in vivo work in this section was done by researchers at the University of 
Michigan and not as part of this PhD project. 
Male and female wild type or Ocn-Wnt10b mice on a C57BL/6J background were fed a 
normal chow diet until 10 weeks of age. From 10-22 weeks of age, the mice were fed a 
western-style diet high in fat and sucrose (Research Diets, D12079B). At 18 weeks of age 
mice were evenly assigned to 1 of 4 groups: the first group remained on the western diet 
until 30 weeks of age, the other 3 groups received TZD treatment for 2, 4 or 8 weeks in 
duration. TZD was administered via the diet with western diet supplemented with 
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Rosiglitazone at 0.175mg/g of diet (Research Diets, D12112601). Two-week-treated 
mice received this diet from 28 to 30 weeks of age; four-week mice from 26 to 30 weeks 
of age; and eight-week mice from 22 to 30 weeks of age. At 29.5 weeks of age, the mice 
were fasted overnight and blood glucose concentrations measured. At 30 weeks of age, 
the mice we euthanized and the tissues isolated for downstream analysis. 
2.1.4. Caloric restriction 
At eight weeks of age C57BL/6NCrl mice were transferred from group housing to single 
housing in new, clean, cages. The diet was changed from standard chow (Special Diet 
Services, UK) to Research Diets D12450B. From 8-9 weeks of age, body mass and ad 
libitum (AL) food consumption was measured daily at 9:30am. Mean food intake was 
calculated over the final 5 days of single housing to allow mice to first adapt to the stress 
of single housing before assessing food consumption. Mice were randomly assigned to 
either remain on AL diet or changed to CR diet, ensuring equal numbers of each sex and 
genotype on each diet. Mice assigned to AL diet continued to have 24-hour access to diet 
D12450B. Mice assigned to CR diet received 70% mass of calculated AL intake. For the 
CR time course, this was 2.1 g/day and for the adiponectin knockout experiment was 2.2 
g/day. CR mice diet was changed to Research Diets D10012703, a micronutrient 
enriched diet used to ensure adequate micronutrient intake. The CR diet was 
administered once daily at 9:30am directly into the cage. For CR timecourses, mice were 
maintained on CR or AL diet for 1, 2, 4 or 6 weeks. For studies in Adipoq KO mice, mice 
were maintained on CR or AL diet for 4 weeks, a duration sufficient for maximum levels 
of hyperadiponectinaemia in the WT mice. 
Given that we have previously observed large increases in both circulating adiponectin 
and BMAT after 6 weeks of calorie restriction121 we used this as the longest time point to 
ensure that we saw the same effects. Subsequently we chose evenly spaced timepoints 
from 0 to 6 weeks to maximise the changes of accurately detecting the dynamic changes 
in these parameters. 
For the adiponectin knockout study, 4 weeks was used for the duration of CR because it 
was by this time point that we observed maximal increases in circulating adiponectin 
concentration. We also saw large improvements in glucose tolerance by 4 weeks CR 
indicating that we could accurately test the hypothesis that adiponectin was contributing 
to CR-induced improvements in glucose tolerance whilst minimising the duration of the 
experiment. This is beneficial in terms of costs, time and, most importantly, animal 
welfare. 
The CR diet D10012703 contains a higher concentration of micronutrients compared to 
the AL diet. This is to ensure that the CR mice, which eat a lower mass of diet, receive 
adequate micronutrients to avoid malnutrition which could confound the results. The 
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result is that the AL diet and CR diet both result in approximately equal masses of 
nutrient mix ingested despite the 30% reduction in macronutrients. 
Whilst the macronutrient concentrations in table 2.1 show that the diets are 
approximately the same composition, some more subtle differences are seen in fat 
source with the CR diet containing proportionally more soy-bean oil and less lard. These 
differences are relatively small and so are not anticipated to influence the result of the 




Diet D12450B D10012703 
Food group grams % (kcal) grams % (kcal) 
Protein 19.2 20 18.9 20 
Carbohydrate 67.3 70 66 70 
Fat 4.3 10 4.2 10 
kcal/gram 3.85 3.77 
Table 2.1 – Diet composition by energy source. Grams and percentage contribution by 
kcal of proteins, carbohydrates and lipids. 
Diet D12450B D10012703 
Ingredient grams kcal grams kcal 
Casein 189.6 758.3 186.0 744.0 
L-Cysteine 2.8 11.4 2.8 10.6 
Corn starch 298.6 1194.3 279.0 1116.1 
Maltodextrin 10 33.2 132.7 46.5 186.0 
Sucrose 331.7 1327.0 321.5 1286.1 
Cellulose, BW200 47.4 0.0 46.5 0.0 
Soybean oil 23.7 213.3 26.6 239.2 
Lard 19.0 170.6 15.3 138.2 
Mineral mix S10026 9.5 0.0 13.3 0.0 
Dicalcium phosphate 12.3 0.0 17.3 0.0 
Calcium carbonate 5.2 0.0 7.3 0.0 
Potassium citrate 15.6 0.0 21.9 0.0 
Vitamin mix 10001 9.5 37.9 13.3 53.1 
Choline bitartrate 1.9 0.0 2.7 0.0 
FD&C yellow dye 0.0 0.0 0.0 0.0 
FD&C blue dye 0.0 0.0 0.0 0.0 
     
Total 1000.0 3845.3 1000.0 3773.3 
 




2.1.5. Blood sampling 
Tail vein blood was acquired from the mice weekly, including prior to commencement of 
the dietary intervention and prior to cull. Mice were not restrained during blood 
sampling to limit stress effects. A razor blade was used to make a small incision on the 
side of the tail and resulting venous blood was collected in EDTA-coated capillary tubes 
(Sarstedt, 16.444). Blood glucose was also measured using a blood glucose monitoring 
system (OneTouch Verio® meter or OneTouch Verio® IQ meter). Blood collected in 
EDTA capillary tube was centrifuged at 2000 rcf for 10 minutes and the upper layer of 
blood plasma transferred to a fresh tube for storage at -80°C. 
2.1.6. Body composition 
Body composition was measured fortnightly in the CR time-course mice and weekly in 
the Adipoq knockout mice. Body composition was measured by time domain nuclear 
magnetic resonance imaging (TD-NMR) using a Minispec LF50 (Bruker, UK) as per 
manufacturer’s instructions. 
2.1.7. Oral glucose tolerance test 
The evening (5-6 pm) prior to oral glucose tolerance test (oGTT) CR mice were given a 
normal daily portion (2.1 g, CR time-course; 2.2 g, Adipoq KO) and AL mice were given 
an average daily dose of diet (3 g, time-course; 3.1 g, Adipoq knockout); all other diet 
was removed. The next day at 12pm an oGTT was performed, corresponding to an 
estimated fasting duration of ~6-12 hours. Mice were administered with 2 mg of D-
glucose (Sigma, G8270) per gram of body mass by oral gavage of 25% w/v D-glucose 
solution. Blood glucose was measured (as above) prior to gavage and 15, 30, 60 and 120 
minutes post-gavage. At each timepoint a blood sample was also taken from the tail vein 
to allow for analysis of plasma insulin concentrations. The oGTT was done 2 days prior 
to cull to allow recovery of the mice. 
2.1.8. Indirect calorimetry 
Adiponectin knockout mice underwent the previously described CR protocol; however, 
at the end of the 4-week dietary intervention, mice were placed in metabolic cages (TSE 
Phenomaster) for 3 days. Mice were fed as usual: AL mice with free access to food and CR 
mice fed in the morning daily. A flow rate of 0.35Lmin-1 was used following calibration, 
with the aim of keeping the respiratory exchange ratio (RER) between 1 and 0.7. Values 
were expressed relative to lean mass of mice. Data was recorded over the 3-day period 
but only the final 24 hours were analysed and presented to avoid the period of adaption 
to the foreign environment. 
2.1.9. Cull and necropsy 
At 5-6 pm on the day prior to termination CR mice were given 1.1 g CR diet whilst AL 
mice were given 1.5 g AL diet and remaining food removed in order to ensure both 
groups of mice were fasted to an equivalent degree. This was done to ensure that any 
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differences between groups reflect effects of longer-term CR, and not simply differences 
between fasted (CR) and non-fasted (AL) mice; a similar approach has been 
recommended by leading experts in animal CR studies160. Mice were culled by cervical 
dislocation followed by decapitation. The following tissues were dissected and frozen 
and/or fixed in 10% neutral-buffered formalin (Sigma): tail vertebrae; brown adipose 
tissue (BAT); humeri; ulnae and radii; inguinal WAT (iWAT); gonadal WAT (gWAT); 
mesenteric WAT (mWAT); tibiae; femurs; gastrocnemius muscle; soleus muscle; 
kidneys; spleen; pancreas; liver; heart; thymus; lumbar vertebrae; and, in Adipoq mice 
only, brain. Selected tissues were also weighed prior to freezing/fixing. 
2.2. Endocrine factors 
2.2.1. Circulating adiponectin 
Circulating adiponectin was quantified using Adiponectin ELISA (R&D, MRP300). Plasma 
was diluted with assay diluent (RD1W) 10,000-fold for mice treated with TZD and 4,000-
fold for mice not receiving TZD. The provided adiponectin standard was prepared and 
serially diluted according to manufacturer’s instructions. Assay diluent (50 µL) was 
added to each well of the provided 96-well anti-adiponectin-antibody-coated plates, 
followed by 50 µL of sample or standard, and the plate incubated for 3 hours at room 
temperature. Wells were aspirated and washed 5 times with 400 µL wash buffer. Mouse 
adiponectin conjugate (100 µL) was added to each well and the plate incubated for 1 
hour at room temperature. All wells were aspirated and washed 5 times again. Substrate 
solution (100 µL) was added to each well and the plate was incubated for 30 minutes at 
room temperature in the dark. Stop solution (100 µL) was then added to each well and a 
plate reader (Infinite 200 Pro, Tecan Life Sciences) used to measure the optical density 
of each well at 450 nm, with a correction against 570 nm. Sample concentrations were 
interpolated from standard curves and corrected for initial dilution. 
2.2.2. Circulating leptin 
Circulating leptin was quantified using leptin ELISA (R&D, MOB00). Plasma was diluted 
20-fold in calibrator diluent (RD5-3) and the provided standard was prepared according 
to the manufacturer’s instructions. Assay diluent (50µl) was pipetting into each well of 
anti-leptin-antibody-coated 96 well microplate as well as 50µl of diluted plasma or 
standard control sample and the plate incubated for 2 hours at room temperature. All 
wells were aspirated and washed 5 times by sequential additions and aspirations of 400 
µl wash buffer. Mouse/rat leptin conjugate (100µl) was added to each well and the plate 
was incubated for 2 hours at room temperature. The plate was washed a further 5 times 
and 100 µl substrate added, the plate was incubated at room temperature for 30 minutes 
in the dark and then 100 µl stop solution added to each well. The optical density of each 
well measured with an Infinite 200 Pro plate reader at 450 nm with a correction against 
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570nm. Sample concentrations were interpolated from standard curve and corrected for 
initial dilution. 
2.2.3. Circulating insulin 
Mouse insulin ELISA (Crystal Chem, 90080) was used to quantify circulating insulin 
concentrations from plasma samples taken during glucose tolerance test. The provided 
mouse insulin standard was diluted to 6.4, 3.2, 1.6, 0.8, 0.4, 0.2, 0.1 and 0 ng/ml. 
Standard or mouse plasma (5µl) was added to each well of a provided 96 well anti-
insulin-antibody-coated plate with 95µl assay diluent. The plate was incubated for 2 
hours at 4°C then washed 5 times with 400 µl wash buffer. Conjugate solution (100µl) 
was added to the plate, incubated for 30 minutes at room temperature and washed as 
before. Substrate solution (100µl) was added and the plate incubated for 40 minutes at 
room temperature before 100 µl of stop solution was added. Absorbance of each well 
was measured with an Infinite 200 Pro plate reader at 450 nm with a correction at 630 
nm and the concentration of the plasma samples interpolated vs the absorbance of the 
standards. 
2.2.4. Circulating IGF-1 
Mouse IGF1 ELISA Kit (Abcam, ab100695) was used to quantify plasma IGF-1 
concentrations. Standards were serially diluted to final concentrations of 2000, 666.7, 
222.2, 74.07, 24.69, 8.23, 2.74 and 0 pg/ml. Plasma from the calorie restriction time-
course was diluted 807-fold in assay diluent A. Standard or diluted sample (100µl) was 
added to each well of the supplied 96 well plate and incubated for 2.5 hours at room 
temperature. The plate was washed by adding 400 µl wash buffer to every well, repeated 
4 times. Biotinylated IGF1 detection antibody (100µl) was added to each well and the 
plate was incubated for 1 hour at room temperature,. Following this, the 4 washes were 
repeated and 100 µl HRP-streptavidin solution was added to each well and the plate 
incubated for 45 minutes at room temperature. The 4 washes were repeated again and 
100 µl of TMB one-step substrate reagent was added to every well followed by an 
incubation for 30 minutes at room temperature in the dark; 50 µl stop solution was then 
added to every well and the absorbance of each well measured with an Infinite 200 Pro 
plate reader at 450nm. Concentrations of the plasma samples were interpolated from 
absorbance of the standards and multiplied by the dilution factor. 
2.2.5. Circulating corticosterone 
Corticosterone ELISA (Enzo, ADI-900-097) was used to quantify circulating 
corticosterone concentrations in CR time-course mice. Protein-bound corticosterone was 
displaced into the plasma by adding 3 µl steroid displacement reagent diluted 1:100 (80-
0925) to 3 µl of plasma, incubated at room temperature for 5 minutes and then made up 
to 150 µl with assay diluent (80-0921). Corticosterone standard (200000 pg/ml, 80-
0916) was serially diluted to 20000, 4000, 800, 160, 32 and 0 pg/ml. Standard or diluted 
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plasma (100µl) was added to each well of the plate (80-0045) followed by 50 µl of 
conjugate (80-0917) and then 50 µl of antibody solution (80-0918). The plate was 
incubated for 2 hours at room temperature then each well was washed with 400 µl wash 
buffer (80-1286), pNpp substrate solution (200µl) (80-0075) was added to each well 
and the plate incubated for 1 hour at room temperature. 50 µl of stop solution (80-0247) 
was added to each well and the optical density of each well was measured with an 
Infinite 200 Pro plate reader at 405 nm with a correction at 580 nm. Plasma 
corticosterone concentrations were calculated from interpolation against absorbance of 
the standards and correction for initial dilution. 
 
2.3. Bone parameters 
2.3.1. Bone isolation 
Bones were dissected from mice as described in section 2.1.4. Soft tissue was removed 
from the bones using scissors, razor blades and abrasive tissue paper in order to limit 
contamination by extraosseous tissue. Bones were fixed in 10% neutral buffered 
formalin solution (Sigma, HT501380-9.5L) for 48 hours at 4ºC then transferred to 0.1M 
Sorensen’s buffer (81 mM KH2PO4, 19 mM Na2HPO4, pH 7.4) at 4ºC. 
2.3.2. Calcified bone µCT scanning 
Bones were embedded in a 30 ml screw top tube in 1% agarose (w/v) in water in 2 
layers of 5 bones per layer. The tubes were scanned in Skyscan 1172 (Bruker) at a pixel 
size of 6.026µm. The camera used was Hamamatsu 10Mp, X-ray voltage used was 54kV 
and current was 185µA with an exposure time of 1767ms. Two-frame averaging was 
applied with a 360° rotation in 0.28° steps. Images were reconstructed using NRecon 
software (Bruker) with a misalignment compensation of 0.5, ring artefact reduction of 5 
and beam-hardening correction of 40%. 
2.3.3. Decalcification 
Bones were decalcified in a solution of 14% EDTA (VWR, cat. no. 20302.260) for 14 days, 
with the EDTA solution replaced every 3 days. After these 2 weeks, the bones were 
washed with Sorensen’s buffer 3 times to ensure complete removal of the EDTA solution. 
Decalcification was performed at 4°C. 
2.3.4. Osmium tetroxide staining 
Bones were stained with 1% osmium tetroxide solution (equal parts 2% osmium 
tetroxide (Agar Scientific, cat. no. AGR1022) and Sorensen’s buffer). The solution was left 




2.3.5. Osmium tetroxide stained bone µCT scanning 
Bones were embedded in agarose as described above. The tubes were scanned in a 
Skyscan 1172 (Bruker) at a pixel size of 12.055µm. The camera used was Hamamatsu 
10Mp, X-ray voltage used was 54kV and current was 185 µA with an exposure time of 
885ms. Four-frame averaging was applied with a 360° rotation in 0.4° steps. Images 
were reconstructed using NRecon software (Bruker) with a misalignment compensation 
of 0.5, ring artefact reduction of 10 and beam-hardening correction of 40%. 
2.3.6. CTAn analysis 
Once bones had been scanned in batches of 5 in each layer it was required to separate 
each bone into an individual stack of images representing one bone, this was done using 
CTAn software (Bruker). The individual bones were separated into specific regions of 
interest, for calcified bones these regions were the trabecular region and cortical region 
and for osmium-tetroxide-stained bones this was the proximal and distal regions of the 
bone. Specific slice numbers and intensity thresholds used for each bone can been seen 
in the table below. Automated region of interest (ROI) drawing was used according to 
instructions from Bruker161. Analysis of these ROIs in calcified bone was achieved using 
built-in custom processing within CTAn software that covered the most common aspects 
of bone biology. Osmium-stained femurs and humeri were analysed as a whole bone 
whilst tibiae were separated into proximal and distal regions with the boundary defined 
as the junction of the tibia and fibula. 
Region Distance from growth 
plate (slices) 





Trabecular 60 200 65 
Cortex 500 200 70 
BMAT N/A N/A 80 
Table 2.3 – Parameters used for trabecular, cortical and bone marrow adipose 
analysis of bone. 
 
2.4. Transcript analysis 
2.4.1. RNA isolation 
Tissues of interest were frozen on dry ice after being dissected. The tissue was then 
ground to a fine powder using a pestle and mortar whilst continually being submersed in 
liquid nitrogen. To approximately 200mg of this powdered tissue, 600 µl Ribozol (VWR 
Chemicals, 1B1304) was added and the tissue homogenised by repeated aspiration and 
expulsed through a 21G needle attached to a Luer-lock syringe. Following 
homogenisation, a further 600 µl of Ribozol was added and the process of 
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homogenisation repeated. The homogenate was stored at room temperature for 10 
minutes to allow dissociation of nucleoproteins and other macromolecular complexes. 
When adipose tissue, or other tissue with high lipid content, was used, the upper lipid 
layer was removed and replaced with an equivalent volume of Ribozol. Chloroform 
(200µl) was added to the tissue homogenate and the tube shaken for 20 seconds to 
ensure thorough mixing of the sample. The sample was incubated at room temperature 
for 3 minutes then centrifuged at 15,000 rcf for 15 minutes at 4°C. The upper layer was 
transferred to a new Eppendorf containing 700 µl isopropanol, gently mixed by 
inversion and incubated at room temperature for 15 minutes. The samples were stored 
at -20°C overnight then centrifuged at 20,000 rcf for 30 minutes at 4°C in order to pellet 
the RNA. The supernatant was removed from the pellet and discarded. Ethanol (1.5ml, 
75%) was added to the pellet and the sample vortexed to wash the pellet. The sample 
was centrifuged at 12,000 rcf for 5 minutes at 4°C. Following this, the supernatant was 
removed and the wash procedure repeated with final removal of the supernatant and 
subsequent air-drying of the RNA pellet for 5 minutes at room temperature. The pellet 
was resuspended in 50 µl nuclease-free water (Fisher) and RNA concentration and 
purity determined by Nanodrop (1000, ThermoFischer). 
2.4.2. Reverse transcription 
Reverse transcription reactions (50 µl total volume) were performed containing: 1 µg 
RNA (from 2.4.1); Reverse transcription buffer (Life Technologies, N8080234) at 1X 
working concentration; 5.5mM MgCL2 (Sigma, M8266); deoxyadenosine triphosphate, 
deoxyguanosine triphosphate, deoxycytidine triphosphate and deoxythymidine 
triphosphate all at 0.5mM each (GeneAmp dNTP mix, Life Technologies, 430442); 0.83 
µM random hexamers (Life Technologies, SO142); 0.8 U/µL RNase inhibitor (Life 
Technologies, 10859710); and 1.25 U/µL Multiscribe reverse transcriptase (Life 
Technologies, 4311235). The samples were incubated in a thermocycler (Techne) at 
25°C for 10 minutes, 37°C for 30 minutes then 95°C for 5 minutes, resulting in a cDNA 
solution. 
2.4.3. qPCR 
A small aliquot of each set of reverse-transcribed cDNA was pooled to generate a 
representative pooled cDNA from each set of samples. This pooled sample was serially 
diluted with RNase-free water to generate a 3, 9, 27, 81 and 243-fold diluted standard 
series. The individual cDNA samples were diluted 4-fold in RNase-free water to ensure 
their concentration fell within the range of the standard series. 
2.4.3.1. Taqman qPCR 
qPCR reactions were run on 384-well plates (Sarstedt, 72.1985.202) as 10 µl reactions 
each containing: 2 µl diluted cDNA solution; 2.75 µl RNase free water; 5 µl 2x Probe Blue 
Mix buffer (PCR Biosystems), PB20.27-20); and 0.25 µl relevant probe and primer mix 
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(listed in section 2.4.4). Plates were incubated in a Lightcycler 480 (Roche) following a 
program consisting: 
Cycle 1 (x1):  95 ºC for 5-10 minutes; 
Cycle 2 (x50): 95 ºC for 10 seconds 
  60 ºC for 30 seconds 
Cycle 3 (x1): 37 ºC (hold) 
 
2.4.3.2. SYBR green qPCR 
qPCR reactions were run on 384-well plates as 10µl reactions each containing: 2µl 
diluted cDNA solution; 2µl RNase free water; 5µl 2x SyGreen Blue master mix (PCR 
Biosystems, PB20.11) and 0.5µl each of forward and reverse primer (CONC) (listed in 
section 2.4.4). Plate was incubated in a Lightcycler 480 (Roche) following a program 
consisting: 
Cycle 1 (x1):  95 ºC for 10 minutes; 
Cycle 2 (x40): 95 ºC for 10 seconds 
  60 ºC for 30 seconds 
Cycle 3 (x1): Melt curve (65 to 95 ºC, at 0.06 ºC/second); 10 acquisitions per ºC  
Cycle 4 (x1): 37 ºC (hold) 
 
2.4.3.3. qPCR primers 





Supplier Sequence/Catalogue # 




Acadm Taqman ThermoFisher Mm01323360_g1 






Bglap Taqman ThermoFisher Mm03413826_mH 










Pgc1a Taqman ThermoFisher Mm01208835_m1 








Tfam Taqman ThermoFisher Mm00447485_m1 
Table 2.4 – Primers used for qPCR. Primers used are listed in alphabetical order. 
Sybrgreen primers were ordered from a custom oligonucleotide company. All primers 
were tested against a standard curve of cDNA and by melt curve analysis , followed by 
running products on a gel, to ensure reaction specificity. Primers were ordered from 
Integrated DNA Technologies (IDT). 
2.4.4. Analysis 
Cycle threshold (ct) was determined using Lightcycler 480 software (Roche) by second 
derivative of the amplification curves. The ct values of the serial diluted cDNA pool 
(described in section 2.4.3) were plotted against their relative concentration to generate 
a standard curve of ct vs concentration. The relative concentration of the unknown 
samples was interpolated against the standard curve, this relative concentration was 
then used as a measure of cDNA transcript quantity in the sample and thus of relative 
expression of the gene of interest. 
2.5. Lipid analysis 
2.5.1. Triglyceride quantification 
Approximately 100 mg of liver tissue was cut from the frozen liver samples and placed in 
1 ml cooled PBS containing 5% v/v IGEPAL CA-630 (Sigma, I8896) on ice. Tissue was 
homogenised using steel ball bearings and high-frequency shaking and this homogenate 
was centrifuged at 12,000 rcf for 10 minutes at 4°C in order to pellet cell debris. The 
supernatant was removed and transferred to a clean Eppendorf and any lipid that had 
collected on the top was resuspended. Pre-prepared 500 mg/dl triglyceride standard 
(Sigma, 17811-1AMP) was serially diluted to 250, 125, 62.5, 31.25, 15.625 and 
7.8125mg/dl, a solution containing no triglyceride standard was included as a negative 
control. Either the standards or liver samples (2µl) were pipetted into a 96-well plate in 
duplicate. Triglyceride concentrations were determined using reagents from Sentinel 
(Sentinel 17624H).  Solution 1 (200µl) was added to each well and the plate incubated at 
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37°C for 10 minutes. Following this, the absorbance of each well in the plate was 
measured at both 546nm and 700nm. The 546nm reading was subtracted from the 
700nm for each well and then the average absorbance for the blank duplicates was 
subtracted from the average absorbance of the samples and standards duplicates. 
Standard absorption was plotted against concentration and the line of best fit calculated 
using a linear regression model (Graph Pad Prism 7). The concentration of the samples 
was interpolated from this line of best fit and was normalised against the mass of liver 
used at the start of the protocol. 
2.5.2. Plasma NEFA quantification 
Non-esterified fatty acid standard solution (Wako Diagnostics, 276-7649) was serially 
diluted to concentrations; 1, 0.5, 0.25 and 0.125mM as well as a blank solution. The 
standard solution or endpoint core plasma (2µl) was pipetted into a 96 well plate in 
duplicate. Reagent 1 (200µl) (Wako Diagnostics, 999-34691, 995-34791) was added to 
each well and the plate incubated at 37°C for 5 minutes. Absorbance of each well was 
measured at 550 and 660nm. Reagent 2 (100µl) (Wako Diagnostics, 991-34891, 993-
35191) was added to each well and the plate was incubated again at 37°C for 5 minutes 
and the absorbance measured at 550 and 660nm. The 660nm reading was subtracted 
from the 550 reading from both measurements and the mean blank absorbance 
subtracted from the mean duplicate absorbance from each sample. Absorbance of the 
standards was plotted against concentration, the line of best fit calculated using a linear 
regression model (Graph Pad Prism 7), and the concentration of the samples was 
interpolated from this line of best fit. 
2.5.3. Liver ceramide quantification 
This work was performed by Ben Thomas (PhD student, Cawthorn Lab) in collaboration 
with Phil Whitfield at the University of the Highlands and Islands. 
Frozen liver tissue (100 mg) was homogenised in ice-cold MeOH using a tissue 
homogeniser. Fifty µl of each sample was combined with100 µl ceramide 17:0 (1 µM in 
MeOH) and 25 µl dihydroceramide 12:0 (2 µM in MeOH). MeOH (1.875 ml) and CHCl3 (4 
ml) were added and the samples were stored on ice for 1 hour with intermittent vortex 
mixing. The samples were then centrifuged at 2,000 rpm for 5 minutes at 4°C and the 
supernatant collected. KCl (0.9%; 1.45 ml per sample) was added to the previously 
acquired supernatant and the samples were centrifuged again at 2000 rpm for 5 minutes 
at 4°C. The resulting lower phase was collected and evaporated under nitrogen until 
completely dry, then reconstituted in 1 ml CHCl3. Solid phase extraction was performed 
via a 100 mg, 3 ml silica isolute. The column was conditioned with 2 additions of 3 ml 
CHCl3 then loaded with 1 ml of the sample. The bound sample was washed with 2 
washes of 3 ml CHCl3 then eluted with 2 additions of 1:1 ethylacetate CHCl3. The 
collected eluate was evaporated and dried under vacuum and reconstituted in 200 µl 
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MeOH. Two µl were injected into the LC-MS/MS for ceramide analysis and 10 µl for 
dihydroceramide analysis. Liquid chromatography was performed using Phenomenex 
kinetex  C8, particle size: 1.7 µm, pore size 100Å, 100 mm x 2.1 mm (00D-4499-AN). 
Mobile phase A was 90% H2O, 9.9% acetonitrile and 0.1% formic acid. Mobile phase B 
was 99.9% acetonitrile and 0.1% formic acid. The gradient was held at 80% mobile 
phase B for 1 minute then gradually increased to 100% mobile phase B over 15 minutes. 
Mobile phase B at 100% was maintained for 1 minute and then equilibrated to storage 
conditions. The flow rate used was 500 µl per minute at 40°C. This lipid extraction 
protocol is based on a 1957 paper by Folch et al.162 
2.6. Protein analysis 
2.6.1. Protein extraction 
Frozen tissue was ground into a fine powder as described in 2.4.1. Approximately 100 
mg of powdered tissue was mixed with 1 ml protein lysis buffer (1% SDS, 12.7mM EDTA, 
60mM Tris, pH 6.8, 1mM Na3VO4, and 1mM NaF) heated to 90°C. The mixture was passed 
by and down a syringe through a 21G needle to ensure complete homogenisation. The 
homogenate was centrifuged at 14,000 rpm for 15 minutes at 4°C to pellet any un-lysed 
cells or large cell debris and the supernatant was transferred to a new Eppendorf tube. 
Protein concentrations was calculated using Pierce BCA protein assay kit (Thermo 
Fischer Scientific, 23225) according to manufacturer’s instructions. 
2.6.2. Immunoblot assay 
From tissue lysates 1 µg, or from plasm a 1.5µl, was mixed with loading buffer with a 
final concentration of 1% SDS, 10% glycerol, 0.0125% bromophenol blue and 60 mM 
Tris-HCl pH 6.8. Proteins were separated by molecular weight by SDS gel electrophoresis 
through either 4-12% or 12% Bis-Tris polyacrylamide gels (BioRad, 3450125/3450119) 
using Criterion cell running tank and PowerPac power supply (BioRad, 1656019). Gels 
were run until the loading buffer ran off the bottom of the gel, the protein was then 
transferred to PVDF blotting membrane (GE Amersham Hybond, 10600023) using a wet 
transfer using Criterion Blotter (BioRad, 1704070) at 350 mA for 150 minutes at 4°C 
ambient temperature. If required, LiCor total protein stain (LiCor, P/N 926-11010) was 
used to quantify the total protein present in each lane according to manufactures 
instructions. The membrane was then blocked in 5% milk powder (ASDA, 11992) in 
TBST for 1 hour at room temperature then washed 3 times in TBST for 5 minutes per 
wash. The membrane was then incubated with the relevant primary antibody (listed 
below) overnight at 4°C or for 1 hour at room temperature then washed 3 times in TBST. 
The membrane was incubated in secondary antibody (see below) in 5% milk for 1 hour 
at room temperature, washed 3 times and then visualised on LiCor Odyssey CLx 




2.6.3. Antibodies used 
Protein 
epitope 







Table 2.5 – Antibodies used for western blotting.  
 
2.7. Statistical analysis 
Statistical analysis was performed using Graph Pad Prism 7. For analyses comparing the 
interaction of two factors, a 2-way analysis of variance (ANOVA) was used to compare 
the significance of contribution to variance by each factor. Additionally, multiple 
comparisons by Sidak’s test were performed when a particular factor was shown to be a 
significant cause of variance. For non-interactive data with more than two variables, a 1-
way ANOVA was used to test for significant variance with the data, when this was 
detected a Tukey’s multiple comparisons test was used to compare specific groups. For 
non-interactive data only containing 2 variables a student’s T test was used to detect 
significant differences between the 2 groups. A significance threshold of 95% was used 
throughout. 
Power calculations were performed prior to commencement of the experiments to 
determine the preferable number of animals per group. BMAT increase effect size was 
calculated from previous studies but the results showed that the study would require in 
excess of 6o mice. This was not in concordance with previous studies and so the decision 
was made to repeat previously used group sizes which had previously shown 




3. Increased Circulating Adiponectin in 
Response to Thiazolidinediones: 
Investigating the Role of Bone Marrow 
Adipose Tissue 
3.1. Introduction 
Thiazolidinediones (TZD) are a class of pharmacological agents that includes the drugs 
rosiglitazone malate and pioglitazone hydrochloride. These drugs are highly selective 
agonists of peroxisome proliferator-activated receptor gamma (PPARγ)163,164 a nuclear 
hormone receptor that is best known for its effect on adipocyte differentiation and 
regulation of adipogenic and lipogenic pathways165-167. In addition, PPARγ plays an 
important role in glucose and lipid homeostasis by altering the secretion of various 
hormones, including decreasing the concentrations of resistin168, leptin 169 and, 
importantly, increasing circulating adiponectin170. Most of the focus on TZDs relates to 
the antidiabetic, insulin-sensitising effects of the drugs. Rosiglitazone, used in the 
present experiment, is a member of the TZD family and was sold under the trade name 
Avandia171. Rosiglitazone was used in diabetic patients to reduce their blood glucose 
concentrations to near normal levels by increasing sensitivity of muscle, liver and 
adipose tissue to insulin172. Despite these promising effects of rosiglitazone and TZD 
drugs in general, they were pulled from the market. They were shown to significantly 
increase the risk of myocardial infarction and heart failure173. In addition to these 
cardiac issues, TZD treatment has also been associated with bone loss, including reduced 
bone formation rate and increased BMAT volume174. Downstream transcriptional targets 
of PPARγ activation include adiponectin175, IGF-1176, TGFβ177 and fatty acid-binding 
protein 4 (FABP4) 178. 
BMAT volume and adiponectin concentrations increase in response to CR, and BMAT has 
been established to secrete adiponectin and act as a significant source of this hormone 
during CR121. We hypothesised that when BMAT and adiponectin are both increased in 
conditions other than CR, that BMAT would also be a significant source of circulating 
adiponectin. Increases in BMAT volume and hyperadiponectinaemia occur 
simultaneously in a wide variety of conditions including type 1 diabetes153,154 and 
aging179,180. Notably, TZD treatment also causes marked BMAT expansion and 
hyperadiponectinaemia and, like CR, exerts insulin-sensitising effects130,175. Thus, we 
hypothesised that the Ocn-Wnt10b mouse, previously shown to resist CR-induced BMAT 
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expansion, would also resist TZD-induced BMAT expansion and that this would 
attenuate or prevent the induction of hyperadiponectinaemia. 
The initial work for this study was performed at The University of Michigan, the samples 
were subsequently brought to The University of Edinburgh for analysis by me. Some of 
this analysis has been previously submitted for award of an MSc in Cardiovascular 
Biology. Therefore, the following figures comprise data generated as part of this PhD 
thesis: Figures 2 – 5 and 8. Data in Figure 1 was generated by researchers at the 
University of Michigan and data in Figures 6 and 7 was submitted as part of the above 
mentioned MSc. 
  
September 2016 | Volume 7 | Article 1281
Original research
published: 21 September 2016
doi: 10.3389/fendo.2016.00128
Frontiers in Endocrinology | www.frontiersin.org
Edited by: 
Basem M. Abdallah, 
University of Southern Denmark, 
Denmark
Reviewed by: 
Melissa Orlandin Premaor, 
Universidade Federal de 
Santa Maria, Brazil  
Jan Tuckermann, 
University of Ulm, Germany
*Correspondence:
William P. Cawthorn  
w.cawthorn@ed.ac.uk
Specialty section: 
This article was submitted 
to Bone Research, 






Sulston RJ, Learman BS, Zhang B, 
Scheller EL, Parlee SD, Simon BR, 
Mori H, Bree AJ, Wallace RJ, 
Krishnan V, MacDougald OA and 
Cawthorn WP (2016) Increased 
Circulating Adiponectin in 
Response to Thiazolidinediones: 
Investigating the Role of Bone 
Marrow Adipose Tissue. 
Front. Endocrinol. 7:128. 
doi: 10.3389/fendo.2016.00128
increased circulating adiponectin in 
response to Thiazolidinediones: 
investigating the role of Bone 
Marrow adipose Tissue
Richard J. Sulston1, Brian S. Learman2, Bofeng Zhang2, Erica L. Scheller2,  
Sebastian D. Parlee2, Becky R. Simon3, Hiroyuki Mori2, Adam J. Bree2, Robert J. Wallace4, 
Venkatesh Krishnan5, Ormond A. MacDougald2,3,6 and William P. Cawthorn1,2,5*
1 University/British Heart Foundation Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University 
of Edinburgh, Edinburgh, UK, 2 Department of Molecular & Integrative Physiology, University of Michigan Medical School, 
Ann Arbor, MI, USA, 3 Program in Cellular and Molecular Biology, University of Michigan Medical School, Ann Arbor, MI, USA, 
4 Department of Orthopaedics, University of Edinburgh, Edinburgh, UK, 5 Musculoskeletal Research, Lilly Research 
Laboratories, Indianapolis, IN, USA, 6 Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, 
USA
Background: Bone marrow adipose tissue (MAT) contributes to increased circulating 
adiponectin, an insulin-sensitizing hormone, during caloric restriction (CR), but whether 
this occurs in other contexts remains unknown. The antidiabetic thiazolidinediones 
(TZDs) also promote MAT expansion and hyperadiponectinemia, even without increasing 
adiponectin expression in white adipose tissue (WAT).
Objectives: To test the hypothesis that MAT expansion contributes to TZD-associated 
hyperadiponectinemia, we investigated the effects of rosiglitazone, a prototypical TZD, in 
wild-type (WT) or Ocn-Wnt10b mice. The latter resist MAT expansion during CR, leading 
us to postulate that they would also resist this effect of rosiglitazone.
Design: Male and female WT or Ocn-Wnt10b mice (C57BL/6J) were treated with or 
without rosiglitazone for 2, 4, or 8 weeks, up to 30 weeks of age. MAT content was 
assessed by osmium tetroxide staining and adipocyte marker expression. Circulating 
adiponectin was determined by ELISA.
results: In WT mice, rosiglitazone caused hyperadiponectinemia and MAT expansion. 
Compared to WT mice, Ocn-Wnt10b mice had significantly less MAT in distal tibiae and 
sometimes in proximal tibiae; however, interpretation was complicated by the leakage 
of osmium tetroxide from ruptures in some tibiae, highlighting an important technical 
consideration for osmium-based MAT analysis. Despite decreased MAT in Ocn-Wnt10b 
mice, circulating adiponectin was generally similar between WT and Ocn-Wnt10b mice; 
however, in females receiving rosiglitazone for 4  weeks, hyperadiponectinemia was 
significantly blunted in Ocn-Wnt10b compared to WT mice. Notably, this was also the 
only group in which tibial adiponectin expression was lower than in WT mice, suggesting 
a close association between MAT adiponectin production and circulating adiponectin. 
However, rosiglitazone significantly increased adiponectin protein expression in WAT, 
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suggesting that WAT contributes to hyperadiponectinemia in this context. Finally, 
rosiglitazone upregulated uncoupling protein 1 in brown adipose tissue (BAT), but this 
protein was undetectable in tibiae, suggesting that MAT is unlikely to share thermogenic 
properties of BAT.
conclusion: TZD-induced hyperadiponectinemia is closely associated with increased 
adiponectin production in MAT but is not prevented by the partial loss of MAT that 
occurs in Ocn-Wnt10b mice. Thus, more robust loss-of-MAT models are required for 
future studies to better establish MAT’s elusive functions, both on an endocrine level and 
beyond.
Keywords: bone marrow adipose tissue, white adipose tissue, brown adipose tissue, thiazolidinedione, 
rosiglitazone, adiponectin, beige adipocyte, UcP1
inTrODUcTiOn
Adipose tissue is typically classified into two broad subtypes, white 
adipose tissue (WAT) and brown adipose tissue (BAT). WAT is 
commonly known for its role in energy storage and release and is 
now established as a major endocrine organ. BAT also mediates 
some endocrine functions but is more widely known for its ability 
to mediate adaptive thermogenesis (1). Through these functions, 
both WAT and BAT impact metabolic homeostasis; hence, the 
global burden of obesity and metabolic disease has motivated 
extensive study of these tissues (2).
In addition to WAT and BAT, adipocytes also exist in the 
bone marrow, and such marrow adipose tissue (MAT) has been 
estimated to account for over 10% of total adipose tissue mass in 
lean, healthy humans (3). We recently revealed that MAT char-
acteristics are region-specific, such that MAT can be classified 
into two broad subtypes: regulated MAT (rMAT), which exists 
in more proximal skeletal sites and consists of adipocytes inter-
spersed with hematopoietic BM; and constitutive MAT (cMAT), 
which exists in more distal regions (e.g., distal tibia, caudal 
vertebrae) and appears histologically similar to WAT, with few 
visible hematopoietic cells (4). These MAT subtypes also differ in 
their lipid composition and response to external stimuli (4). Both 
rMAT and cMAT appear to be developmentally and functionally 
distinct to WAT and BAT, and therefore MAT may represent a 
third general class of adipose tissue (5, 6). Despite these advances, 
knowledge of MAT formation and function remains relatively 
limited (2). However, research from others and us suggests that, 
like WAT, MAT is an endocrine organ that can exert local and 
systemic effects (3, 7).
The appreciation of WAT as an endocrine organ derives largely 
from the discovery in the mid-1990s of two adipocyte-derived 
hormones, leptin and adiponectin, each of which impacts meta-
bolic homeostasis (8–10). These two hormones have since been 
mentioned in over 40,000 publications, reflecting the extensive 
depth of WAT research. Circulating leptin concentrations corre-
late directly with body fat percentage and are therefore increased 
in obesity. In contrast, adiponectin concentrations are decreased 
in obesity and insulin-resistance; hence, hypoadiponectinemia is 
now an established biomarker for increased risk of cardiometa-
bolic disease. Conversely, circulating adiponectin is elevated in 
conditions of leanness and insulin sensitivity, such as during 
caloric restriction (CR) (2). This counterintuitive observation has 
been dubbed the “adiponectin paradox”: why should circulating 
adiponectin increase when the amount of WAT, the presumed 
source of adiponectin, is decreased? Moreover, CR can cause 
hyperadiponectinemia without increasing expression or secre-
tion of adiponectin from WAT (2), suggesting that other tissues 
contribute to this effect. Our recent research has highlighted a 
potential explanation for this paradox, revealing, unexpectedly, 
that MAT is a source of circulating adiponectin during CR (3).
Our studies into MAT and CR were motivated by the striking 
observation that, in contrast to WAT and BAT, MAT accumu-
lates during CR (3, 11, 12). The biochemical phenotype of this 
CR-responsive MAT remains to be elucidated; however, we 
have since shown that these increases occur predominantly in 
regions of rMAT rather than cMAT (2). This phenomenon led 
us to investigate if MAT contributes to increased circulating 
adiponectin during CR. After confirming that MAT expresses 
and secretes adiponectin (3), we then tested if MAT accumula-
tion is required for CR-associated hyperadiponectinemia. To do 
so, we used Ocn-Wnt10b mice, a transgenic model in which the 
secreted ligand, Wnt10b, is expressed in osteoblasts from the Ocn 
promoter (13). Because Wnt10b simulates osteoblastogenesis and 
inhibits adipogenesis, these mice have increased bone formation 
and decreased bone marrow volume (3, 13). We found that 
Ocn-Wnt10b mice also resist CR-associated MAT expansion, 
both in rMAT and cMAT (2, 3). Notably, hyperadiponectinemia 
during CR is also blunted in these mice, despite no differences 
in adiponectin expression in WAT (3). Finally, impaired MAT 
expansion also coincides with blunted hyperadiponectinemia 
in a separate mouse model of CR (14) and during CR in rabbits 
(12). Together, these observations suggest that MAT expansion is 
required for CR-induced hyperadiponectinemia, supporting the 
conclusion that MAT is a source of circulating adiponectin in this 
context.
To further investigate this endocrine function, we sought 
to determine if MAT also influences circulating adiponectin 
beyond CR. For example, increases in both MAT and circulating 
adiponectin occur in many other conditions, including aging, 
estrogen deficiency, type 1 diabetes, cancer treatment, and in 
response to fibroblast growth factor-21 or glucocorticoid therapy 




fed Western diet 
(D12450B)
ages (weeks)  
fed TZD diet 
(D12112601)
group sizes for each sex 
and genotype
0 22–30 N/A WT male, 5; Ocn-Wnt10b 
male, 5
WT female, 6; Ocn-Wnt10b 
female, 4
2 22–28 28–30 WT male, 3; Ocn-Wnt10b 
male, 7
WT female, 5; Ocn-Wnt10b 
female, 3
4 22–26 26–30 WT male, 5; Ocn-Wnt10b 
male, 5
WT female, 5; Ocn-Wnt10b 
female, 3
8 N/A 22–30 WT male, 5; Ocn-Wnt10b 
male, 5
WT female, 4; Ocn-Wnt10b 
female, 5
3
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(2). Notably, these increases also coincide during treatment with 
thiazolidinediones (TZDs), a class of insulin-sensitizing, antidia-
betic drugs that act as agonists for the nuclear hormone receptor, 
peroxisome proliferator-activated receptor gamma (PPARγ) (15, 
16). Binding and subsequent activation of PPARγ causes it to 
activate the expression of its transcriptional targets, including 
adiponectin and other lipid-metabolism-associated genes such 
as fatty acid-binding protein 4 (Fabp4) (17). Thus, TZDs, such 
as rosiglitazone, significantly increase circulating adiponectin 
in rodent models and human patients (18, 19). Importantly, 
preclinical studies suggest that such hyperadiponectinemia is 
required for the full insulin-sensitizing effects of TZDs (20). 
Despite the beneficial effects of TZDs in improving glucose toler-
ance, their clinical use has been restricted owing to increased risk 
of myocardial infarction and bone fractures (21, 22); the latter 
may relate to the ability of TZDs to drive MAT expansion. If so, 
MAT expansion may be detrimental to the clinical utility of these 
drugs. However, it is notable that TZDs can increase circulating 
adiponectin without increasing adiponectin expression in WAT 
(23, 24), and that some studies suggest that TZD action is inde-
pendent of WAT (25). Thus, given the contribution of MAT to 
increased circulating adiponectin during CR, we hypothesized 
that MAT also contributes to TZD-induced hyperadiponectine-
mia. If so, MAT expansion may play a role in the beneficial 
insulin-sensitizing effects of TZDs.
Herein, we investigated this hypothesis by feeding wild-type 
(WT) and Ocn-Wnt10b mice a Western diet to induce obesity and 
glucose intolerance, followed by treatment with rosiglitazone, a 
prototypical TZD. We postulated that, as in CR, these mice would 
resist TZD-induced MAT expansion. As secondary analyses, we 
also investigated the contribution of WAT to TZD-mediated 
hyperadiponectinemia and the possibility, suggested previously 
(26), that MAT has BAT-like properties. Our results shed light 
on MAT’s characteristics and highlight technical considerations 
that will be important for future research into MAT formation 
and function.
MaTerials anD MeThODs
animals and animal care
Ocn-Wnt10b mice (Wnt10b) or non-transgenic controls (WT) 
were on a C57BL/6J background and were bred in-house, as 
described previously (13). The University of Michigan Committee 
on the Use and Care of Animals approved all animal experiments, 
with daily care of mice and rabbits overseen by the Unit for 
Laboratory Animal Medicine (ULAM).
Diets and rosiglitazone (TZD) Treatment
Male WT (n = 18), male Wnt10b (n = 22), female WT (n = 20), 
and female Wnt10b (n = 15) mice were fed a standard labora-
tory chow diet (Research Diets, D12450B) from weaning until 
10 weeks of age. From 10 to 22 weeks of age, all mice were fed a 
high-fat, high-sucrose Western diet (Research Diets D12079B), 
with the goal of promoting diet-induced obesity and glucose 
intolerance. The rationale for this was that, if Ocn-Wnt10b mice 
resisted hyperadiponectinemia, they might also be less responsive 
to the metabolic effects of TZD treatment. Thus, mice were fed 
a Western diet prior to TZD treatment, with the aim of allowing 
detection of metabolic improvements upon TZD administration. 
At 18 weeks of age, mice were fasted overnight; body mass and 
fasting glucose were then recorded and body fat, lean mass, 
and free fluid were measured in conscious mice using an NMR 
analyzer (Minispec LF90II; Bruker Optics, Billerica, MA, USA). 
These measurements were then used as a basis to assign mice 
to four evenly matched groups (with similar body mass, fat 
mass, and fasting glucose), with each group corresponding to a 
different duration of rosiglitazone (TZD) treatment. Mice were 
then treated with or without TZD from 22 to 30 weeks of age. 
TZD was administered in the diet (Research Diets D12112601) 
by supplementing diet D12450B with rosiglitazone at 0.175 mg/g 
diet; based on daily consumption of D12450B, this concentration 
was estimated to give a final dose per mouse of 15 mg/kg body 
mass per day. This approach is similar to that used in previous 
studies investigating rosiglitazone-induced MAT accumulation 
(26–28). The four experimental groups were as follows: control 
mice (0 weeks’ TZD), which continued to receive Western diet 
D12079B from 22 to 30 weeks of age; 2 weeks’ TZD mice, which 
received D12079B from 22 to 28 weeks and D12112601 from 28 
to 30 weeks; 4 weeks’ TZD mice, which received D12079B from 
22 to 26 weeks and D12112601 from 26 to 30 weeks; and 8 weeks’ 
TZD mice, which received D12112601 from 22 to 30  weeks. 
Numbers of mice per group and diet durations are described 
further in Table 1. At 29.5 weeks of age, blood glucose concentra-
tions were recorded after an overnight fast to assess the effects of 
TZD treatment. At 30  weeks of age, serum was sampled, mice 
were humanely euthanized, and tissues were isolated for further 
analysis.
Blood collection and serum  
adiponectin analysis
Blood was sampled from the lateral tail vein of mice using 
Microvette CB 300 capillary collection tubes (Sarstedt, Newton, 
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NC, USA). Blood glucose was measured using an Accu-Chek 
Aviva glucometer. To obtain serum, blood samples were allowed 
to clot on ice for 2 h before centrifuging at 3,800 RCF for 5 min 
at 4°C. Serum adiponectin was determined using an ELISA kit 
(catalog no. MRP300) from R&D Systems (Bio-Techne Ltd., 
Abingdon, UK) according to the manufacturer’s instructions.
Osmium Tetroxide staining  
and μcT analysis
Tibiae were isolated and, after removal of external soft tissue, fixed 
in formalin at 4°C. Fixed tibiae were decalcified in 14% EDTA for 
14 days and then washed in Sorensen’s Phosphate buffer (81 mM 
KH2PO4, 19  mM Na2HPO4  ⋅  7H2O, pH 7.4). Decalcified tibiae 
were stored in Sorensen’s Phosphate buffer at 4°C until ready to be 
stained with osmium tetroxide. To do so, osmium tetroxide solu-
tion (2% w/v; Agar Scientific, UK) was diluted 1:1 in Sorensen’s 
Phosphate buffer. Tibiae were then stained in this 1% osmium 
tetroxide solution for 48  h at room temperature, then washed, 
and stored in Sorensen’s Phosphate buffer at 4°C prior to micro 
computed tomography (μCT) analysis.
Micro computed Tomography analysis
Layers of four to five stained tibiae were arranged in parallel 
in 1% agarose in a 30-mL universal tube and mounted in a 
Skyscan 1172 desktop micro CT (Bruker, Kontich, Belgium). 
The samples were then scanned through 360° using a step of 
0.40° between exposures. A voxel resolution of 12.05  μm was 
obtained in the scans using the following control settings: 54 kV 
source voltage, 185  μA source current with an exposure time 
of 885 ms. A 0.5-mm aluminum filter and two-frame averaging 
were used to optimize the scan. After scanning, the data were 
reconstructed using Skyscan software NRecon v1.6.9.4 (Bruker, 
Kontich, Belgium). The reconstruction thresholding window 
was optimized to encapsulate the target image. Volumetric 
analysis was performed using CT Analyser v1.13.5.1 (Bruker, 
Kontich, Belgium).
real-time Quantitative Pcr
RNA was extracted from tissue using RNA STAT60 reagent (Tel-
Test, Inc.) according to the manufacturer’s instructions. Synthesis 
of cDNA was done using TaqMan reverse transcription reagents 
(Thermo Fisher Scientific) using 1 μg of RNA template per reac-
tion, as per manufacturer’s instructions. Transcript expression 
was then analyzed by quantitative PCR (qPCR) in 10 μL duplicate 
reactions using qPCRBIO SyGreen Mix (part number PB20.11; 
PCR Biosystems, UK) and 1–4 μL of cDNA template. Reactions 
were loaded into 384-well qPCR plates (part number 72.1985.202; 
Sarstedt, UK) and run on a Light Cycler 480 (Roche). Transcript 
expression was calculated based on a cDNA titration loaded on 
each plate and was presented relative to expression of the house-
keeping gene Ppia. Primers for Adipoq and Ppia were described 
and validated previously (3).
immunoblot analysis
Frozen tissue was processed as described previously (12). The 
resulting protein lysates were separated by size using gradient 
(4–12%) polyacrylamide gels (BioRad). Protein was then trans-
ferred to Immobilon-FL membrane (Millipore) for 150  min at 
350  mA, 4°C, using a Criterion wet-transfer system (BioRad). 
Post-transfer, the membranes were blocked in 5% milk for 1 h at 
room temperature, then immunoblotted with primary antibody 
in 5% bovine serum albumin overnight at 4°C. Membranes were 
then incubated in 1:15,000-diluted fluorescently labeled second-
ary antibody (LiCor) for 1  h at room temperature. Signal was 
detected using the LiCor Odyssey system and band intensities 
quantified using LiCor Image Studio Lite software. The following 
primary antibodies were used: rabbit anti-adiponectin antibody 
(Sigma, A6354-200UL) diluted 1:1,000 in 5% BSA; rabbit anti-
uncoupling protein 1 (UCP1) antibody (Sigma, U6382) diluted 
1:10,000 in 2.5% milk; and rabbit anti-β-actin antibody (Abcam, 
ab8227) diluted 1:1,000 in 5% BSA.
Data Presentation and statistical analysis
Data are presented as box and whisker plots overlaid with 
individual data points for each animal. Boxes indicate the 25th 
and 75th percentiles; whiskers display the range; and horizontal 
lines in each box represent the median. Group sizes are described 
in Table 1. Statistical analysis was done using GraphPad Prism 
6 software, with significant differences assessed by two-way 
ANOVA using a Tukey or Sidak post hoc test for multiple com-
parisons, as appropriate. A P-value <0.05 was considered statisti-
cally significant. A significant influence of TZD treatment, across 
all treatment groups, is indicated by †. For multiple comparisons, 
asterisks (*) indicate significant differences between genotypes 
within each TZD group, while hash signs (#) indicate significance 
between TZD-treated and non-TZD-treated controls within each 
genotype.
resUlTs
effects of TZD on WaT Mass and Fasting 
glucose Do not Differ between WT and 
Ocn-Wnt10b Mice
Circulating adiponectin is decreased in states of obesity and 
glucose intolerance (29), while TZDs modulate both fat mass 
and glucose homeostasis. Therefore, after treating WT and Ocn-
Wnt10b mice with or without rosiglitazone for 2, 4, or 8 weeks, we 
first assessed body mass, fat mass, and fasting glucose, primarily 
as readouts of TZD action but also as parameters that might 
influence circulating adiponectin. While body masses of female 
or male mice did not differ with TZD treatment (Figures 1A,C), 
across both genotypes, TZD was associated with significant loss of 
gonadal WAT (gWAT), a visceral adipose depot, in both females 
(P = 0.027) and males (P = 0.006) (Figures 1B,D). Conversely, 
the mass of inguinal WAT (iWAT), a subcutaneous depot, sig-
nificantly increased with TZD treatment in males (P  =  0.002) 
(Figure 1D). Analysis of fasting glucose revealed no effects of TZD 
in female mice (Figure 1E), whereas TZD significantly decreased 
fasting glucose across WT and Ocn-Wnt10b males (Figure 1F). 
These findings are consistent with previous studies demonstrat-
ing that rosiglitazone decreases gWAT mass (26, 27), increases 
subcutaneous WAT (30), and ameliorates hyperglycemia (16); 
FigUre 1 | effects of rosiglitazone on body mass, fat mass, and fasting glucose. Male and female mice were fed a control Western diet only or a Western 
diet supplemented with rosiglitazone for 2, 4, or 8 weeks, as described in Section “Materials and Methods.” (a,c) Body masses of females (a) and males (c) were 
recorded prior to necropsy at 30 weeks of age. (B,D) Masses of iWAT and gWAT were recorded at necropsy for female (B) and male mice (D) and are shown as 
percentage of total body mass. (e,F) Fasting blood glucose, as recorded at 29.5 weeks of age. For (a–F), a significant influence of TZD treatment, across all 
treatment groups, is indicated by † (P < 0.05), †† (P < 0.01) or ††† (P < 0.001). Within each genotype, significant differences between untreated controls (0-week 
TZD) and individual durations of TZD treatment are indicated by ### (P < 0.001). Within each TZD treatment group (0-, 2-, 4-, or 8-week TZD), there were no 
statistically significant differences between WT and Ocn-Wnt10b mice.
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however, it is unclear why rosiglitazone influenced iWAT mass 
and fasting glucose in males but not in females. In contrast to 
these effects of rosiglitazone, body mass, WAT mass, or fasting 
glucose did not differ between WT and Ocn-Wnt10b mice within 
each TZD treatment group (Figures 1A–F). Thus, differences in 
peripheral adiposity or glucose homeostasis, which can influence 
circulating adiponectin, did not occur between WT and Ocn-
Wnt10b mice.
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TZD increases rMaT and cMaT Volume in 
WT Mice, and These effects are Partially 
Blunted in Ocn-Wnt10b Mice
Having characterized these peripheral metabolic parameters, 
we next investigated the impact of TZD on MAT expansion and 
whether this differs between WT and Ocn-Wnt10b mice. To 
do so, we first used an approach based on staining tibiae with 
osmium tetroxide, which covalently binds to unsaturated lipids 
within bone marrow and thereby acts as a strong contrast agent 
for MAT detection by μCT (31). As shown in Figure 2A, osmium 
staining in the proximal diaphysis, corresponding to rMAT, was 
markedly increased in females of both genotypes following 4- or 
8-week TZD treatment. Statistical analyses confirmed that, across 
all groups of females, TZD significantly influenced the volume 
of rMAT, as well as that of cMAT and total MAT (P < 0.0001 for 
each) (Figures 2B,C). Multiple comparisons were then made to 
assess the effect of each duration of TZD treatment in each geno-
type of mice, relative to untreated controls. This revealed that, in 
female WT mice, TZD treatment for 4 or 8 weeks significantly 
increased rMAT volume in proximal tibiae and cMAT volume 
in distal tibiae (Figures  2A,B). Thus, total tibial MAT volume 
was also significantly increased by 4- or 8-week TZD in WT 
females (Figure 2C). Similar effects of TZD were also observed 
in Ocn-Wnt10b females (Figures 2A–C), and rMAT volume did 
not significantly differ between genotypes (Figure 2B). However, 
cMAT volume was markedly lower in Ocn-Wnt10b females within 
each TZD treatment group (Figure 2B). Total tibial MAT volume 
was also significantly decreased in Ocn-Wnt10b compared to WT 
females following 8 weeks’ TZD (Figure 2C).
Compared to the female mice, osmium staining was less 
pronounced in the rMAT of TZD-treated males (Figure  2D). 
Nevertheless, statistical analysis across all groups of males 
revealed a significant influence of TZD on the volumes of rMAT 
(P = 0.0015), cMAT (P = 0.0006), and total MAT (P = 0.0003) 
(Figures  2E,F). Multiple comparisons further revealed that, in 
WT males, treatment with TZD for 8  weeks, but not shorter 
durations, significantly increased volumes of rMAT, cMAT, and 
total MAT (Figures 2E,F). This also occurred for cMAT and total 
MAT, but not rMAT, in Ocn-Wnt10b males (Figures 2E,F). As 
found for female mice, male Ocn-Wnt10b mice had significantly 
decreased cMAT volume compared to their WT counterparts 
(Figure 2E), and this also occurred for total MAT volume in the 
0-, 4-, and 8-week TZD groups (Figure 2F).
cortical Bone ruptures significantly 
Decrease Detectable rMaT Volume
The above observations suggest that Ocn-Wnt10b males 
and females partially resist TZD-induced MAT expansion, 
predominantly as a result of a lower cMAT volume than WT 
mice. Indeed, rMAT volume did not differ between genotypes 
in any of the TZD treatment groups. However, when analyzing 
the μCT scans, we noticed that the decalcified cortical bone had 
ruptured in tibiae from all male mice and in a subset of females. 
The ruptures always occurred in proximal tibial diaphysis, as 
indicated by representative scans of non-ruptured (intact) and 
ruptured tibiae (Figure 3A). Cross sections show that ruptures 
allowed escape of the bone marrow, resulting in decreased 
osmium staining compared to intact tibiae (Figure  3A). This 
loss of signal suggests that the ruptures might have confounded 
measurement of MAT volume. To address this, we quantified 
the volumes of cMAT, rMAT, and total MAT in female tibiae, 
comparing bones from non-TZD-treated mice (all of which 
were intact) with intact or ruptured bones from TZD-treated 
mice. The volume of cMAT did not differ between intact and 
ruptured bones (Figure 3B), indicating that these ruptures did 
not affect detection of cMAT in the distal tibia. However, in 
TZD-treated WT mice, the detectable volume of rMAT and total 
MAT was significantly lower in ruptured compared to intact 
bones (Figure 3B). Indeed, in both WT and Ocn-Wnt10b mice, 
TZD-induced expansion of rMAT and total MAT was strongly 
significant for intact bones, but not when ruptures were present 
(Figure 3B). This impaired rMAT detection likely explains why 
TZD-induced rMAT expansion was less marked in male than in 
female mice (Figure 2B vs. Figure 2E), because all male bones 
were ruptured. Importantly, for intact tibiae, TZD-induced 
expansion of rMAT and total MAT was significantly blunted in 
Ocn-Wnt10b compared to WT mice (Figure 3B). This suggests 
that, in addition to decreased cMAT (Figures  2B,E), Ocn-
Wnt10b mice are at least mildly resistant to rMAT expansion 
during TZD treatment.
adipocyte Transcript expression in Tibiae 
confirms TZD-induced MaT expansion
Given the confounding influence of these bone ruptures, we 
next pursued other approaches to further assess tibial MAT 
content. MAT expansion during CR or rosiglitazone treatment 
has previously been monitored by qPCR analysis of adipocyte 
marker expression in intact bones, including transcripts for 
adiponectin (Adipoq) and fatty acid-binding protein 4 (Fabp4) 
(3, 26). Thus, we next used qPCR to assess Adipoq and Fabp4 
expression in whole tibiae. As shown in Figures 4A–D, across 
all groups of female or males, expression of Adipoq and Fabp4 
was significantly affected by TZD treatment (P  <  0.0001 for 
each). Multiple comparisons confirmed that 4- or 8-week 
TZD significantly increased Adipoq in WT males and females 
(Figures 4A,C) and Fabp4 in males and females of each genotype 
(Figures  4B,D). TZD treatment for 2  weeks was also associ-
ated with increased Adipoq in Ocn-Wnt10b males (Figure 4C); 
increased Fabp4 in WT females (Figure  4B); and increased 
Fabp4 in males of each genotype (Figure  4D). Transcript 
expression within each TZD treatment group generally did not 
differ between WT and Ocn-Wnt10b mice, with the exception 
of decreased Adipoq in 4-week TZD females (Figure 4A) and 
decreased Fabp4 in 8-week TZD males (Figure 4D). However, 
two-way ANOVA revealed that genotype significantly influ-
enced Fabp4 in females (P = 0.0184) and males (P = 0.0339), 
while there was a significant genotype–TZD interaction that 
influenced Adipoq expression in females (P  =  0.0193) and 
males (P = 0.0297).
Collectively, these results suggest that TZD increases tibial 
adipocyte content and that there is some level of resistance to 
this effect in Ocn-Wnt10b mice. Thus, together with the osmium 
FigUre 2 | rosiglitazone increases rMaT and cMaT volume in WT mice and cMaT expansion is blunted in Ocn-Wnt10b mice. Male and female tibiae 
were dissected at necropsy. For each mouse, one tibia was decalcified in EDTA, stained with 1% osmium tetroxide, and analyzed by μCT scanning, as described in 
Section “Materials and Methods.” (a,D) Representative μCT scans of stained tibiae from female (a) and male mice (D). The dashed line indicates the tibia–fibula 
junction as the boundary between rMAT and cMAT. (B,c,e,F) For female (B,c) and male mice (e,F), μCT scans were used to determine the volumes of rMAT 
(proximal to tibia–fibula junction), cMAT (distal to tibia–fibula junction), and total MAT (whole tibia), as indicated. In (B,e), volumes of rMAT and cMAT are presented 
on the same y-axis scale. A significant influence of TZD treatment, across all treatment groups, is indicated by † (P < 0.05), †† (P < 0.01) or ††† (P < 0.001). Within 
each genotype, significant differences between TZD-treated mice and untreated controls are indicated by # (P < 0.05), ## (P < 0.01) or ### (P < 0.001). Within 
each TZD treatment group, statistically significant differences between WT and Ocn-Wnt10b mice are indicated by * (P < 0.05), ** (P < 0.01), or *** (P < 0.001).
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FigUre 3 | cortical bone ruptures significantly decrease detectable rMaT volume. All male and some female tibiae had ruptured cortical bone near the 
proximal end, causing a large reduction in signal. (a) Representative 3D models of intact (non-ruptured) and ruptured tibiae from 8-week-TZD-treated females, with 
cross-sectional images showing loss of MAT signal (dark regions within bone marrow cavity). Gray squares across the 3D models indicate the slices from which 
cross-sectional images are taken. Scale bars = 500 μm. (B) Tibiae from female WT or Ocn-Wnt10b mice were categorized into bones from mice untreated with 
TZD, all of which were intact; intact bones from TZD-treated mice; and ruptured bones from TZD-treated mice. The volume of cMAT, rMAT, and total MAT in these 
bones was determined from μCT scans. Statistically significant differences between untreated (intact), TZD-treated (intact), and TZD-treated (ruptured) samples are 
indicated by ## (P < 0.01) or ### (P < 0.001). Within each group, statistically significant differences between WT and Ocn-Wnt10b mice are indicated by  
* (P < 0.05), ** (P < 0.01), or *** (P < 0.001).
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tetroxide analyses of MAT volume (Figures  2 and 3), it seems 
likely that Ocn-Wnt10b mice partially resist TZD-induced MAT 
expansion, but this is not prevented entirely.
TZD induces hyperadiponectinemia  
to a similar extent in WT and  
Ocn-Wnt10b Mice
Given this mild resistance of Ocn-Wnt10b mice to MAT expan-
sion, we next investigated if TZD-induced hyperadiponectinemia 
was altered in these mice. To do so, we used an ELISA to measure 
serum adiponectin concentrations. Across both genotypes 
and all TZD groups, treatment with TZD was associated with 
significantly increased circulating adiponectin (P  <  0.0001 for 
males or females) (Figure  5). Genotypic differences were not 
detected in males; however, in females, there was a significant 
influence of genotype (P = 0.0466) and a significant interaction 
between genotype and TZD treatment (P = 0.0248), indicating 
that effects of TZD differ between WT and Ocn-Wnt10b females. 
Consistent with this, multiple comparisons showed significantly 
FigUre 5 | TZD induces hyperadiponectinemia to a similar extent in WT and Ocn-Wnt10b mice. Serum was isolated from mice at 30 weeks of age and 
ELISA used to determine concentrations of total adiponectin in female and male mice, as indicated. For each sex, statistical significance for the influence of TZD 
across all groups, and for differences between TZD-treated and untreated mice (within each genotype) or WT and Ocn-Wnt10b mice (within each TZD group), are 
presented as described for Figure 2.
FigUre 4 | TZD increases adipocyte marker expression in tibiae, suggesting MaT expansion. Male and female tibiae were dissected at necropsy, and total 
RNA was isolated from one tibia of each mouse. Expression of Adipoq (a,c) and Fabp4 transcripts (B,D) in female and male mice was determined by qPCR and is 
presented normalized Ppia mRNA expression. Statistical significance is presented, as described in Figure 2, for the influence of TZD across all groups, and for 
differences between TZD-treated and untreated mice (within each genotype) or WT and Ocn-Wnt10b mice (within each TZD group).
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decreased circulating adiponectin in Ocn-Wnt10b compared 
to WT females following 4 weeks’ TZD (Figure 5). Thus, while 
TZD-induced hyperadiponectinemia was similar between WT 
and Ocn-Wnt10b males, this effect of TZD was mildly blunted in 
female Ocn-Wnt10b mice.
TZD increases adiponectin Protein 
expression in WaT
The above observations demonstrate that, despite having 
significantly decreased cMAT and being partially resistant to 
TZD-induced rMAT expansion, Ocn-Wnt10b mice undergo 
FigUre 6 | rosiglitazone treatment or Wnt10b transgene expression does not alter adiponectin transcript expression in WaT. At necropsy, iWAT and 
gWAT were dissected, and total RNA was isolated from portions of each tissue. Expression of Adipoq in female (a) and male mice (B) was determined by qPCR 
and is presented normalized Ppia mRNA expression. Across all groups, statistically significant effects of TZD are presented as described for Figure 2, while 
significant effects of genotype are described in the text. There were no statistically significant differences between TZD-treated and untreated mice (within each 
genotype) or between WT and Ocn-Wnt10b mice (within each TZD group), as determined by two-way ANOVA.
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hyperadiponectinemia to a similar extent to their WT counter-
parts. Thus, factors beyond MAT might have a greater influence 
over TZD-induced hyperadiponectinemia. To address this pos-
sibility, we next investigated the effects of TZD and genotype on 
adiponectin expression in WAT. In WT and Ocn-Wnt10b females, 
TZD did not influence Adipoq expression in iWAT or gWAT, 
either when comparing individual treatment durations or when 
effects were assessed across all groups (Figure 6A). However, in 
female iWAT, Adipoq transcripts varied significantly by genotype 
(P = 0.0095), with expression diverging as TZD duration increased 
(Figure 6A). Given that Wnt10b transgene expression is restricted 
to osteoblasts, this genotypic difference in WAT was unexpected. 
Across all groups of males, TZD treatment had a minor influence 
on Adipoq transcript levels in both iWAT and gWAT (P = 0.0269 
and P  =  0.0461, respectively), although multiple comparisons 
found no significant effects of TZD between individual treatment 
groups (Figure  6B). As for females, male iWAT also exhibited 
genotypic variation (P =  0.0096), although in this case Adipoq 
expression tended to be greater in Ocn-Wnt10b than in WT mice 
(Figure 6B).
These findings show that WAT Adipoq expression is influenced 
only modestly by TZD, in contrast to the marked TZD-mediated 
increases in circulating adiponectin (Figure 5). Indeed, our above 
observations in female mice are consistent with previous reports 
demonstrating that TZDs can increase circulating adiponectin 
without increasing Adipoq expression in WAT (23, 24). However, 
other studies have reported a disparity between adiponectin 
expression at the transcript and protein level (32, 33). Therefore, 
we next used fluorescence-based immunoblotting to detect and 
quantify adiponectin protein expression. As shown in Figure 7A, 
across all groups of female mice, there was a significant influence 
of TZD on adiponectin protein expression in iWAT and gWAT 
(P  <  0.0001 for both), with adiponectin typically increased 
in WAT of TZD-treated mice compared to untreated controls. 
Multiple comparisons further confirmed that, for females of each 
genotype, TZD treatment for 2 or 8 weeks significantly increased 
adiponectin protein in gWAT or iWAT, respectively (Figure 7A). 
As for females, across all groups of male mice, TZD had a signifi-
cant influence on adiponectin protein in iWAT (P = 0.004) and 
gWAT (P = 0.0004) (Figure 7B). Based on multiple comparisons, 
adiponectin was significantly elevated in iWAT and gWAT of 
WT males after 2 weeks of TZD, and in gWAT of Ocn-Wnt10b 
males after 2 or 4  weeks of TZD (Figure  7B). These results 
demonstrate that rosiglitazone significantly increases expression 
FigUre 7 | rosiglitazone increases adiponectin protein expression in WaT in a depot- and sex-specific manner. At necropsy, iWAT and gWAT were 
dissected, and total protein was isolated from portions of each tissue. Lysates were separated by SDS-PAGE and expression of adiponectin protein determined by 
immunoblotting; β-actin expression was analyzed as a loading control. Immunoblots shown in (a,B) are representative of three mice per group. Samples from 
Ocn-Wnt10b mice are labeled “Tg.” Band intensities from these blots and further blots of the remaining samples were quantified using Image Studio Lite software. 
Adiponectin expression was then normalized to expression of β-actin for (a) Males and (B) Females, with representative blots shown beneath. For each sex, 
statistically significant differences between TZD-treated and untreated mice (within each genotype) or between WT and Ocn-Wnt10b mice (within each TZD group) 
are presented as described for Figure 2.
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of adiponectin protein in WAT of female and male mice. Thus, it 
seems likely that, with this regimen of rosiglitazone treatment, 
WAT makes at least a partial contribution to TZD-induced 
hyperadiponectinemia.
TZD induces UcP1 Protein expression in 
BaT but not in WaT or Tibiae
While these studies focused on the relationship between MAT 
and adiponectin, they also provided the opportunity to assess 
other properties of MAT; indeed, it remains unclear to what 
extent MAT’s characteristics overlap with those of WAT and BAT. 
The key function of BAT is to mediate adaptive thermogenesis 
via uncoupled respiration, which is dependent on expression of 
uncoupling protein 1 (UCP1). TZDs dose-dependently increase 
UCP1 protein and Ucp1 transcripts in BAT and can upregulate 
Ucp1 in WAT and whole tibiae (26, 34). Based on the latter, it has 
been suggested that MAT may have BAT-like characteristics (26). 
However, others have argued that elevated Ucp1 expression alone, 
without assessment of UCP1 protein, is insufficient evidence for 
a tissue’s thermogenic capacity (35). Indeed, the relative protein 
expression of UCP1 between MAT and BAT remains to be firmly 
established. Thus, to further study the BAT-like properties of 
MAT, we next analyzed UCP1 expression in BAT, WAT, and 
tibiae, both at the transcript and protein level.
FigUre 8 | rosiglitazone increases UcP1 mrna and protein in BaT not in WaT or tibiae. Total RNA and protein were isolated from interscapular BAT, 
gWAT, iWAT, and whole tibiae. (a,B) Ucp1 transcript expression in each tissue of female (a) and male mice (B) was quantified by qPCR and normalized to 
expression of Ppia mRNA. In each tissue, statistically significant differences between TZD-treated and untreated mice (within each genotype) or between WT and 
Ocn-Wnt10b mice (within each TZD group) were determined by two-way ANOVA and are presented as described for Figure 2. (c) Protein lysates from BAT were 
separated by SDS-PAGE and expression of UCP1 protein determined by immunoblotting; β-actin expression was analyzed as a loading control. Immunoblots are 
representative of three mice per group. Samples from Ocn-Wnt10b mice are labeled “Tg.” UCP1 protein could not be detected in gWAT, iWAT, or tibiae (data not 
shown).
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As shown in Figures 8A,B, across all groups of female or male 
mice, TZD strongly influenced Ucp1 expression in BAT (females, 
P  =  0.0002; males, P  <  0.0001). Multiple comparisons further 
confirmed that, relative to untreated controls, each duration of 
TZD significantly increased BAT Ucp1 in males of each genotype 
(Figure 8B), while this also occurred for females with 2 weeks’ TZD 
treatment (Figure  8A). Across-group effects of TZD were also 
detected in female gWAT (P = 0.014), female tibiae (P < 0.0001), 
male gWAT (P = 0.0051), and male tibiae (P = 0.0017), wherein 
TZD-treated groups typically had greater Ucp1 expression than 
untreated controls (Figures  8A,B). Analysis of genotypic dif-
ferences via multiple comparisons confirmed that, relative to 
untreated mice, Ucp1 was significantly elevated in Ocn-Wnt10b 
female tibiae or gWAT after 4 or 8 weeks’ TZD, respectively, and 
in WT male gWAT, after 8 weeks’ TZD (Figures 8A,B). Each of 
these groups also had significantly greater Ucp1 expression than 
their untreated WT or Ocn-Wnt10b counterparts, respectively; 
however, such genotypic differences were uncommon, and geno-
type generally did not influence Ucp1 expression in any of the 
tissues analyzed.
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These data demonstrate that rosiglitazone increases Ucp1 
expression in BAT, gWAT, and tibiae, consistent with results in 
previous studies (26, 34). However, relative to expression in BAT, 
Ucp1 expression in untreated mice was over 500-fold lower in 
gWAT, 1,500-fold lower in iWAT, and 10,000-fold lower in tibiae 
(Figures 8A,B). Thus, even with TZD treatment, Ucp1 expression 
in these tissues is negligible, raising questions over its functional 
relevance. To further address this, we next analyzed UCP1 expres-
sion at the protein level. As shown in Figure 8C, in females and 
males of either genotype, TZD robustly increased UCP1 expres-
sion in BAT; however, in gWAT, iWAT, or whole tibiae, we could 
not detect UCP1 protein expression (data not shown). Together, 
these observations suggest that MAT is unlikely to possess the 
thermogenic properties of BAT.
DiscUssiOn
Herein, we pursued studies in Ocn-Wnt10b mice to investigate 
the hypothesis that MAT expansion contributes to TZD-induced 
hyperadiponectinemia. We found that, regardless of TZD treat-
ment, Ocn-Wnt10b mice have significantly less cMAT than WT 
mice and likely resist TZD-induced rMAT accumulation. Despite 
this loss of cMAT and mild resistance to rMAT expansion, cir-
culating adiponectin is generally similar between WT and Ocn-
Wnt10b mice. Moreover, we found that TZD significantly increases 
adiponectin protein expression in WAT. Together, these findings 
suggest that WAT, rather than MAT, is the key mediator of TZD-
induced hyperadiponectinemia, at least under these conditions of 
TZD treatment. However, as discussed in Section “Contribution 
of MAT and WAT to TZD-Induced Hyperadiponectinemia,” fur-
ther consideration of these findings suggests that MAT makes at 
least some contribution to TZD-induced hyperadiponectinemia. 
As a secondary aim, we also addressed the hypothesis that MAT 
has BAT-like properties. We found that, in contrast to BAT, UCP1 
protein is undetectable in tibiae, suggesting that MAT is unlikely 
to have the thermogenic capacity of BAT.
As further discussed below, these findings shed new light on 
the function of MAT and have implications worth considering for 
future MAT research.
contribution of MaT and WaT to  
TZD-induced hyperadiponectinemia
We previously identified MAT as a source of increased circulat-
ing adiponectin during CR, a conclusion based, in part, on the 
finding that Ocn-Wnt10b mice resist both CR-associated MAT 
expansion and hyperadiponectinemia (2, 3).
Herein, we find that, regardless of TZD treatment, cMAT 
volume is significantly lower in Ocn-Wnt10b than in WT mice. 
Unfortunately, tibial ruptures confounded measurement of rMAT 
volume; however, analysis of intact tibiae, without ruptured sam-
ples, suggests strongly that Ocn-Wnt10b mice also partially resist 
rMAT accumulation in response to TZD treatment. Despite this 
loss of cMAT and mild resistance to rMAT expansion, circulating 
adiponectin is generally similar between WT and Ocn-Wnt10b 
mice. Superficially, this suggests that MAT expansion per  se 
does not contribute to hyperadiponectinemia under these TZD 
treatment conditions. However, this conclusion is less certain 
when several other key factors are taken into account.
One such factor is the likely contribution of WAT. Unlike 
during CR, adiponectin protein expression in WAT is increased 
under these conditions of TZD treatment, which may override any 
effects of suppressed MAT expansion. These increases are more 
pronounced for adiponectin protein than for Adipoq transcripts, 
with TZD affecting the Adipoq transcripts only in male WAT 
(Figure 6). These findings echo previous reports of sex-specific 
differences in WAT adiponectin expression, and of a disconnect 
between adiponectin expression at the transcript and protein 
level (32, 33). Notably, these effects on WAT are inconsistent 
with the finding that TZDs can increase circulating adiponectin 
without increasing adiponectin expression in WAT (23, 24). This 
disparity is likely a result of the higher dose of rosiglitazone used 
in our study. Indeed, WAT adiponectin expression is unaltered 
by lower TZD doses (24, 36) but significantly increased at higher 
rosiglitazone concentrations (18). Thus, as discussed further 
below (“Implications of TZD Dose on the Capacity of Ocn-Wnt10b 
Mice to Resist MAT Expansion and Hyperadiponectinemia”), a 
lower dose of rosiglitazone would likely be required if we were to 
further investigate the contribution of MAT to TZD-associated 
hyperadiponectinemia.
Considering these findings, it seems likely that WAT makes 
at least some contribution to hyperadiponectinemia under these 
conditions of rosiglitazone treatment. However, the effect of 
TZD on WAT adiponectin expression (Figures 6 and 7) is far less 
consistent and pronounced than that which occurs for circulating 
adiponectin concentrations (Figure 5). In contrast, these changes 
in circulating adiponectin are closely reflected by the increases 
in tibial adiponectin expression (Figure 4). For example, when 
comparing Ocn-Wnt10b and WT mice, circulating adiponectin 
is lower only in the 4-week TZD females (Figure 5); hence, it is 
striking that this is also the only group in which tibial adiponectin 
expression is lower in Ocn-Wnt10b mice (Figure 4A). Together, 
these observations show that circulating adiponectin is closely 
associated with tibial adiponectin expression and less tightly 
associated with gross changes in rMAT and cMAT volume. This 
underscores the importance of analyzing MAT through multiple 
approaches, including transcriptional markers, rather than 
focusing solely on MAT volume via osmium tetroxide staining. 
Perhaps, more importantly, this close association suggests that 
adiponectin production from MAT contributes, at least in part, 
to TZD-induced hyperadiponectinemia.
implications of TZD Dose on the capacity 
of Ocn-Wnt10b Mice to resist MaT 
expansion and hyperadiponectinemia
Previous studies have used a wide range of doses of rosiglita-
zone to investigate its impact on adiponectin or bone marrow 
adiposity. For example, Nawrocki et al. treated mice with 10 mg/
kg/day to examine the effects on circulating adiponectin and 
glucose homeostasis (20), while 20 mg/kg/day was used in two 
more recent studies investigating effects of rosiglitazone on bone 
marrow adiposity (26, 27). A much lower dose of 3 mg/kg/day 
was also found to cause MAT expansion in mice, but whether 
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this promotes hyperadiponectinemia was not reported (28, 37). 
Thus, in the present study, we used 15 mg/kg/day to ensure robust 
effects on MAT and circulating adiponectin. As in the above 
studies (26–28), we did so by administering rosiglitazone in the 
diet, based on measurements of body mass and estimated daily 
food intake. However, because of variation in body masses and 
daily food consumption, some mice may have exceeded the target 
dose of 15  mg/kg/day. As discussed above, this relatively high 
dose may explain the increased adiponectin expression in WAT, 
thereby complicating interpretation of any contribution from 
MAT. Such high doses may also have overwhelmed the ability of 
Ocn-Wnt10b mice to more robustly resist MAT expansion. Thus, 
a lower rosiglitazone dose may limit these confounding effects 
and thereby be more suitable for addressing our hypothesis in 
Ocn-Wnt10b mice.
limitations of Ocn-Wnt10b Mice as a 
Model resistant to MaT expansion
One reason that we have not pursued such follow-up studies 
is that Ocn-Wnt10b mice may be too limited a model in which 
to robustly address MAT’s endocrine functions. For example, 
while CR- or TZD-induced MAT expansion is blunted in 
these mice, such expansion is still marked in comparison 
to untreated Ocn-Wnt10b controls (Figures  2 and 3) (3). 
Moreover, distal tibiae of Ocn-Wnt10b mice remain laden with 
MAT (Figures  2A,D) and, while cMAT volume is lower in 
Ocn-Wnt10b mice, this likely reflects restrictions imposed by 
decreased bone marrow volume (3), rather than resulting from 
a direct inhibition of adipogenesis. Thus, as we have recently 
argued elsewhere (7), future research of MAT would benefit 
enormously from development of new mouse models that 
more robustly resist MAT formation, developmentally and/or 
in response to CR, TZDs, or other stimuli that promote MAT 
expansion.
confounding effects of Bone ruptures on 
Osmium Tetroxide-Based rMaT analysis
The present study reveals that cortical bone ruptures can con-
found osmium-based MAT detection. This issue, which has not 
been reported previously, provides further support for taking a 
multifaceted approach to MAT analysis. While TZDs can cause 
bone loss and fractures (38), it is unlikely that the ruptures 
occurred in vivo over the course of rosiglitazone treatment: such 
an injury would have dramatically impacted mobility and behav-
ior of the mice, which was not apparent during daily inspections; 
and the ruptures also occurred in tibiae of males untreated with 
rosiglitazone, demonstrating that they are not a consequence 
of TZD treatment. Instead, it is likely that ruptures occurred 
ex vivo as a result of methodological issues. In particular, after 
fixing tibiae in formalin post-necropsy there was a very long time 
span, ~30 months, before most of these bones were decalcified 
and analyzed by osmium tetroxide staining. This holdup largely 
resulted from delays associated with one of our lead authors 
moving to a new institution, during which time the fixed tibiae 
were stored in PBS at 4°C and shipped by air from the USA to the 
UK. Although these storage conditions would not be expected to 
promote cortical ruptures, it is notable that no ruptures occurred 
in a subset of female tibiae that were stored in PBS for a shorter 
duration (~12 months), without air transport, before decalcifica-
tion and osmium analysis. Moreover, at both the University of 
Michigan and the University of Edinburgh, we have analyzed 
hundreds of osmium-stained mouse bones from other studies, 
none of which has undergone such long-term storage or air 
transport, and among which no ruptures have ever been detected. 
Thus, one possibility is that exposure to low air pressure during 
air transport can cause a pressure differential that promotes bone 
ruptures. It remains possible that other factors also contributed 
to this phenomenon; however, our findings strongly suggest that 
fixed bones should not undergo long-term storage or exposure 
to low atmospheric pressure if MAT volume is to be determined 
accurately using osmium tetroxide staining.
BaT-like Thermogenic Function is 
Unlikely in MaT
There is extensive interest in “beige” or “brite” (brown-in-white) 
adipocytes, which develop in WAT in response to diverse external 
stimuli, including cold exposure or TZD treatment, and which 
share some properties of brown adipocytes (39–41). This so-
called “browning” of WAT can increase energy consumption 
and may thereby contribute to TZD-associated improvement 
in metabolic health. Therefore, whether MAT can also undergo 
browning or has BAT-like characteristics has been a subject of 
some interest. Krings et al. found that, in mice treated for 4 weeks 
with rosiglitazone (20 mg/kg/day), transcript expression of brown 
adipocyte markers is increased in tibiae, supporting the possibil-
ity that MAT has BAT-like characteristics (26). This is consistent 
with our finding that rosiglitazone influences tibial Ucp1 mRNA 
expression (Figure 8). However, Krings et al. further highlighted 
that, compared to BAT, Ucp1 expression is 16,000-fold lower in 
tibiae, which agrees closely with our data showing a 10,000- to 
25,000-fold decrease in tibiae compared to BAT. In addition, even 
with rosiglitazone treatment, we find that Ucp1 transcripts remain 
400- to 7,000-fold lower in tibiae than in BAT (Figures 8A,B). 
Crucially, at this level of Ucp1 expression, we could not detect 
UCP1 protein, whereas rosiglitazone-induced increases in UCP1 
protein in BAT are readily detectable (Figure 8C).
UCP1 is the hallmark of brown adipocytes and the key media-
tor of adaptive thermogenesis, and therefore the above findings 
strongly suggest that bone marrow adipocytes are unlikely to 
possess BAT-like thermogenic properties. One limitation of 
our study, and that of Krings et  al., is that we analyzed whole 
bones rather than isolated marrow adipocytes. However, both 
brown and beige adipocytes are further defined by their high 
mitochondrial content and the multilocular morphology of their 
lipid droplets (41), neither of which is observed in bone marrow 
adipocytes (3, 4, 12, 42). This raises further doubts about the 
notion that MAT has BAT-like characteristics, an issue that we 
recently discussed in greater depth elsewhere (5). Nevertheless, it 
remains possible that, under a different TZD treatment regimen 
or in response to other stimuli, MAT is capable of undergoing 
browning. Indeed, while we were unable to detect UCP1 protein 
in WAT or whole tibiae, previous studies have detected UCP1 in 
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WAT following TZD treatment (41). Moreover, effects of TZDs 
on Ucp1 expression in BAT are dose-dependent (34). This sup-
ports the possibility that TZD-mediated browning of WAT and 
MAT requires an optimal regimen of TZD treatment, in which 
case the conditions in our study may simply have been unsuitable 
for inducing a browning response. Thus, there is ample scope for 
future studies to further investigate whether MAT has BAT-like 
properties, both at the molecular and functional levels.
Other strengths and limitations  
of This study
This study is the first to address the novel hypothesis that MAT 
contributes to hyperadiponectinemia in conditions beyond CR. 
The experimental design is strengthened by including both male 
and female mice, as well as by analysis of several durations of TZD 
treatment. The discovery of the confounding effects of cortical 
ruptures is partly a strength, in that it highlights an important 
technical consideration for future MAT research; however, pres-
ently this was a limitation because it prevented thorough meas-
urement of rMAT volume. As discussed above, another limitation 
is that the dose of rosiglitazone may have been too high, and may 
have varied slightly between mice because of differences in body 
mass and daily food intake. Administration of lower doses by 
daily injection or oral gavage could be one approach to overcome 
this issue. Finally, a key limitation of this study is that our findings 
are based on only a single cohort of mice. Ideally, these experi-
ments would be repeated in a second cohort, with particular care 
taken to avoid cortical ruptures; this would allow more robust 
determination of rMAT volume in Ocn-Wnt10b mice. However, 
as noted above (“Limitations of Ocn-Wnt10b Mice as a Model 
Resistant to MAT Expansion”), Ocn-Wnt10b mice may not 
be sufficiently robust as a model of impaired MAT formation. 
For example, adipocyte marker expression in tibiae is generally 
similar between WT and Ocn-Wnt10b mice (Figure  4). This 
limitation of the Ocn-Wnt10b model undermines the rationale 
for repeating the present studies in a second cohort. Instead, we 
feel strongly that it would be more productive and scientifically 
beneficial to focus efforts on developing new mouse models that 
more robustly resist MAT expansion. Such models could then 
be used to better address the present hypothesis, as well as other 
aspects of MAT function.
Beyond these particular issues, one broader limitation is that 
our experiments were based only in mice; it remains unclear if 
the relationship between TZD-induced MAT expansion and 
hyperadiponectinemia also exists in humans. It is well established 
that TZDs increase circulating adiponectin in humans (16), but 
their effects on MAT are less clear. Indeed, one study finds that 
rosiglitazone decreases bone marrow adiposity in the lumbar 
vertebrae (43), whereas a more recent report finds that pioglita-
zone, another TZD, increases femoral and lumbar vertebral bone 
marrow adiposity (44). Unfortunately, neither of these studies 
assessed circulating adiponectin, and there remain very few clini-
cal studies assessing the effect of TZDs on MAT. Thus, there is a 
strong rationale for future research to establish how TZDs affect 
MAT accumulation in humans and whether this is associated 
with changes in circulating adiponectin.
cOnclUsiOn
There are four main conclusions from our study. First, under these 
TZD treatment conditions, it is likely that both WAT and MAT 
make some contribution to TZD-induced hyperadiponectinemia. 
Second, UCP1 expression in MAT is negligible, and therefore 
MAT is unlikely to have the thermogenic capacity of BAT. Third, 
cortical bone ruptures confound measurement of MAT volume 
by osmium tetroxide staining, and therefore care must be taken 
when processing bones for such analysis. Moreover, osmium-
based assessment of MAT volume can differ from measurement 
of MAT content based on expression of bone marrow adipocyte 
transcripts; hence, multiple approaches should be used to assess 
MAT content, including analysis of molecular markers, rather 
than relying solely on osmium tetroxide staining. Finally, while 
Ocn-Wnt10b mice have been useful as a model resistant to MAT 
formation, development of more robust loss-of-MAT models 
would be of great benefit to future MAT research.
aUThOr cOnTriBUTiOns
RS and WC designed all figures and wrote the manuscript, with 
ES, HM, and OM providing additional critical revisions. WC, 
BL, ES, VK, and OM contributed to the conception and design 
of the experiments. BL oversaw mouse breeding and colony 
management. RS, BL, BZ, ES, SP, BS, HM, AB, RW, OM, and WC 
contributed to data acquisition, analysis, and/or interpretation. 
All authors gave final approval for publication of the manuscript 
and agree to be accountable for all aspects of the work presented 
herein.
FUnDing
This work was supported by grants from the National Institutes 
of Health (R24 DK092759 to OM; K99-DE024178 to ES; 
R25 DK088752 to BZ; S10-RR026475-01 to the University 
of Michigan School of Dentistry microCT Core; and P30 
DK089503 to the Michigan Nutrition Obesity Research Center, 
which oversaw NMR analysis of mouse body composition and 
provided a Pilot/Feasibility grant to HM). RS is supported by 
a British Heart Foundation 4-year PhD Studentship. WC is 
supported by a Career Development Award (MR/M021394/1) 
from the Medical Research Council (UK) and by a Chancellor’s 
Fellowship from the University of Edinburgh, and previously by 
a Lilly Innovation Fellowship Award and a Postdoctoral Research 
Fellowship from the Royal Commission for the Exhibition of 
1851 (UK). SP and BS were supported by a Training Grant from 
the University of Michigan Training Program in Organogenesis 
(T32-HD007505). Analysis of microCT imaging data was sup-
ported by a Bioinformatics Award provided through a British 
Heart Foundation Centre of Research Excellence grant.
16
Sulston et al. MAT and TZD-Induced Hyperadiponectinemia
Frontiers in Endocrinology | www.frontiersin.org September 2016 | Volume 7 | Article 128
reFerences
1. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell 
(2014) 156(1–2):20–44. doi:10.1016/j.cell.2013.12.012 
2. Scheller EL, Burr AA, MacDougald OA, Cawthorn WP. Inside out: bone 
marrow adipose tissue as a source of circulating adiponectin. Adipocyte (2016) 
5(3):251–69. doi:10.1080/21623945.2016.1149269
3. Cawthorn WP, Scheller EL, Learman BS, Parlee SD, Simon BR, Mori H, 
et al. Bone marrow adipose tissue is an endocrine organ that contributes to 
increased circulating adiponectin during caloric restriction. Cell Metab (2014) 
20(2):368–75. doi:10.1016/j.cmet.2014.06.003 
4. Scheller EL, Doucette CR, Learman BS, Cawthorn WP, Khandaker S, Schell B, 
et al. Region-specific variation in the properties of skeletal adipocytes reveals 
regulated and constitutive marrow adipose tissues. Nat Commun (2015) 
6:7808. doi:10.1038/ncomms8808 
5. Scheller EL, Cawthorn WP, Burr AA, Horowitz MC, MacDougald OA. 
Marrow adipose tissue: trimming the fat. Trends Endocrinol Metab (2016) 
27(6):392–403. doi:10.1016/j.tem.2016.03.016 
6. Suchacki KJ, Cawthorn WP, Rosen CJ. Bone marrow adipose tissue: formation, 
function and regulation. Curr Opin Pharmacol (2016) 28:50–6. doi:10.1016/ 
j.coph.2016.03.001 
7. Sulston RJ, Cawthorn WP. Bone marrow adipose tissue as an endocrine 
organ: close to the bone? Horm Mol Biol Clin Investig (2016). doi:10.1515/
hmbci-2016-0012 
8. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional 
cloning of the mouse obese gene and its human homologue. Nature (1994) 
372(6505):425–32. doi:10.1038/372425a0 
9. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum 
protein similar to C1q, produced exclusively in adipocytes. J Biol Chem (1995) 
270(45):26746–9. doi:10.1074/jbc.270.45.26746 
10. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene 
dysregulated in obesity. J Biol Chem (1996) 271(18):10697–703. doi:10.1074/
jbc.271.18.10697 
11. Devlin MJ. Why does starvation make bones fat? Am J Hum Biol (2011) 
23(5):577–85. doi:10.1002/ajhb.21202 
12. Cawthorn WP, Scheller EL, Parlee SD, Pham HA, Learman BS, Redshaw 
CM, et al. Expansion of bone marrow adipose tissue during caloric restric-
tion is associated with increased circulating glucocorticoids and not with 
hypoleptinemia. Endocrinology (2016) 157(2):508–21. doi:10.1210/en. 
2015-1477 
13. Bennett CN, Ouyang H, Ma YL, Zeng Q, Gerin I, Sousa KM, et al. Wnt10b 
increases postnatal bone formation by enhancing osteoblast differentiation. 
J Bone Miner Res (2007) 22(12):1924–32. doi:10.1359/jbmr.070810 
14. Zgheib S, Mequinion M, Lucas S, Leterme D, Ghali O, Tolle V, et al. Long-
term physiological alterations and recovery in a mouse model of separation 
associated with time-restricted feeding: a tool to study anorexia nervosa 
related consequences. PLoS One (2014) 9(8):e103775. doi:10.1371/journal.
pone.0103775 
15. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, 
Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for 
peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem (1995) 
270(22):12953–6. doi:10.1074/jbc.270.22.12953 
16. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med (2004) 351(11):1106–18. 
doi:10.1056/NEJMra041001 
17. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, et al. Fatty 
acid binding protein 4 is increased in metabolic syndrome and with thiazoli-
dinedione treatment in diabetic patients. Atherosclerosis (2007) 195(1):e150–8. 
doi:10.1016/j.atherosclerosis.2007.04.045 
18. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, 
et  al. PPARgamma ligands increase expression and plasma concentrations 
of adiponectin, an adipose-derived protein. Diabetes (2001) 50(9):2094–9. 
doi:10.2337/diabetes.50.9.2094 
19. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, et al. 
The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, 
and type 2 diabetic subjects. Diabetes (2002) 51(10):2968–74. doi:10.2337/
diabetes.51.10.2968 
20. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, 
et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and 
reduced responsiveness to peroxisome proliferator-activated receptor gamma 
agonists. J Biol Chem (2006) 281(5):2654–60. doi:10.1074/jbc.M505311200 
21. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction 
and death from cardiovascular causes. N Engl J Med (2007) 356(24):2457–71. 
doi:10.1056/NEJMoa072761 
22. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and frac-
tures in type 2 diabetes: a meta-analysis. Can Med Assoc J (2009) 180(1):32–9. 
doi:10.1503/cmaj.080486 
23. Rasouli N, Yao-Borengasser A, Miles LM, Elbein SC, Kern PA. Increased 
plasma adiponectin in response to pioglitazone does not result from increased 
gene expression. Am J Physiol Endocrinol Metab (2006) 290(1):E42–6. 
doi:10.1152/ajpendo.00240.2005 
24. Pita J, Panadero A, Soriano-Guillén L, Rodríguez E, Rovira A. The insulin 
sensitizing effects of PPAR-γ agonist are associated to changes in adiponectin 
index and adiponectin receptors in Zucker fatty rats. Regul Pept (2012) 
174(1–3):18–25. doi:10.1016/j.regpep.2011.11.004 
25. Burant CF, Sreenan S, Hirano K, Tai TA, Lohmiller J, Lukens J, et al. Troglitazone 
action is independent of adipose tissue. J Clin Invest (1997) 100(11):2900–8. 
doi:10.1172/JCI119839 
26. Krings A, Rahman S, Huang S, Lu Y, Czernik PJ, Lecka-Czernik B. Bone 
marrow fat has brown adipose tissue characteristics, which are attenuated with 
aging and diabetes. Bone (2012) 50(2):546–52. doi:10.1016/j.bone.2011.06.016 
27. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik 
B. Rosiglitazone induces decreases in bone mass and strength that are rem-
iniscent of aged bone. Endocrinology (2007) 148(6):2669–80. doi:10.1210/
en.2006-1587 
28. Ackert-Bicknell CL, Shockley KR, Horton LG, Lecka-Czernik B, Churchill GA, 
Rosen CJ. Strain-specific effects of rosiglitazone on bone mass, body 
composition, and serum insulin-like growth factor-I. Endocrinology (2009) 
150(3):1330–40. doi:10.1210/en.2008-0936 
29. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical impli-
cations. Diabetologia (2012) 55(9):2319–26. doi:10.1007/s00125-012-2598-x 
30. Carey DG, Cowin GJ, Galloway GJ, Jones NP, Richards JC, Biswas N, et al. 
Effect of rosiglitazone on insulin sensitivity and body composition in type 2 
diabetic patients [corrected]. Obes Res (2002) 10(10):1008–15. doi:10.1038/
oby.2002.137 
31. Scheller EL, Troiano N, Vanhoutan JN, Bouxsein MA, Fretz JA, Xi Y, et al. 
Use of osmium tetroxide staining with microcomputerized tomography to 
visualize and quantify bone marrow adipose tissue in vivo. Methods Enzymol 
(2014) 537:123–39. doi:10.1016/B978-0-12-411619-1.00007-0 
32. Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron 
JC, et  al. Sexual differentiation, pregnancy, calorie restriction, and aging 
affect the adipocyte-specific secretory protein adiponectin. Diabetes (2003) 
52(2):268–76. doi:10.2337/diabetes.52.2.268 
33. Wiesenborn DS, Menon V, Zhi X, Do A, Gesing A, Wang Z, et al. The effect 
of calorie restriction on insulin signaling in skeletal muscle and adipose tissue 
of Ames dwarf mice. Aging (Albany NY) (2014) 6(10):900–12. doi:10.18632/
aging.100700 
34. Kelly LJ, Vicario PP, Thompson GM, Candelore MR, Doebber TW, Ventre J, 
et al. Peroxisome proliferator-activated receptors gamma and alpha mediate 
in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expres-
sion. Endocrinology (1998) 139(12):4920–7. doi:10.1210/endo.139.12.6384 
35. Nedergaard J, Cannon B. UCP1 mRNA does not produce heat. Biochim 
Biophys Acta (2013) 1831(5):943–9. doi:10.1016/j.bbalip.2013.01.009 
36. Moore GB, Pickavance LC, Briscoe CP, Clapham JC, Buckingham RE, Wilding JP. 
Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, 
rosiglitazone, through regulation of visceral fat gene expression. Diabetes Obes 
Metab (2008) 10(3):251–63. doi:10.1111/j.1463-1326.2007.00697.x 
37. Styner M, Pagnotti GM, Galior K, Wu X, Thompson WR, Uzer G, et  al. 
Exercise regulation of marrow fat in the setting of PPAR gamma agonist 
treatment in female C57BL/6 mice. Endocrinology (2015) 156(8):2753–61. 
doi:10.1210/en.2015-1213 
38. Riche DM, King ST. Bone loss and fracture risk associated with thiazoli-
dinedione therapy. Pharmacotherapy (2010) 30(7):716–27. doi:10.1592/
phco.30.7.716 
39. Petrovic N, Walden TB, Shabalina IG, Timmons JA, Cannon B, 
Nedergaard  J. Chronic peroxisome proliferator-activated receptor gamma 
(PPARgamma) activation of epididymally derived white adipocyte cultures 
17
Sulston et al. MAT and TZD-Induced Hyperadiponectinemia
Frontiers in Endocrinology | www.frontiersin.org September 2016 | Volume 7 | Article 128
reveals a population of thermogenically competent, UCP1-containing adipo-
cytes molecularly distinct from classic brown adipocytes. J Biol Chem (2010) 
285(10):7153–64. doi:10.1074/jbc.M109.053942 
40. Ohno H, Shinoda K, Spiegelman BM, Kajimura S. PPAR agonists induce a 
white-to-brown fat conversion through stabilization of PRDM16 protein. Cell 
Metab (2012) 15(3):395–404. doi:10.1016/j.cmet.2012.01.019 
41. Harms M, Seale P. Brown and beige fat: development, function and therapeutic 
potential. Nat Med (2013) 19(10):1252–63. doi:10.1038/nm.3361 
42. Tavassoli M. Ultrastructural development of bone marrow adipose cell. Acta 
Anat (Basel) (1976) 94(1):65–77. doi:10.1159/000144545 
43. Harslof T, Wamberg L, Moller L, Stodkilde-Jorgensen H, Ringgaard S, 
Pedersen SB, et al. Rosiglitazone decreases bone mass and bone marrow fat. 
J Clin Endocrinol Metab (2011) 96(5):1541–8. doi:10.1210/jc.2010-2077 
44. Grey A, Beckley V, Doyle A, Fenwick S, Horne A, Gamble G, et al. Pioglitazone 
increases bone marrow fat in type 2 diabetes: results from a randomized 
controlled trial. Eur J Endocrinol (2012) 166(6):1087–91. doi:10.1530/
EJE-11-1075 
Conflict of Interest Statement: RS, BL, BZ, ES, SP, BS, HM, AB, and RW have 
nothing to disclose. WC held a postdoctoral fellowship funded by Eli Lilly and 
Company. VK is employed by Eli Lilly and Company. OM has received research 
funding from Eli Lilly and Company.
Copyright © 2016 Sulston, Learman, Zhang, Scheller, Parlee, Simon, Mori, Bree, 
Wallace, Krishnan, MacDougald and Cawthorn. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 






The overall aim of this chapter was to test if, as for CR, TZD-induced 
hyperadiponectinaemia is significantly blunted when BMAT expansion is impaired. As 
discussed in the paper, some elements of the experiment limited the interpretation of 
the results. It appeared that the TZD dose, which was relatively high, was powerful 
enough to overcome the resistant effect of the Ocn-Wnt10b transgene on BMAT 
expansion. Multiple comparisons showed that, following TZD treatment, the Ocn-
Wnt10b mice have significantly lower cBMAT volume than wild-type mice. However, this 
may reflect a decrease in medullary cavity volume rather than a specific decrease in 
BMAT volume given that, anecdotally, the medullary cavity appeared full of BMAT in the 
distal portion of the tibia. I was unable to measure the medullary cavity volume in these 
mice because this requires µCT analysis of calcified bones, but in this study the bones 
underwent µCT scanning only after decalcification. In the proximal tibia fewer significant 
differences were seen, indicating that the Ocn-Wnt10b mice may not effectively resist 
TZD-induced BMAT expansion. Additionally, the issue of bone ruptures also added 
uncertainty to the interpretation of the results by limiting the confidence in rBMAT 
volumes of some bones. Fortunately, the adipocyte transcript data helped fill some 
knowledge gaps left by the ruptures and allow some firmer conclusions to be gained 
from the results. 
The results have been discussed in depth in the published paper; however, several other 
relevant, papers have since been published. Thus, MRI analyses of human 
premenopausal women found that vertebral BMAT volume is a significant predictor of 
circulating adiponectin, although so were other white adipose tissue depots181. This 
provides further evidence for the role of BMAT contributing to hyperadiponectinaemia 
in alternative contexts to calorie restriction. Despite this, it has also been shown that 
there is no association between BMAT and circulating adiponectin in control, obese and 
type II diabetic groups182. This is a diverse group of subjects so it is not clear if the 
relationship between BMAT and adiponectin only exists in more controlled subsets of 
people i.e. premenopausal women or non-obese diabetics. 
Studies in anorexic patients show that adiponectin is negatively correlated with BMD183 
and given that BMAT is often inversely associated with BMD, there is support for the 
possibility that in anorexia nervosa, BMAT and adiponectin may be positively associated. 
Little further work has been performed using the Ocn-Wnt10b mice given their 
presumed limited ability to resist BMAT expansion in the face of robust stimuli. Future 
work from others in the Cawthorn Lab is attempting to develop a mouse model that 
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completely lacks BMAT whilst maintaining normal development of other adipose depots. 
If successful, these models will enable researchers to examine how stimuli that normally 
cause BMAT expansion and hyperadiponectinaemia affect adiponectin plasma 




4. Skeletal changes caused by variation in 
calorie restriction duration. 
4.1. Introduction 
4.1.1. How CR affects the skeleton 
 
CR causes a wide variety of skeletal changes. As described previously, calorie restriction 
increases BMAT but the causes and consequences of BMAT expansion during CR remain 
to be firmly established. The increase in BMAT has been hypothesised to occur for a 
variety of reasons. One proposed mediator is low concentrations of circulating leptin,  an 
adipocyte-derived satiety hormone that acts by inducing feeding behaviours when its 
concentration falls184. CR is known to decrease leptin levels 185. Indications for leptin 
driving the accumulation of BMAT can be seen in experiments showing that mice lacking 
leptin (ob/ob mice) or leptin receptors (db/db mice) have very high volumes of BMAT, 
and leptin administration to ob/ob mice causes a reduction in BMAT140,186,187. The 
relationship between leptin and haematopoiesis may also influence BMAT expansion: 
leptin is required for effective haematopoiesis188 and BMAT has been shown to be a 
negative regulator of overall haematopoesis189. Low leptin may therefore cause a 
reduction in red, haematopoietic marrow, which would then allow space for the BMAT to 
expand into. 
Some evidence exists that leptin is neither sufficient nor required for BMAT expansion 
and that glucocorticoids, such as corticosterone, are a more important regulator129. 
Indeed, leptin administration to mice not deficient in leptin actually causes a decrease in 
BMAT187,190. A caveat to the observation that BMAT expansion is more closely associated 
with glucocorticoids than leptin during CR is that the results were obtained in rabbits 
and therefore more research is required into the relationship between glucocorticoids, 
leptin and BMAT. An alternative to both glucocorticoids and leptin as regulators of BMAT 
expansion is the role of IGF-1 and GH. Rats with low IGF-1, either through 
hypophysectomy or genetic alteration, showed significantly more BMAT in female 
tibiae141. 
Along with increases in BMAT, reductions in bone mineralisation and strength are also 
observed in response to CR. Bone loss is associated with age and weight loss191 and a 
chronic 20% reduction in calories has also been shown to reduce bone mass192. It could 
be suggested that bone integrity decreases in these contexts due to reduced mechanical 
stress on the bone caused by reduced weight; however, research has shown that, 
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compared to girls with typical body weight, both ballet dancers and girls with anorexia 
nervosa show reduced bone mineral density despite ballet dancers having increased 
physical activity 193. These differences were only present when adjusted to be relative to 
fat mass, indicating that fat mass is important for determining bone mineral density193. 
Site-specific differences within bone have also been observed in response to calorie 
restriction. Cortical bone decreases during CR but trabecular bone does not194. 
Insulin has been proposed as a potential molecular influencer of bone, particularly in CR. 
High fat mass and obesity are associated with hyperinsulinaemia195 and, conversely, 
insulin is lower in lean and calorie-restricted states196. It has been shown that, in vitro, 
insulin is able to stimulate osteoblast-like cell growth197. In vivo, localised injection of 
insulin has been shown to increase bone formation in mice198. This suggests that CR-
induced bone loss may be caused by hypoinsulinaemia. 
As mentioned above, leptin is significantly decreased during calorie restriction. Leptin 
treatment in ob/ob mice has been shown to greatly increase bone growth199 and leptin is 
also able to inhibit osteoclast formation in vitro200. Therefore, leptin may also be a 
positive regulator of bone mass. 
Glucocorticoids are an anti-inflammatory group of steroid hormones. Glucocorticoids are 
elevated during caloric restriction129 and are well established to cause a reduction in 
bone density and strength201,202. Given the overlapping roles of glucocorticoids and 
leptin on both bone mineral density and BMAT expansion I aimed to evaluate the 
relationship between changes in these hormones and effects on both bone integrity and 
BMAT expansion during CR. If these endocrine factors are mediators of bone loss and 
BMAT expansion, then we would expect the changes in their circulating levels to precede 
or coincide with these skeletal effects of CR. 
Finally, adiponectin has also been proposed as regulator of bone density. Research in 
humans has shown that increased circulating adiponectin is associated with reduced 
bone mineral density 203 and although the association with bone density was maintained, 
another study did not show an association between adiponectin and fracture risk204. 
Transgenic mice overexpressing adiponectin show reduced bone mineral content in the 
femurs of the females but not the males205 and a further study using the same model 
showed significant decreases in tibial bone parameters206. 
4.2. Results 
4.2.1. Body mass changes during caloric restriction 
 
In order to confirm if the CR protocol had functioned as expected I first measured the 
body mass of the mice over the course of the experiment. I expected to observe a 
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decrease in body mass in the CR mice compared to the ad libitum (AL)-fed mice. Figure 
4.1 shows the body mass of both male (A) and female (B) mice measured every week for 
6 weeks. In both sexes, mice were randomly assigned to AL or CR diet and so at the start 
of the experiment (week 0) both groups had the same body mass, indicating no pre-
existing difference between the two dietary groups. After one week of the experiment 
both male and female CR mice showed a sharp and significant decrease in body mass 
whilst the AL mice continued at the same rate of body mass increases observed prior to 
intervention (data not shown). In both sexes, CR mice continued to decrease their body 
mass until 3 weeks post-intervention, at which point they both reached minimal body 
mass. From 4-6 weeks post-intervention, the CR mice showed increases in body mass 
compared to their nadir but remained significantly reduced compared to the AL mice, 
which continued to increase in body mass. Two-way ANOVA showed that both diet and 
duration of the experiment were significant contributors to the variance in the data. A 
significant interaction was also detected in both sexes, confirming a divergence between 
the AL and CR diets. Whilst these results are not surprising, they confirm that the CR 
intervention was acting as predicted and thereby lay a foundation for the further 
characterisation these mice, as discussed below. 
 
Figure 4.1 – Body mass in male and female mice across 6 weeks CR diet. Male (A) 
and female (B) mice were weighed weekly. Mean body mass is shown with error bars 
indicating ± SD. Statistical significance was determined by 2-way ANOVA, source of 
variance significance is shown above the data and multiple comparisons for AL vs CR at 
each time point determined using Sidak’s correction are indicated on the data, ***: p < 
0.001. Number used Male AL 0w – 21; 1w – 21; 2w – 16; 3w – 13; 4w – 11; 5w – 8; 6w – 
6. Male CR 0w – 22; 1w – 22; 2w – 17; 3w – 11; 4w – 11; 5w – 6; 6w – 6. Female AL 0w- 
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23; 1w – 23; 2w – 23; 3w – 12; 4w – 12; 5w – 7; 6w – 6. Female CR 0w – 23; 1w – 23; 2w 
– 23; 3w – 16; 4w – 13; 5w – 9; 6w – 6. 
 
4.2.2. Tibial and femoral changes in bone marrow adipose tissue 
 
We have previously observed large increases in tibial BMAT after 6 weeks of CR 
compared to mice on an AL diet121,129 yet the mechanisms underlying this effect and over 
what time frame it occurs are less well understood. Additionally, the BMAT changes in 
bones other than tibiae are also less well characterised. To address these gaps in 
knowledge, we analysed BMAT at several skeletal sites after mice had undergone CR for 
1-6 weeks. Both sexes underwent CR for 2, 4 or 6 weeks and a 1-week CR group was also 
included for males; a 1-week CR in females could not be completed owing to time 
constraints. Figure 4.2 shows tibial BMAT separated into proximal and distal regions, 
which correspond to rBMAT and cBMAT, respectively. The interface between the 
proximal and distal section is located at the junction between the tibia and fibula. In male 
mice (Fig. 4.2.A) proximal tibial BMAT showed significant regulation by both diet and 
duration, and an interaction between these factors. Additionally, multiple comparison 
analysis showed a significant difference between the 6-week AL and CR groups. This 
pattern of significance was repeated in proximal tibial BMAT of females (B). In the distal 
tibia both males (C) and females (D) the % BMAT was greater than in the proximal tibia, 
consistent with previous observations121. In male distal tibiae ANOVA identified 
duration, but not diet itself, as a significant source of variance. This may reflect the 
‘constitutive’ nature of distal tibial BMAT, which is less influenced by diet and other 
exogenous stimuli207. In the female distal tibia both diet and duration were significant 
but no interaction was seen. Multiple comparisons did not reveal any significant 
differences in male or female distal BMAT. Male and female humeri were also analysed 
but no BMAT was detectable in these bones and therefore the data is not shown. 
 
Here we see that, as expected, there are large increases in tibial BMAT, particularly in the 
proximal regions. It is likely that we observe larger differences in BMAT volume in the 
proximal tibia compared to the distal tibia because the distal region is constitutively full 
of BMAT as indicated by the BMAT percentage occupancy in the region of 100% in all 
groups of the distal tibia. In some cases the measured BMAT volume exceeded 100% of 
the measured marrow cavity volume; this likely results from dilation of the marrow 
cavity after decalcification and because osmium-stained samples are scanned at a 
slightly lower resolution than the calcified samples (from which the marrow cavity 
volume is measured). For durations under 6 weeks we see very few significant 
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differences, indicating that the CR-induced increases in BMAT occur predominantly 
between 4-6 weeks of CR. Yet, diet was a significant source of variance in proximal tibiae 
for both sexes, indicating that there is likely a mild effect on BMAT over all durations of 
CR. 
 
Figure 4.2 – Tibial BMAT percentage occupancy of medullary cavity. Tibiae were 
dissected from mice post-cull, decalcified and stained with osmium tetroxide. µCT was 
used to quantify BMAT volume and medullary cavity volume. BMAT (% medullary 
cavity) was then calculated for (A) male proximal tibia, (B) female proximal tibia, (C) 
male distal tibia and (D) female distal tibia. All data are presented as box-and-whisker 
plots showing median, interquartile range and range. Statistical significance was 
determined by 2-way ANOVA, source of variance significance is shown above the data 
and multiple comparisons determined using Sidak’s correction are indicated on the 
data,*: p < 0.05; ****: p < 0.0001. Numbers per group: Male AL 1w – 5; Male CR 1w – 5; 
Male AL 2w – 5; Male CR 2w – 6; Male AL 4w – 5; Male CR 4w – 5; Male AL 6w – 6; Male 
CR 6w – 6; Female AL 2w – 9; Female CR 2w – 10; Female AL 4w – 6; Female CR 4w – 7; 
Female AL 6w – 6; Female CR 6w – 6. 
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Given that there were strong data to support CR induced BMAT increases all (1, 2, 4 and 
6 week) durations were analysed. Femoral BMAT accumulation has been shown after 6 
and 12 weeks of CR133 but whether this occurs with shorter durations remains unknown. 
Given the expense of µCT analysis, I focussed my femoral BMAT analysis on my 2- and 6-
week groups, reasoning that there may be no differences before 6 weeks and so to 
analyse all time points preceding this could be fruitless. Figure 4.3 shows the percentage 
of BMAT in whole femurs of both male and female mice. In male femurs (A) ANVOA 
detected a borderline-significant interaction between duration and diet, with multiple 
comparisons revealing a significant difference between CR and AL mice after 6 weeks. 
Female femoral BMAT showed greater differences with both diet and duration identified 
as significant sources of variance with a significant interaction between these factors 
(Figure 4.3B). Multiple comparisons showed significant differences between AL and CR 
females at both 2- and 6-week time points. 
 
From these data it appears that the female mice are more responsive than males to CR-
induced increases in femoral BMAT. Females also appear to exhibit more rapid increases 
in BMAT than males. 
 
Figure 4.3 – Femoral BMAT percentage occupancy of medullary cavity. Femurs 
were dissected from mice post-cull, were decalcified and stained with osmium tetroxide. 
µCT was used to quantify BMAT volume and medullary cavity volume. (A) BMAT 
percentage occupancy of the medullary cavity in male femur. (B) BMAT percentage 
occupancy of the medullary cavity in female femur. Data are presented and statistical 
significance was determined as described for Figure 4.2. Numbers per group: Male AL 
2w – 5; Male CR 2w – 6; Male AL 6w – 6; Male CR 6w – 6; Female AL 2w – 9; Female CR 




Figure 4.4 shows 3D reconstructions of tibiae and femurs scanned by µCT. One 
representative bone with the median BMAT volume was selected per group. A and B 
show the male and female tibiae whilst panels C and D show the male and female femurs. 
Qualitative increases in BMAT volume can be observed as duration on the diet increases, 
particularly in 6-week mice, which agrees with the quantitative data above. The 





Figure 4.4 – 3D renders of tibias and femurs staining with osmium tetroxide. Tibia 
and femurs were dissected from mice post-cull, were decalcified and stained with 
osmium tetroxide. µCT was used to scan the bones and the resulting scans were 
visualised using CTvox (Bruker) software. T/F junction represents tibia/fibula junction. 
(A) Male tibia. (B) Female tibia. (C) Male femur. (D) Female femur.  
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4.2.3. Transcript level changes in adiposity 
 
A secondary method for the measurement of adiposity in bones is to quantify mRNA 
transcripts associated with adipocytes. Here we examine transcript levels of Adipoq 
(Adiponectin), Lep (Leptin) and Fabp4 (Fatty Acid Binding Protein 4), all of which are 
primarily expressed by adipocytes. We can infer that bone tissue with higher 
concentrations of these adipocyte transcripts is likely to have higher volumes of BMAT. 
In Figure 4.5 tibial expression of these adipocyte markers is shown. ANOVA revealed 
that, in male tibiae, diet contributed significantly to variance in Adipoq and Fabp4, while 
experiment duration was significant for all three adipocyte markers. Additionally, 
multiple comparisons revealed significant differences in Adipoq expression tibiae of 4-
week males. No interaction effects were seen. In females fewer significant differences 
were observed; diet was a significant source of variance for Lep expression whilst 
duration was significant for Adipoq expression. These data indicate some tibial BMAT 




Figure 4.5 – Adipocyte transcript markers of male and female tibia. Tibiae were 
dissected from mice post-cull and frozen. They were homogenised in liquid nitrogen and 
RNA extracted. The RNA was reverse transcribed to cDNA and qPCR used to quantify 
expression of Adipoq, Lep and Fabp4.  Data are presented in arbitrary units relative to 
the geometric mean concentration of housekeeping gene Ppia and ribosomal RNA 18S 
(Rn18s). (A) Adipoq in the male tibia. (B) Adipoq in the female tibia (C) Lep in the male 
-62- 
 
tibia. (D) Lep in the female tibia. (E) Fabp4 in male tibia. (F) Fabp4 in female tibia. Data 
are presented and statistical significance was determined as described for Figure 4.2. 
Numbers per group: see Figure 4.2. 
 
Figure 4.6 shows expression of these adipocyte markers in femurs of the mice. No 
significant variance is attributable to diet in either sex for any of the transcript markers. 
Experimental duration was a significant source of variance in male and female Adipoq 
and male and female Fabp4. These data do not show the same pattern observed in 
femurs stained by osmium tetroxide, which showed significant effects of CR, particularly 
in female femurs. Therefore, the transcript markers may not be an accurate marker of 




Figure 4.6 – Adipocyte transcript markers of male and female femur. Transcript 
expression in femurs was done as described for tibiae in Figure 4.5. (A) Adipoq in the 
male femur. (B) Adipoq in the female femur (C) Lep in the male femur. (D) Lep in the 
female femur. (E) Fabp4 in male femur. (F) Fabp4 in female femur. Data are presented, 
numbers used and statistical significance was determined as described for Figure 4.2 
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Finally, humeri were also analysed for the same adipocyte transcript markers. My 
rationale was that, despite not seeing any BMAT by osmium staining, transcript markers 
may be more sensitive in detecting changes on a molecular level, which might precede 
the lipid accumulation that osmium staining detects on a more gross anatomical level. No 
significant effects of diet were detected on overall variance in any markers, yet a 
significant difference by multiple comparison was seen in Lep expression in male 
humeri. Notably, humeral Lep expression was far lower than that seen in tibiae and 
femurs, which is consistent with the lack of detectable BMAT in osmium-stained humeri. 
Some significant durational effects were observed in male and female Adipoq, male Lep 
and male Fabp4. The durational effects seen in all bones likely reflect a change in 
expression of these factors as mice age and may be related to the increased BMAT 




Figure 4.7 – Adipocyte transcript markers of male and female humerus. Transcript 
expression in femurs was done as described for tibiae in Figure 4.5. (A) Adipoq in the 
male humerus. (B) Adipoq in the female humerus (C) Lep in the male humerus. (D) Lep 
in the female humerus. (E) Fabp4 in male humerus. (F) Fabp4 in female humerus. Data 
are presented, numbers used and statistical significance was determined as described 





4.2.4. Calcified tissue measurement of tibia, femur and humerus 
 
The above findings show that the effects of CR on BMAT volume are both duration 
dependent and skeletal site specific. Differences were also seen between males and 
females. It is well known that there is a strong link between increased BMAT volume and 
decreased bone tissue integrity, but it is unclear if BMAT expansion plays a causal role in 
bone loss. Thus, to explore the temporal relationship between these phenomena during 
CR, I next measured the architecture of the tibia, femur and humerus by µCT and also 
examined the transcript expression of osteocalcin (Bglap), an osteoblast-derived 
hormone that can be used as a biomarker of bone formation and osteoblast activity208. 
To determine how tibiae, femurs and humeri respond to CR these bones were scanned 
by µCT prior to osmium staining, allowing the quantification of markers of trabecular 
and cortical integrity. These data are presented in tables over the following pages, which 
show the mean +/- standard deviation (SD) as well as the ANOVA results for the 
contribution of diet and duration on total variance of the dataset. Additionally, p values 
for multiple comparisons between the AL and CR mice are shown. 
The methodology for scanning and analysis of the bones was performed in accordance 
with the recommendations set out in Bouxsein et al.209 which also shows representative 
images and 3D renders for the trabecular and cortical bone209. 
In trabecular bone the primary readouts include the bone volume fraction (BV/TV, %), 
which is a measure of the ratio of the volume of calcified tissue in the trabecular region 
to the total volume within the trabecular region of interest; trabecular number (Tb.N, 
1/mm), which is a count of the number of trabeculae per unit of length; trabecular 
thickness (Tb.Th, mm), which is a measure of the mean thickness of the trabeculae.; and 
trabecular separation (Tb.Sp, mm), which is a measure of the mean distance between 
trabeculae. These four factors have been described as the key variables to be shown 
when describing trabecular bone morphology209. 
In the cortical bone I analysed the following: the total cross-sectional area inside the 
periosteal envelope (the tissue on the outside of the bone) (Tt.Ar, mm2), which is a 
measure of the tissue found within the periosteum, calcified or otherwise; cortical bone 
area (Ct.Ar), which is the total bone area found within the periosteum; and the cortical 
area fraction (Ct.Ar/Tt.Ar, %), which is a measure of the percentage of the total 
endosteal area that is bone tissue. As with the trabecular bone, these are the key 
readouts for describing cortical bone morphology209; however, the readout for average 
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cortical thickness is not shown here for reasons described in the discussion of this 
chapter. 
Table 4.1 shows the morphological parameters described above for the trabecular bone 
of the tibia in male and female mice. In males we see that there were significant effects in 
all parameters caused by duration of diet yet none in relation to diet itself. The same 
pattern emerges in the females. This indicates that the tibial trabeculae do not respond 
to CR yet changes are observed with age of the mice. The trabeculae region analysed (as 
described in the methods) is near the proximal region of the long bones, therefore these 
results appears to be counterintuitive based on previous data showing large increases in 
BMAT volume in the proximal tibia of both males and females and considering that such 
BMAT expansion is often associated with loss of calcified tissue. However, they are 
consistent with previous studies showing that CR does not cause trabecular bone loss in 
mice194. 
In table 4.2 shows parameters for the cortex of the tibia. Some significant effects were 
caused by diet, with the tibial cortex of male CR mice being smaller than AL controls. 
This was particularly evident for Ct.Ar, indicating that the endosteum has shrunk whilst 
the periosteum has remained constant. The same effect occurred in females with CR 
mice exhibiting lower Ct.Ar and Ct.Ar/Tt.Ar than the AL controls. This again indicates 
that the endosteum is shrinking and likely to a greater extent than the male mice given 
the greater degrees of significance seen in the Ct.Ar/Tt.Ar parameter. This bone loss in 
males and females may reflect the previously observed CR-induced increase in BMAT 
volume, especially considering that it is the inner membrane of the cortical bone that is 
being reduced. 
Table 4.3 shows the trabecular parameters for the femurs. In male mice no significance 
was observed for any of the parameters whereas in females both diet and duration were 
significant effectors of total variance of the data with multiple comparisons showing that 
BV/TV was significantly down and Tb.Sp up in CR mice compared to AL. This indicates a 
modest and longer-term reduction in the trabecualae of female femurs. These results 
reflect the BMAT volume data which showed small increases in BMAT volume of male 
femurs compared to far larger increases in female femur BMAT. This may show that the 
femoral trabeculae respond more rapidly to changes in BMAT volume when compared to 
the tibial trabeculae. 
Quantification of the femoral cortex morphology is shown in table 4.4. Diet was a 
significant source of variation in the male mice in the Ct.Ar and Ct.Ar/Tt.Ar with 
significant differences detected by multiple comparison after 6 weeks of CR compared to 
6 weeks of AL diet in these parameters. Female mice showed far greater losses in 
femoral cortex caused by CR. Diet was a significant source of variance in all parameters 
measured and multiple comparisons showed significant differences after 2 weeks of CR 
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diet in Ct.Ar and Ct.Ar/Tt.Ar. This indicates a more rapid loss of bone tissue in the femurs 
of females mice compared to males which is reflective of the greater CR-induced 
increases in femoral BMAT volume of female mice giving further evidence of a link 
between bone loss and BMAT volume. 
The final bone to be analysed was the humerus, given the previous results showing no 
detectable BMAT in the humeri of male or female mice we hypothesised that there would 
be no significant changes in bone parameters if there is a link between BMAT and bone 
loss in CR. As shown in table 4.5, neither male nor female mice displayed diet related 
significant differences in trabecular parameters. In the cortex of the humeri some 
significant effects of the diet were observed. In males the Ct.Ar and Ct.Ar/Tt.Ar showed 
diet as a significant source of variance, additionally, multiple comparisons showed 6 
week differences in Ct.Ar and 4 and 6 week differences in Ct.Ar/Tt.Ar. In the females a 
similar pattern was observed but to a slightly greater extent, with all parameters 
showing diet as a significant source of variance, Ct.Ar with 4 and 6 week differences in 
CR compared to AL and a 6 week difference in Ct.Ar/Tt.Ar. This again shows that the 
cortex of bones appears to be more reactive to CR-induced bone loss than the trabeculae. 





Tibia Femur Humerus 
Trabeculae Cortex Trabeculae Cortex Trabeculae Cortex 
Male No change ↓ No change ↓ No change ↓ 





Tibial Trabecular Analysis 
Male Mean ± SD Source of variance 
Multiple comparisons AL 
vs CR P value 
  Experiment duration Diet Duration Interaction Experiment duration 






variance P value 
% total 























































































0.372 0.3007 0.2314 91.43 <0.0001 0.7914 0.2894 0.9998 0.993 0.1567 0.878 
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 Table 4.1a – Tibial trabeculae morphological parameters. Tibiae of male mice were dissected post-cull and scanned by µCT. A representative section 
containing 100 slices was isolated and analysed with CTAn automation software. Statistical significance was determined by 2-way ANOVA and multiple 





Female Mean ± SD Source of variance 
Multiple 
comparisons AL vs 
CR P value 
  Experiment duration Diet Duration Interaction Experiment duration 
  2 weeks 4 weeks 6 weeks 
% total 
variance P value 
% total 
variance P value 
% total 






























































0.789 0.1172 0.7286 59.6 <0.0001 0.8635 0.6408 0.9998 0.726 0.9874 
 Table 4.1b – Tibial trabeculae morphological parameters. Tibiae of female mice were analysed as disclosed in table 4.1a. 
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Tibial Cortical analysis 
Male Mean ± SD Source of variance 
Multiple comparisons AL vs 
CR P value 
  Experiment duration Diet Duration Interaction Experiment duration 
  1 week 2 weeks 4 weeks 6 weeks 
% total 
variance P value 
% total 












weeks Diet AL CR AL CR AL CR AL CR 
















13.05 0.0145 13.74 0.0918 4.881 0.4887 0.1369 0.9942 0.2838 0.9239 
















41.19 <0.0001 3.617 0.4891 3.364 0.5202 0.0358 0.5123 0.0249 0.0044 
















12.85 0.005 30.44 0.0007 6.26 0.2388 0.9967 0.6001 0.6347 0.0081 




Female Mean ± SD Source of variance 
Multiple comparisons 
AL vs CR P value 
  Experiment duration Diet Duration Interaction Experiment duration 
  2 weeks 4 weeks 6 weeks 
% total 
variance P value 
% total 
variance P value 
% total 
variance P value 
2 
weeks 4 weeks 
6 
weeks Diet AL CR AL CR AL CR 











0.243 0.5221 0.6373 6.601 0.252 0.06976 0.985 0.9916 0.971 0.9975 











0.119 32.85 <0.0001 6.91 0.1043 4.916 0.1952 0.2797 0.0048 0.0131 











3.38 51.73 <0.0001 1.513 0.5091 8.767 0.0265 0.0895 <0.0001 0.0002 




Femoral Trabecular analysis 
Male Mean ± SD Source of variance 
Multiple 
comparisons AL 
vs CR P value 
  Experiment Duration Diet Duration Interaction 
Experiment 
duration 
  2 weeks 6 weeks 
% total 
variance P value 
% total 
variance P value 
% total 
variance P value 
2 
weeks 6 weeks Diet AL CR AL CR 
BV/TV 85.66 ± 1.384 85.83 ± 2.107 85.62 ± 1.202 
85.221 ± 
1.977 0.1248 0.878 1.074 0.6532 0.7951 0.6988 0.9835 0.9073 






0.00265 5.897 0.2459 4.294 0.3197 10.69 0.1235 0.9506 0.1088 






0.000545 0.07605 0.9043 0.488 0.7609 2.273 0.5133 0.8339 0.9086 
Tb.N 15.31 ± 0.589 15.22 ± 0.492 15.14 ± 0.649 15.92 ± 0.562 7.81 0.1719 4.741 0.2825 12.66 0.0866 0.9566 0.06 
 Table 4.3a – Femoral trabeculae morphological parameters. Tibiae of male mice were analysed as disclosed in table 4.1a. 
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Female Mean ± SD Source of variance 
Multiple 
comparisons 
AL vs CR P 
value 
  Experiment Duration Diet Duration Interaction 
Experiment 
duration 













weeks Diet AL CR AL CR 





80.6 ±  
2.31 14.56 0.0052 35.3 <0.0001 8.258 0.0304 0.7892 0.0048 





0.0467 ±  
0.00378 10.52 0.0157 42.38 <0.0001 1.175 0.3983 0.3069 0.079 
Tb.Sp 0.0165 ± 0.000372 
0.0165 ± 
0.000360 
0.0166 ±  
0.000450 
0.0174 ±  
0.000580 14.09 0.0134 20.76 0.0034 11.53 0.024 0.9733 0.0076 
Tb.N 15.2 ± 0.829 
15.7 ± 
0.700 
16.5 ±  
0.950 
17.4 ±  
1.05 7.94 0.0419 40.56 <0.0001 0.4198 0.6281 0.3354 0.2103 




Femoral Cortical Anlaysis 
Male Mean ± SD Source of variance 
Multiple 
comparisons 
AL vs CR P 
value 
  Experiment Duration Diet Duration Interaction 
Experiment 
duration 


















0.137 2.39 ± 0.150 
2.42 ± 





0.0710 1.01 ± 0.0425 
0.907 ± 
0.0966 28.73 0.01 0.4623 0.7208 2.873 0.3771 0.348 0.0266 
Ct.Ar/Tt.Ar 41.3 ± 1.56 
39.2 ± 
1.02 42.4 ± 1.74 37.5 ± 2.57 47.72 0.0002 0.3576 0.6949 7.35 0.0869 0.1325 0.0004 




Female Mean ± SD Source of variance 
Multiple 
comparisons AL 
vs CR P value 
  Experiment Duration Diet Duration Interaction 
Experiment 
duration 
  2 weeks 6 weeks % total 
variance P value 
% total 






weeks 6 weeks Diet AL CR AL CR 
Tt.Ar 2.25 ± 0.0708 
2.17 ± 
0.102 2.26 ± 0.102 
2.03 ± 
0.172 34.33 0.0003 5.519 0.1091 7.07 0.0714 0.1391 0.0015 






0.0682 68.37 <0.0001 1.177 0.2854 12.68 0.0013 0.001 <0.0001 
Ct.Ar/Tt.Ar 44.9 ± 2.11 
42.3 ± 
2.46 49.0 ± 0.902 42.8 ± 1.88 48.24 <0.0001 12.31 0.0053 7.99 0.0214 0.0128 <0.0001 




Humeral Trabecular Analysis 
Male Mean ± SD Source of variance 
Multiple 
comparisons AL vs 
CR P value 
  Experiment duration Diet Duration Interaction Experiment duration 
  2 weeks 4 weeks 6 weeks 
% total 
variance P value 
% total 
variance P value 
% total 


























































0.776 6.198 0.1804 4.58 0.506 0.3326 0.9506 0.9287 0.8116 0.6712 
Table 4.5a – Humeral trabeculae morphological parameters. Humeri of male mice were analysed as disclosed in table 4.1a. 
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Female Mean ± SD Source of variance 
Multiple 
comparisons AL vs 
CR P value 
  Experiment duration Diet Duration Interaction Experiment duration 
  2 weeks 4 weeks 6 weeks 
% total 
variance P value 
% total 
variance P value 
% total 


























































1.24 1.342 0.5054 9.372 0.2212 0.2121 0.9648 0.917 0.9832 0.9931 




Humeral Cortex Analysis 
Male Mean ± SD Source of variance 
Multiple comparisons 
AL vs CR P value 
  Experiment duration Diet Duration Interaction Experiment duration 
  2 weeks 4 weeks 6 weeks 
% total 
variance P value 
% total 
variance P value 
% total 













































2.87 42.08 <0.0001 13.95 0.021 2.976 0.3959 0.1961 0.0039 0.0042 




Female Mean ± SD Source of variance 
Multiple comparisons 
AL vs CR P value 
  Experiment duration Diet Duration Interaction Experiment duration 
  2 weeks 4 weeks 6 weeks 
% total 
variance P value 
% total 
variance P value 
% total 











































2.30 46.03 <0.0001 2.362 0.4499 7.648 0.0867 0.1527 0.0356 <0.0001 




In addition to the µCT measurements of bone integrity we can also measure transcript 
markers of bone turnover to assess bone loss or gain in response to CR. Bglap is the gene 
encoding osteocalcin, a protein secreted exclusively by osteoblasts that is a marker of 
bone formation and increased mineralisation210. We measured transcript concentrations 
in the tibia, femur and humerus of male and female mice. 
In male tibiae, duration was a significant source of variation but no other effects were 
seen. In female tibiae, diet was a significant effect indicating that female tibiae are more 
responsive to CR than male tibia, at least with regards to Bglap. 
In the femurs both diet and duration were significant sources of variation in the data set 
in male mice. Multiple comparisons showed significant effects in 1, 2 and 4 weeks but 
not in 6 weeks. No significant effects were seen in the female mice. This early effect in 
the male femurs may show that Bglap transcript levels responds early to calorie deficit 
but adaption has occurred by 6 weeks of being on the diet. 
In male humeri diet and duration are both significant with a significant interaction 
between them. There were significant differences between AL and CR mice in the 1-, 2- 
and 4-week groups, again indicating a rapid response followed by possible adaptation to 
CR by 6 weeks. This is further confirmed in female humeri, where diet was a significant 





Figure 4.8 – Bglap expression of male and female tibia, femur and humerus. Tibiae, 
femurs and humeri were dissected from mice post-cull and frozen. They were 
homogenised in liquid nitrogen and RNA extracted. The RNA was reverse transcribed to 
cDNA and qPCR used to quantify concentrations of Bglap.  Data is presented in arbitrary 
units relative to the geometric mean concentration of housekeeping gene Ppia and 
ribosomal RNA 18S (A) Bglap in the male tibia. (B) Bglap in the female tibia (C) Bglap in 
the male femur. (D) Bglap in the female femur. (E) Bglap in male humerus. (F) Bglap in 
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female humerus. All data points shown with median, interquartile range and range 
shown by box and whisker plot. Statistical significance was determined by 2-way 
ANOVA, source of variance significance is shown above the data and multiple 
comparisons determined using Sidak’s correction are indicated on the data, *: p < 0.05; 
**: p < 0.01; ***: p < 0.001. Numbers used as described in Figure 4.2. 
Overall, we see that, as expected, CR does exert large effects on bone morphology. Whilst 
transcript analysis cannot provide information on the site of bone loss it can help in 
confirming results seen by µCT.  
4.2.5. Circulating factors that can affect bone structure 
 
As mentioned in the introduction to this chapter, corticosterone, leptin and IGF-1 have 
each be proposed to play a role in both BMAT expansion and bone loss during CR. Thus, I 
measured the circulating concentrations of these 3 factors at weekly time points 
throughout the experiment to further establish their relationship with BMAT expansion 
and bone loss during CR. 
AS shown in Figure 4.9A, in males, circulating corticosterone was significantly different 
between AL and CR mice, shown by diet being a significant source of variance. 
Additionally, duration was a significant source of variance and there was a significant 
interaction between diet and duration. At 1 and 2 weeks into the experiment, multiple 
comparisons showed significant differences between AL and CR mice. In the female mice, 
diet and duration were both significant sources of variance and a significant interaction 
was also detected. No multiple comparison differences were found to be significant. In 
males there appears to be a rapid increase in circulating corticosterone followed by a 
gradual reduction, perhaps indicating an initial stress response followed by 
acclimatisation to the diet. This effect can also be seen in the females. Data for the 6 week 
time point was collected but  showed a very large spike in concentration across all 
groups. This increase is almost certainly caused by different blood sampling conditions 
at the 6-week time point compared to the preceding time points. This was caused by the 
blood being taken in an unfamiliar setting at with differing housing conditions 
immediately prior to blood sampling. The reason for this variation in conditions was due 
to the mice being culled immediately after the blood sampling. For this reason, the 6 
week data was excluded from the analysis to prevent this erroneous data from 
confounding the other results. This technical issue was rectified for subsequent 
experiment including the data shown in chapter 6.  
Diet was a significant source of variance in male leptin circulating concentrations and an 
interaction effect was also detected (Figure 4.9C). Multiple comparisons showed that 
there were significant differences between AL and CR mice at 4 and 5 weeks into the 
experiment. It appears that leptin gradually decreased in CR mice until 2 weeks, after 
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which they maintain a constant but low level of circulating leptin. The AL mice gradually 
increased their circulating leptin levels, with no plateau detected after 5 weeks. In 
females, diet was a significant source of variance and an interaction between diet and 
duration was also detected. There were significant differences between AL and CR 
groups at the 3- and 4-week time points. The female mice appear to follow a similar 
pattern to the male mice but within a smaller dynamic range, the leptin on the CR mice 
did not go as low as the male mice and likewise, the leptin of the female AL mice did not 
go as high as the male mice. This may relate to sex differences in total fat mass, as 
reported in Chapters 5 and 6. The 6-week time point was excluded as previously 
mentioned. 
For circulating IGF-1 in both males and females, diet was a significant source of variance 
with an interaction also detected in the females. Duration was also a significant source of 
variance in male mice. Multiple comparisons did not reveal any significant differences 
between AL and CR males at any time points but did show a significant difference at 3 
weeks in female mice. In both male and female mice IGF-1 concentrations declined in 
response to CR but the data showed more variation across the duration of the 
experiment and within each time point, making it harder to draw firmer conclusions 




Figure 4.9 – Circulating corticosterone, leptin and IGF-1 in male and female plasma 
over 5 weeks of CR diet. (A) Male circulating corticosterone increased during CR. (B) 
Female circulating corticosterone showed moderate increases in response to CR. (C) 
Male leptin was significantly decreased during CR. (D) Female leptin was moderately 
decreased during CR. (E) Male circulating IGF-1 was mildly decreased by CR. (F) Female 
circulating IGF-1 was mildly decreased by CR. Mean concentration is shown with error 
bars indicating ± SD. Statistical significance was determined by 2-way ANOVA, source of 
variance significance is shown above the data and multiple comparisons determined 
using Sidak’s correction are indicated on the data, *: p < 0.05; **: p < 0.01; ***: p < 0.001. 
Numbers used: all male groups 5 per group. Female AL 0w – 8; 1w – 8; 2w to 5w – 5. 






Preceding this work, little was known about the interaction between duration of CR and 
BMAT increases. Six weeks of CR has been well established to increase BMAT121,133 yet 
little is known about whether shorter CR durations can also promote BMAT expansion. 
When combining all the previous results we can build up a picture of what is happening 
in each bone during CR, both in terms of BMAT expansion and loss of calcified tissue. My 
findings show that in male tibiae there are no changes in distal BMAT volume. This is 
consistent with previous results showing near maximal occupation of the marrow cavity, 
leaving very little room for BMAT expansion118,207. In the proximal tibia there are large 
increases in BMAT volume after 6 weeks but very few changes preceding this, although 
at 4 weeks some of the CR mice do show an increase over their AL counterparts. The 
adipocyte transcript markers are inconsistent in reflecting these changes, with only 
milder overall diet effects seen, and so these may not be a good reflection of overall 
BMAT volume despite their use previously129,211. 
4.3.1. Relationship between BMAT expansion and bone loss during CR 
BMAT has been suggested to contribute to bone loss212. Thus, given that we see large 
increases in BMAT volume only at 6 weeks in male tibiae, I also expected to see large 
decreases in calcified bone parameters at this timepoint. In both the cortex and the 
trabeculae of male tibiae I saw large durational effects, indicating that male tibiae are 
changing over the course of the experiment, irrespective of diet. Despite seeing no 
dietary changes in trabeculae, the cortex does show a reduction in %BV, specifically after 
6 weeks of CR. This is consistent with previous research highlighting the preferential 
loss of cortical bone over trabecular bone during CR194. Moreover, it supports the 
possibility that BMAT expansion contributes to cortical bone loss during CR. However, 
Bglap expression in male tibiae does not show any dietary effects and so this may not be 
an accurate measure of overall bone integrity. 
In female tibiae there is also a large increase in the proximal BMAT volume after 6 weeks 
of CR. As for males, this change generally is not mirrored by increases in adipocyte 
transcript gene concentrations. In contrast to males, females did show increases in distal 
tibial BMAT during CR. From the calcified measures of female tibiae I did not see any 
effects on trabecular bone but instead saw large effects in the cortex of these bones. Like 
male mice, Bglap transcripts in the female tibiae did not reflect the decreases in bone 
parameters seen by µCT, again highlighting µCT as a more robust approach to assess 
skeletal effects. Notably, the loss of cortical bone in female tibiae occurred by 4 weeks of 
CR, yet no significant increases in BMAT volume were detected at this timepoint. Thus, it 
may be that calcified bone loss precedes the expansion of BMAT.  
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In male femurs I saw modest increases in BMAT volume after 6 weeks but no changes 
after 2 weeks. As for tibiae, this change was not reflected in the adipocyte transcript 
markers in the femur.  Relating these BMAT changes to µCT parameters of bone loss, we 
do not see any overlap in trabecular bone, but cortical %BV decreases significantly after 
6 weeks. This provides further evidence for concurrent BMAT expansion and bone loss, 
particularly in the cortex. Bglap expression in male femurs shows a starkly opposite 
pattern to the µCT parameters, with significant differences seen at 1, 2 and 4 weeks of 
CR, but not 6 weeks. Thus, it may be that Bglap expression is a rapid responder to calorie 
deficit and its longer-term effects are not seen until osteocalcin concentrations have 
been altered for a greater period of time. Female femurs show more rapid increases in 
BMAT volume, with significant differences at both 2 and 6 weeks of CR. If the hypothesis 
that BMAT expansion causes bone loss is true, then we would expect to see more rapid 
decreases in bone occurring around 2 weeks of CR. The cortex of female femurs showed 
significant differences between AL and CR at both 2 and 6 weeks, whilst trabecular 
losses were limited to just 6 weeks. As before, Bglap expression is not reflective of bone 
loss parameters, with no changes in Bglap seen as a result of CR. Given that we see few 
trabecular losses it may be the case that trabecular degradation occurs more slowly or 
with a lower priority than cortical bone, given that here we see far earlier changes in 
cortical bone. These data show that, in the femur, BMAT expansion coincides with bone 
loss, supporting the concept of BMAT-expansion-induced bone loss.  
As no BMAT was detectable in male or female humeri the adipocyte transcript data may 
not reflect adipocyte content, but instead may give hints to the early adipogenesis 
direction of skeletal stem cells within the bone marrow. We saw a large increase in Lep 
in male humeri after 6 weeks of CR, which may represent early programming prior to 
increased adipogenesis. However, humeral Lep expression is far lower than in the tibia 
or femur and so may not present much biological relevance. Despite seeing no BMAT in 
humeri, we saw large CR-associated decreases in cortical bone of both male and female 
humeri and large decreases in Bglap transcripts, particularly in males. This suggests that 
BMAT may be entirely unrelated to bone loss, at least in the humerus. 
4.3.2. Endocrine mediators of BMAT expansion during CR 
I found that, as previously proposed129,187, leptin is decreased and corticosterone is 
increased in response to CR. This makes it hard to determine if one over the other is 
more important in the expansion of BMAT. Speculatively, the magnitude of change in 
leptin is great than that of corticosterone and so this could indicate that leptin plays a 
more significant role, however further work is required to confirm this. 
4.3.3. Limitations and future directions 
Whilst the adipocyte genes did not reveal any major changes and ended up being non-
reflective of osmium-tetroxide-measured changes in BMAT, it may be the case that the 
transcript concentrations of these genes are disconnected from the protein 
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concentrations. It could be that these genes are further regulated at the protein level 
rather than transcript and if this is the case protein analysis by western blot or ELISA 
would give more accurate answers on bone adiposity. The same could be said for Bglap, 
analysis of the osteocalcin protein could give more answers regarding bone turnover. 
Additionally, considering that osteocalcin is a secreted protein, osteocalcin 
concentrations could also be determined from plasma samples taken throughout the 
experiment. 
For tibial analysis of Adipoq, Lep, Fabp4 and Bglap, at some time points not all mice could 
be included. This was caused by early attempts to split the frozen tibia at the tibia/fibula 
junction prior to RNA extraction to allow analysis of the proximal and distal tibia 
separately. Unfortunately, these attempts failed as the RNA yield from the smaller 
portions of bone, particularly the distal tibia, was too low to allow for effective reverse 
transcription. This resulted in lower than normal number for these groups and so the 
results may be less reliable given that they were underpowered. 
Additionally, the BMAT quantification via osmium tetroxide staining may also be limited 
by the number of animals analysed. There appear to be trends for increased BMAT at 
earlier time points in the male and female tibiae that do not breach the significance 
threshold. More mice per group would raise the power to statistically detect these more 
nuanced changes. 
Based on visual inspection of the data it appears that the µCT intensities in the 4 week 
tibia are lower than the other times points in male and female tibiae. This is likely a 
technical effect given that the 4 week bones were analysed later than the others. The 
differing intensities are likely due to unintentional variation introduced either during 
staining or scanning. This could be in the form of different batches of osmium tetroxide 
or differing amounts of time between staining and scanning introduced by variation in 
availability of the µCT scanner. 
Interestingly, it has been demonstrated that adiponectin can have a positive effect on 
bone mineral density. Mice with adenoviral overexpression of adiponectin have 
increased bone mass compared to lacZ-overexpressing controls213. It was shown that 
this effect is caused by a dual action of adiponectin to suppress osteoclasts and induce 
osteoblasts213. This is paradoxical to our results here where we see large increases in 
adiponectin coinciding with losses in bone density. 
We observed very large increases in the concentration of corticosterone in both female 
CR and AL mice at the 6-week time point (data excluded). This may have been caused by 
a change in location at this time point prior to blood sampling. Specifically, at the point of 
cull the mice were transferred to our ex vivo facility to allow for rapid processing of 
tissues. In the cohort analysed for corticosterone the blood was taken from the mice in 
this ex-vivo facility and transfer of the animals may have caused a large stress response, 
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confounding the results. In future cohorts we performed the blood sampling in the 
normal animal facility in which the mice were well habituated to having blood sampled 
in. Future work could quantify circulating corticosterone in my later cohorts to obtain 
more representative concentrations for corticosterone at the 6-week time point. This 
procedure was also performed on the mice used for leptin and IGF-1 quantification and 




5. Determination of the temporal 
relationships between BMAT expansion, 
adiponectin and metabolic adaptations 
induced by caloric restriction 
. 
5.1. Introduction 
Our previous work found that BMAT is an important source of adiponectin during CR121, 
based on the observation that mice resistant to BMAT expansion also showed blunted 
hyperadiponectinaemia. In parallel to this, the mice also showed attenuation of CR-
induced mitochondrial biogenesis in skeletal muscle but not in liver; however, they also 
had unaltered glucose homeostasis, as determined by glucose tolerance testing. These 
findings suggest that BMAT, through adiponectin or perhaps other factors, may be 
contributing to a subset of systemic metabolic effects of CR. However, this remains to be 
firmly established. Thus, the goal of the studies in this chapter was to determine the 
temporal relationships between BMAT expansion and metabolic adaptations to CR. 
5.1.1. Metabolic consequences and mechanism of CR 
The reported metabolic benefits of CR are numerous, including reducing cholesterol, 
fasting glucose and insulin, C-reactive protein and systolic and diastolic blood 
pressure214. In addition to reduced fasting insulin, insulin sensitivity is also improved196 
as well as improved mitochondrial function215. Despite the effects of CR being well 
defined, the mechanism behind these effects is less so, with many hypotheses focussing 
on the effect of CR on mitochondrial function. In particular, adiponectin is known to be 
elevated in CR and correlates inversely with fat mass101 but positively correlates with 
increased fatty acid oxidation and a reduction in peripheral lipid accumulation216. 
Overexpression of adiponectin has been shown to prevent some of the damaging effects 
of diet-induced obesity such as hyperinsulinemia and hyperglycaemia217 and can even 
prevent metabolic dysregulation in morbidly obese ob/ob mice218. Furthermore, chronic 
treatment of db/db mice with adiponectin has been shown to alleviate some of the 
diabetic symptoms of these mice, including hyperglycaemia and hepatic steatosis219. 
Despite these effects being well known, the time frame in which adiponectin increases 
and induces metabolic effects is less well understood. Despite this, there is some 
evidence that adiponectin acts as a rapid mediator of insulin sensitivity. For example, 
administration of the hormone fibroblast growth factor 21 (FGF21) causes very rapid 
increases in insulin sensitivity yet this effect is abrogated in Adipoq KO mice, indicating 
that adiponectin contributes to these rapid metabolic improvements. However, whether 
this is the case in CR is unknown220. 
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Mitochondria are classically described as the power houses of the cell and are the site of 
oxidative phosphorylation, where large quantities of ATP are synthesised via the 
electron transport chain and ATP synthase. CR has been shown to have an important 
effect of increasing mitochondrial number and this has been proposed to be a 
mechanism of action for CR’s beneficial metabolic effects221. Data from rats exposed to a 
40% CR diet from weaning to 12 months of age show that CR induces an increase in 
proliferation of mitochondria with a decrease in ROS generation and no reduction in ATP 
output222. Additionally, they showed that this effect was dependent on peroxisome 
proliferation-activated receptor coactivator 1α (PGC-1α)222. This phenomenon is also 
observed in humans: healthy participants fed a 25% CR diet for 6 months showed 
increased expression of mitochondrial function genes including PGC-1α and 
transcription factor A mitochondria (TFAM) in Vastus lateralis muscle from the 
quadriceps215. However, the ability of CR to increase mitochondrial number is 
controversial, with some data suggesting no role for CR in these increases223-225. A final 
gene of interest is medium-chain acyl-CoA dehydrogenase (Acadm or Mcad), a 
mitochondrial gene involved in fatty acid metabolism.  Along with PGC1α and TFAM, 
Acadm has been shown to increase with CR and may provide another readout of 
mitochondrial function and number226. 
5.1.2. Long-term vs short-term CR 
Fasting can be considered the shortest duration of CR. Despite the short time involved, 
large metabolic effects are seen as the body acts to maintain energy homeostasis77. Few 
studies have investigated the durational effects of CR and the time frames needed to 
elicit particular effects. One study feeding rats a 40% restricted diet for either 2 weeks, 2 
months or 6 months showed that some effects occur rapidly and are maintained, such as 
a reduction in reactive oxygen species (ROS) production, whilst some effects occur 
rapidly but are lost over time, including decreased serum non-esterified fatty acid 
(NEFA) levels227. Furthermore, some effects take a long time to develop, such as 
decreased mass-adjusted oxygen consumption227. Crucially, no studies have examined 
the relationship between CR duration, BMAT expansion, hyperadiponectinaemia and 
metabolic adaption. 
5.1.3. Sexual dimorphisms in response to CR 
 
Differential effects of CR have been reported with males and females. The most widely 
studied is the effect on fertility: CR has been shown to have a negative effect on female 
fertility yet no effect on males228-230. This may link back to cardio-metabolic health given 
that premenopausal women are more resistant to obesity-induced heart disease 
compared to males231.  In addition, some metabolic adaptations that are present in males 
are absent in females in response to CR including reduced plasma lipoprotein 
concentrations232. One striking difference between males and females is the difference in 
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loss of fat mass in response to CR. Men loose more fat mass than females but the exact 
mechanism causing this is not well known233 and interestingly, not all studies show this 
effect234. One recent study also revealed sex differences in CR-induced weight loss and 
improvements in glucose homeostasis: compared to females, males displayed greater 
weight loss, decreases in fasting insulin and the HOMA-IR index (a proxy for insulin 
resistance), and improvements in an oral glucose tolerance test235. However, the 
mecahnisms underlying these sex differences, and whether they relate to effects on 
BMAT and/or circulating adiponectin, remain unknown. 
5.1.4. Aims of the chapter 
This present chapter aims to address two interconnected questions. Firstly, given the 
results presented in the previous chapter, here I examined the corresponding metabolic 
effects present across the same time points of CR. This is to provide answers about the 
contribution of expanding BMAT to metabolic adaptions during calorie restriction. The 
second question is the role adiponectin is playing during CR, by looking at the temporal 
increases in adiponectin and how these correspond with the temporal metabolic 
adaptions. Whilst both the BMAT expansion, hyperadiponectinaemia and metabolic 
adaptions will be purely associative, establishing these temporal relationships will begin 
to inform the potential causal role of BMAT expansion and/or hyperadiponectinaemia in 
the metabolic benefits of CR. 
 
5.2. Results 
5.2.1. Basic measures of CR on whole body composition 
As shown in Chapter 4, CR decreased body mass in both male and female mice,. 
However, to assess the metabolic effects it is necessary to measure the impact of CR on 
body composition. Indeed, lipectomy recapitulates many of the metabolic benefits of 
CR236, suggesting that loss of fat mass contributes to such CR-induced metabolic effects. 
Moreover, lean tissues such as skeletal muscle are a key site of glucose disposal and 
thereby influence metabolic homeostasis237. Therefore, to begin addressing the time-
dependent metabolic effects of CR, I first analysed body composition to assess fat and 
lean mass. 
Given that both sexes of mice are displaying a decrease in body mass, we can further 
characterise the tissue loses to specific tissue groups by time domain nuclear magnetic 
resonance (TD-NMR) which can quantify body composition based on the local 
environment of the protons in the mice as either in a lean, fat or liquid environment. 
Mice were analysed every 2 weeks. Figure 5.1 shows the fat and lean masses of both 
male and female mice expressed in absolute amount (g) and as a percentage of total 
body mass for each mouse. For both sexes there were no differences between AL and CR 
groups at the baseline (0 week) time-point, indicating no pre-existing differences in body 
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composition between the groups. For male fat mass, both in absolute terms (5.1A) and as 
a percentage (5.1C), significant decreases occurred after the first measurement at 2-
weeks post-CR. This was followed by a maintenance of fat mass from weeks 2 to 4 and an 
increase between weeks 4 to 6. Multiple comparisons revealed that, at all time points, fat 
masses in CR males were significantly lower than the corresponding time point in AL 
mice, except for percentage fat mass at the 6-week time point. This indicates that the 
body mass decreases observed in figure 5.1 are, at least in part, driven by catabolism of 
fatty tissues. These is likely to be mostly accounted for by white adipose tissues, 
however this cannot be determined by TD-NMR alone. The other major tissue type 
detectable by TD-NMR is lean mass. In males, absolute lean mass (E) significantly 
decreased across 2,4 and 6 weeks of CR. However, unlike fat mass, percentage lean mass 
(G) was greater in CR vs AL males at the 2- and 4-week time points, with no significant 
differences detected after 6 weeks of CR. This indicates that CR differentially affects lean 
mass and fat mass in male mice. Whilst lean mass decreases in absolute terms, CR males 
become leaner in terms of percentage body mass. This indicates that whilst males 
catabolise some lean tissue during CR, this is being relatively protected whilst fat loss 
accounts disproportionately for their overall loss of body mass.  
In female mice a different result is seen to the males. ANOVA revealed that, for female 
absolute fat mass (B), diet was not a significant source of variance. A similar result was 
seen for females’ percentage fat mass (D), where there was no significant effect from diet 
over the entire data set and only duration is a source of variance; however, the effect of 
diet (p = 0.062) was near the threshold for significance, albeit with CR females tending to 
have higher percent fat mass than their AL counterparts. This result shows that, rather 
than catabolising fat, females may preferentially be protecting their fat mass during CR. 
As seen previously, the female mice have decreased body mass during CR (Figure 4.1) 
and so given that they are not losing fat mass it seems likely that they may show a 
reduction in lean mass. This was observed in absolute terms (F), with a significant 
source of variation caused by diet and multiple comparisons revealing significant 
differences at all post-intervention time points. When quantified as percentage of body 
mass the dietary effect is no longer observed, showing that the female mice are losing 
lean mass proportionally to the loses in body mass during CR.  
Together, these data show that male mice catabolise both fat and lean tissue in response 
to CR, with a preference for fatty tissues. In contrast, females do not catabolise fat mass 






Figure 5.1 – Body composition determined by TD-NMR in male and female mice 
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over 6 weeks CR diet. Male and female mice underwent TD-NMR every two weeks. (A) 
Male fat mass expressed in grams. (B) Female fat mass expressed in grams. (C) Male fat 
mass expressed as percentage of body mass. (D) Female fat mass expressed as 
percentage of body mass. (E) Male lean mass expressed in grams. (F) Female lean mass 
expressed in grams. (G) Male lean mass expressed as percentage of body mass. (H) 
Female lean mass expressed as percentage of body mass. |Data are presented as mean ± 
SD of the following numbers of mice per group: male AL (n=x), male CR (n=x), female AL 
(n=x), female CR (n=x). Statistical significance was determined by 2-way ANOVA, source 
of variance significance is shown above the data and multiple comparisons determined 
using Sidak’s correction are indicated on the data, *: p < 0.05; **: p < 0.01; ***: p < 0.001. 
Number used Male AL 0w – 21; 1w – 21; 2w – 16; 3w – 13; 4w – 11; 5w – 8; 6w – 6. Male 
CR 0w – 22; 1w – 22; 2w – 17; 3w – 11; 4w – 11; 5w – 6; 6w – 6. Female AL 0w- 23; 1w – 
23; 2w – 23; 3w – 12; 4w – 12; 5w – 7; 6w – 6. Female CR 0w – 23; 1w – 23; 2w – 23; 3w 
– 16; 4w – 13; 5w – 9; 6w – 6. 
5.2.2. Absolute adipose depot mass changes caused by different durations 
of CR 
Whilst TD-NMR can detect changes in lipid-associated protons, it cannot specifically 
attribute these changes to adipose tissue given that lipids exist in many other tissue 
types. To investigate if WAT mirrors the gross changes in fat mass, specific adipose 
depots from each group of mice were dissected and weighed post-mortem. Figure 5.2 
shows the absolute mass of three typical WAT depots as well as the thermogenic BAT. 
Inguinal WAT (iWAT) is found subcutaneously around the groin and can extend into the 
dorso-lumbar region. Gonadal WAT (gWAT) is found around the gonads and is a visceral 
adipose depot. Also found viscerally is the mesenteric WAT (mWAT) which is found 
outside the intestines of the mice. For male iWAT and gWAT (5.2A), diet was a significant 
source of variation indicating that the reduced fat mass detected by TD-NMR is at least 
partly related to decreased iWAT and gWAT mass.  Duration also significantly affected 
gWAT mass, which increased over time in the AL mice but not in the CR males. Indeed, 
multiple comparisons revealed that CR males had significantly less gWAT than AL males 
at 4 and 6 weeks (5.2A). In the mWAT (A) of the male mice, no significant differences 
were observed.  
Findings for females were also consistent with the TD-NMR, with female WAT depots (B) 
not showing any significant differences caused by diet. Duration of the experiment 
significantly influenced both iWAT and gWAT masses in females, but not the mass of 
mWAT. These data further support the conclusion that, during CR, male mice catabolise 
fat mass whilst female mice do not. Moreover, it shows that the fat mass in question is 
adipose tissue, specifically gWAT and to a lesser extent iWAT. 
A further fatty tissue that is distinct to WAT is BAT, which acts to burn fatty acids to 
generate heat, rather than to synthesise ATP. Some studies have found that CR in rodents 
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or humans decreases BAT activity238-240, although variable effects on BAT mass have 
been reported238,241. Nevertheless, given that BAT contains a high proportion of lipid, I 
postulated that altered BAT mass may contribute to some of the fat mass changes seen 
by TD-NMR. Thus, BAT was dissected from the interscapular region and weighed. In 
males (C) no significant differences were observed in absolute BAT mass, indicating that 
the fat mass differences seen by TD-NMR are not influenced by changes in BAT mass. In 
contrast, in females (D) diet was a significant source of variation, with a significant 
difference detected by multiple comparison between AL and CR after 2 weeks of CR and 
a trend after 4 weeks. There was also a significant interaction in females, with BAT mass 





Figure 5.2 – WAT and BAT depot masses in male and female mice across 6 weeks 
CR diet. Male and female mice were culled by cervical dislocation and tissues were 
dissected and weighed. (A) iWAT, gWAT and mWAT depot masses in male mice. (B) 
iWAT, gWAT and mWAT depot masses in female mice. (C) Male BAT mass. (D) Female 
BAT mass. All data points shown as box and whisker plots with median, interquartile 
range and range. Statistical significance was determined by 2-way ANOVA, source of 
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variance significance is shown above the data and multiple comparisons determined 
using Sidak’s correction are indicated on the data,*: p < 0.05; **: p < 0.01. Numbers used 
as described in figure 4.2. 
 
5.2.3. Relative adipose depot mass changes caused by different durations 
of CR 
As for TD-NMR, these tissue masses can also be quantified as a percentage of the total 
body mass for each mouse. This can provide more insight into the relative bias for tissue 
gains or losses compared to the absolute changes. In the male WAT depots, no significant 
effect was seen for iWAT or mWAT; however a significant effect caused by both diet and 
duration was observed in the gWAT (5.3A). No significant effects were seen for BAT (C), 
in concordance with results for absolute BAT mass. These findings indicate that, of the 
depots analysed, gWAT is the most preferentially metabolised adipose depot in males. In 
females (D) ANOVA showed that diet was a significant source of variation for iWAT and 
BAT, with interactions detected for BAT. Thus, percent iWAT tended to be greater in CR 
vs AL females across all time points, while multiple comparisons revealed significantly 
increased BAT in CR vs AL females at 2 and 4 weeks of CR. Again, this is in concordance 
with results for absolute mass of BAT and further indicates that BAT increases during CR 





Figure 5.3 – WAT and BAT depot mass percentages in male and female mice across 
6 weeks CR diet. Male and female mice were culled by cervical dislocation and tissues 
were dissected, weighed and presented as a percentage of total body mass for individual 
mice. (A) iWAT, gWAT and mWAT depot masses in male mice. (B) iWAT, gWAT and 
mWAT depot masses in female mice. (C) Male BAT mass. (D) Female BAT mass. All data 
points shown with median, interquartile range and range shown by box and whisker 
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plot. Statistical significance was determined by 2-way ANOVA, source of variance 
significance is shown above the data and multiple comparisons determined using Sidak’s 
correction are indicated on the data,*: p < 0.05; ***: p < 0.001. Numbers used as 
described in figure 4.2. 
 
5.2.4. Total and percentage masses of liver and spleen in response to 
different durations of CR. 
In addition to adipose depots other tissues typically lose mass during CR, but the speed 
at which these changes occur is not well characterised. Both liver and spleen have been 
shown to decrease in mass in response to CR over a duration of 3 months160. However, 
only male mice were analysed and so little is known how the liver and spleen of females 
reacts to CR. Both sexes showed diet as a significant source of variation in total liver 
mass, with males also showing significant differences by multiple comparisons after 4 
and 6 weeks of CR (Figure 5.4 A and B). In terms of liver as a percentage of total body 
mass, both sexes showed no significant diet effects (E and F). Thus, whilst the livers of 
the CR mice are smaller than the AL controls, the loses are proportional to decreases in 
body mass and there is not preferential catabolism or protection of the liver in response 
to CR. 
Even greater effects of CR were noted for spleen masses, which significantly decreased 
after 2, 4 and 6 weeks of CR in both sexes (C, D). In males there was also a significant 
duration effect, with spleen masses tending to decrease from weeks 1-2 and then 
remaining near week 2 levels at weeks 4 and 6 (C). When spleen mass was expressed as 
a percentage of total body mass, males continued to show a significant effect of duration 
but decreases associated with CR were only borderline significant (G). In contrast, 
females (H) maintained the significant CR influence seen for total spleen mass (D), with a 
strong effect both overall and at the 2-, 4- and 6-week time points. This indicates that 
whilst both sexes are decreasing spleen mass in response to CR, the decreases in males 
are less disproportionate to their body mass losses whereas females exhibit a greater 




Figure 5.4 – Liver and spleen masses and percentage masses in male and female 
mice over 6 week CR diet. The liver and spleen were dissected and weight once the 
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mice had been culled (A) Male liver mass expressed in grams. (B) Female liver mass 
expressed in grams. (C) Male spleen mass expressed in grams. (D) Female spleen mass 
expressed in grams. (E) Male liver mass expressed as percentage of body mass. (F) 
Female liver mass expressed as percentage of body mass. (G) Male spleen mass 
expressed as percentage of body mass. (H) Female spleen mass expressed as percentage 
of body mass. All data points shown with median, interquartile range and range shown 
by box and whisker plot. Statistical significance was determined by 2-way ANOVA, 
source of variance significance is shown above the data and multiple comparisons 
determined using Sidak’s correction are indicated on the data,*: p < 0.05; **: p < 0.01; 
***: p < 0.001. Numbers used as described in figure 4.2. 
 
5.2.5. Circulating total and HMW adiponectin 
A primary aim of these CR studies was to determine the relationship between CR-
induced hyperadiponectinaemia and CR-induced metabolic adaptions, as well as changes 
in BMAT and bone microarchitecture (as assessed in Chapter 4). Once the basic 
physiology of the mice had been established, and the model validated by confirming the 
basic and well-known effects of CR, work to quantify the concentrations of circulating 
adiponectin could begin. I measured total and HMW adiponectin by ELISA and also 
calculated the ratio between the two. Male total circulating adiponectin (Figure 5.5A) 
was significantly influenced by both diet and duration of CR, with an interaction between 
these factors. The same pattern occurred in females (Figure 5.5B), with multiple 
comparisons also revealing a similar pattern between males and females at each week of 
CR. Both sexes showed increases in circulating adiponectin until 4 weeks after 
commencement of CR, followed by a relative plateau in concentrations. HMW 
adiponectin in males (C) and females (D) showed significant variance caused by both 
diet and duration of the experiment. By multiple comparison, male mice showed 
differences between AL and CR groups at 1 and 4 weeks after starting the diet whilst 
females showed differences after 2, 3 and 4 weeks. Males also showed a drop in HMW 
adiponectin at week 3 of CR, though the reasons for this are unclear. When combining 
these two measurements into the ratio of total adiponectin as high molecular weight 
multimers we see no significant differences in females (F) and an effect only from 
duration of the experiment in males (E). This indicates that the changes in HMW 





Figure 5.5 – Total, HMW and ratio of adiponectin in male and female mice over 6 
weeks CR diet. Plasma obtained from tail vein bleeds and decapitation was quantified 
for circulating concentrations of total adiponectin and high molecular weight multimers 
by ELISA. (A) Male total adiponectin. (B) Female total adiponectin. (C) Male high 
molecular weight adiponectin. (D) Female high molecular weight adiponectin. (E) Male 
high molecular weight to total adiponectin ratio. (F) Female high molecular weight to 
total adiponectin ratio. Mean measurement is shown with error bars indicating ± SD. 
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Statistical significance was determined by 2-way ANOVA, source of variance significance 
is shown above the data and multiple comparisons determined using Sidak’s correction 
are indicated on the data,*: p < 0.05; **: p < 0.01; ***: p < 0.001. Number used as 
described in figure 4.9. 
 
5.2.6. CR-induced improvements in glucose tolerance 
The above observations showed that hyperadiponectinaemia occurs after two weeks of 
CR in females but only after three weeks of CR in males and is not maximal until week 4 
of CR in either sex. This raises the question of how such hyperadiponectinaemia relates 
to metabolic benefits of CR. Glucose tolerance tests (GTT) are used to assess the speed 
and extent to which organisms react to a glucose load; this reflects both glucose-
stimulated insulin secretion and also insulin sensitivity. Therefore, I next used GTTs in to 
assess effects of CR on systemic glucose homeostasis. Mice were given an oral dose of 
glucose by gavage and their ability to clear the glucose was measured (figure 5.6). In all 
GTTs 2-way ANOVAs were performed but, unlike previous analysis, the effect of duration 
of the test was not considered, solely the contribution to variance by diet. In all sexes and 
durations, diet was a significant source of variance within the data indicating that, by 1 
week in male mice and by 2 weeks in female mice, improvements in glucose tolerance 
were already being caused by CR. Multiple comparisons revealed some sex differences in 
these effects of CR. Thus, compared to their AL counterparts, CR males showed 
significant differences between all time points across the GTTs except for 15-minutes 
post-gavage in the 4-week CR group. In contrast, in females fewer time points differed 
significantly between AL and CR groups. This indicates that the females are showing 
improvements in glucose tolerance to a lesser extent than the males in response to the 
CR diet, consistent with observations in humans235. 
To further quantify the glucose tolerance response, area under the curve (AUC) analysis 
was performed in two different ways. The first was to take the bottom of the area as the 
0 mM glucose measurement, whereas the second method used the fasting glucose 
concentration for each individual mouse as the baseline for AUC analysis; each method 
has its benefits. For example, when looking at the 0 mM AUC calculation we can measure 
the total glucose load experienced by the mouse over the course of the procedure, but 
the downside of this is that fasting glucose differences can significantly affect the result 
irrespective of any relative differences across other time points. For this reason, AUCs 
calculated against the fasting glucose baseline for each individual mouse are also used. 
This removes differences in fasting glucose as a confounding factor in the analysis and 
purely looks at the increases from the baseline and the speed at which the mice are able 
to reduce their glucose to pre-gavage concentrations. In summary, using a value of zero 
as the base of the area under the curve we can acquire a measure of the total glucose 
present in the circulation over the course of the test. Using the fasting glucose 
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concentration as the bottom of the area allows us to quantify the response to the glucose 
bolus specifically without being influenced by the initial fasting glucose concentration. 
In the male AUC relative to 0 mM glucose (A) all time points show a significant difference 
between AL and CR groups indicating improved glucose tolerance, likely due to 
improvements in initial fasting glucose. However, when comparing to the AUC baselined 
to the fasting glucose some of these differences were no longer present. The CR mice 
after 2 and 6 weeks of CR maintain their reduced AUC, indicating improved glucose 
clearance irrespective of fasting glucose; this was not observed after 4 weeks of CR, the 
reasons for which are unclear. In females a similar pattern to the males is seen for AUCs 
relative to 0 mM glucose, with improvements in glucose tolerance seen at all time points. 
Unlike the males, the female mice showed no differences in AUC relative to fasting 
glucose concentrations. This indicates that the improvements seen in the female GTT are 
solely due to improvements in fasting glucose and that the response to the glucose dose 
is the same between AL and CR mice. This represents an important sex difference 




Figure 5.6 – Glucose tolerance tests blood glucose over time in male and female 
mice over 6 weeks CR diet/ Blood concentrations of glucose were measured using 
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Verio blood glucose monitor from tail vein incisions. Measurements were taken before 
oral glucose dose then 15, 30 60 and 120 minutes after administration. (A) GTT in male 
1 week diet mice. (B) GTT in male 2 week diet mice. (C) GTT in female 2 week diet mice.  
(D) GTT in male 4 week diet mice. (E) GTT in female 4 week diet mice. (F) GTT in male 6 
week diet mice. (G) GTT in female 6 week diet mice Mean measurement is shown with 
error bars indicating ± SD. Statistical significance was determined by 2-way ANOVA, 
source of variance significance is shown above the data and multiple comparisons 
determined using Sidak’s correction are indicated on the data,*: p < 0.05; **: p < 0.01; 
***: p < 0.001. Number used male AL and CR 1w – 5; AL and CR 2w – 6; AL 4w – 5; CR 4w 
– 4; AL and CR 6w – 6. Female AL 2w – 7; CR 2w – 6; AL 4w – 5; CR 4w – 6; AL and CR 6w 
– 6. 
 
Figure 5.7 – AUC for glucose tolerance test for glucose analysed relative to 0mM 
and individual fasting glucose in male and female mice across 6 weeks CR diet. AUC 
analysis was performed on GTT plots for individual mice and the baseline for calculation 
was either the 0 mM glucose concentration or the glucose concentration of the fasting 
glucose at 0 minutes into the test. (A) Male GTT AUC relative to 0 mM glucose. 
(B)Female GTT AUC relative to 0 mM glucose. (C) Male GTT AUC relative to fasting 
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glucose concentration. (D) Female GTT AUC relative to fasting glucose concentration. All 
data points shown with median, interquartile range and range shown by box and 
whisker plot. Statistical significance was determined by 2-way ANOVA, source of 
variance significance is shown above the data and multiple comparisons determined 
using Sidak’s correction are indicated on the data,*: p < 0.05; **: p < 0.01; ***: p < 0.001. 
Numbers used as described in figure 5.6. 
5.2.7. Reverse feeding and lean mass GTT 
 
One possibility is that technical issues were influencing the diet and sex effects observed 
in the GTT. On the evening before the GTT, AL mice were re-fed with a full daily ration of 
AL diet and CR mice were re-fed a full daily ration of CR diet, i.e. 70% of the mass of the 
AL ration. The logic for this approach is that both groups of mice will have consumed all 
of their diet by 07.00 the following morning, such that doing the GTT at 12.00 would 
represent a fast of at least 5 hours. However, it is likely that the CR mice will have 
consumed all of their diet sooner, leading to a longer fasting period than for the AL 
groups. Therefore, to test if this feeding regimen was adversely influencing the outcome, 
a subsequent GTT was performed which involved feeding the CR mice the normal AL 
pre-GTT ration, and the AL mice the normal CR pre-GTT ration. This was to test if the 
effects observed above resulted from long-term CR and not from short-term fasting 
effects. Mice underwent the GTT procedure as usual and the plots of the GTT are shown 
in figure 5.8A. The mean points for both the standard pre-GTT feeding and reversed diet 
are shown. I saw that the AL mice fed the CR diet pre-GTT performed in a similar manner 
to the AL mice fed the normal pre-GTT AL diet. In contrast the CR mice, when fed the AL 
diet before the GTT, had higher glucose levels than CR mice that had been fed the CR diet 
pre-GTT (Figure 5.8A). However, whether mice were fed an AL ration or a CR ration pre-
GTT, CR significantly improved glucose tolerance. This validated my previous GTT 
results by showing that reversing the feeding between the AL and CR mice before the 
GTT does not alter the conclusion that long-term CR improves glucose tolerance. 
Another technical issue to address relates to whether the administered glucose dose is 
calculated relative to lean body mass or to total body mass. Lean mass is a major site of 
glucose uptake and this plays a large role during a GTT 242. In our GTTs (Fig. 5.6) we 
administered glucose based on total body mass; however, unlike males, female mice lose 
lean mass rather than fat mass during CR. Therefore, we hypothesised that females may 
be resisting CR-induced improvements in glucose tolerance because, compared to males, 
they have a lower proportional lean mass and are therefore receiving a higher relative 
dose of glucose relative to lean mass. To test this, a group of female mice were fed either 
AL or CR diet for 2 weeks then underwent a GTT with glucose administered relative to 
lean mass (‘lean mass GTT’) rather than body mass (‘body mass GTT’). The plot for this 
lean mass GTT is shown in figure 5.8. All points, excluding 0 minutes, were significantly 
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different by multiple comparison between AL and CR mice, this is more than for the body 
mass GTTs in figure 5.6 and may indicate that glucose administration relative to lean 
mass-produces greater differences between the dietary groups. To directly assess this, I 
next compared AUCs from the lean mass GTT with those from the body mass GTT (C and 
D). Glucose dosing alone did significantly influence the outcome, with lower AUCs for the 
lean mass than for the body mass GTTs, regardless of how the AUCs were calculated 
(Figure. 5.8C-D). This was expected, because the lean mass dosing provided a lower total 
amount of glucose to the mice than the body mass dosing. However, if females’ altered 
body composition were a major explanation for their resistance to CR-induced GTT 
improvements, then we would expect the CR effect to be greater for the lean mass GTT 
than for the body mass GTT. This was not the case: for both the 0 MM AUCs and the 
fasting glucose AUCs, glucose dosing did not affect the influence of CR on the GTT 
outcome (no interaction detected by two-way ANOVA). Indeed, for either glucose dosing 
regimen, CR significantly decreased the 0 mM AUCs (Fig. 5.8C) but not the fasting glucose 
AUCs (Fig. 5.8D). As discussed above, the improvements in the 0 mM AUCs are likely 
driven by decreased fasting glucose in the CR mice. Together, these data show that the 
lean mass GTT did not significantly influence the CR effect. Thus, we can conclude that 
the lean mass deficiency in the female mice is not responsible for the differing glucose 






Figure 5.8 – Reversed pre-GTT feeding regime and lean mass relative glucose dose 
alterations on glucose tolerance tests. Male CR mice were given AL diet before the 
GTT fast whilst AL mice were given the CR diet pre-fast, a GTT was performed as normal. 
In female mice glucose was administered relative to lean mass and compared to 
previously acquired body mass data. AUC was calculated relative to 0 mM glucose and 
fasting glucose concentration. (A) Male mice fed either normal or alternate diet pre-fast. 
(B)Female mice given glucose relative to either body mass or lean mass. Mean 
measurement is shown with error bars indicating ± SD. (C) AUC from body or lean mass 
glucose dose relative to 0 mM glucose concentration. (D) AUC from body or lean mass 
glucose dose relative to fasting glucose concentration. All data points shown with 
median, interquartile range and range shown by box and whisker plot. Statistical 
significance was determined by 2-way ANOVA, source of variance significance is shown 
above the data and multiple comparisons determined using Sidak’s correction are 
indicated on the data,*: p < 0.05; **: p < 0.01; ***: p < 0.001. Numbers used standard diet 
AL and CR 2w – 6; reverse fed groups AL and CR – 2. AL relative to body mass – 7; CR 
relative to body mass 6; AL relative to lean mass – 4; CR relative to lean mass – 4. 
5.2.8. Insulin changes during GTT 
One reason for variation in response to glucose tolerance tests is altered secretion of 
insulin into the blood. We measured plasma concentrations of insulin during GTTs in the 
-112- 
 
2- and 6-week cohorts to examine if glucose-induced insulin secretion was altered 
between CR and AL mice and could account for the diet and/or sex differences in glucose 
tolerance. Two and six weeks were chosen for analysis as these were the minimum and 
maximum durations present for both sexes. A significant diet effect was seen by ANOVA 
for both durations of diet and both sexes, however a significant effect caused by the 
duration of the GTT was only present in the male 2-week diet group. This was a surprise 
given that previous studies suggest that insulin should increase post—glucose 
administration243. One possibility is that the peak in insulin preceded the first 
measurement at 15 minutes, which may also explain why AUC analysis did not show any 
differences (data not shown) Of importance, CR did not enhance insulin secretion in any 
of the groups assessed; hence, it is clear that the ability of CR to improve glucose 
tolerance in males, but not in females, is not related to diet- or sex-associated effects on 
on insulin secretion. 
 
Figure 5.9 – Plasma insulin concentrations during GTT in male and female mice 
scorss 6 week CR diet. Plasma insulin concentrations were measured by ELISA. 
Measurements were taken before oral glucose dose then 15, 30 60 and 120 minutes after 
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administration. (A) Insulin concentration across GTT in male 2 week diet mice. (B) 
Insulin concentration across GTT in female 2-week diet mice. (C) Insulin concentration 
across GTT in male 6-week diet mice. (D) Insulin concentration across GTT in female 6 
week diet mice Mean measurement is shown with error bars indicating ± SD. Statistical 
significance was determined by 2-way ANOVA, source of variance significance is shown 
above the data. No multiple comparisons determined using Sidak’s correction were 
found to be significant. Number used as described in figure 5.6. 
5.2.9. Effects on mitochondrial biogenesis in gastrocnemius muscle 
Previous research has suggested that certain mRNA transcripts are altered in muscle 
tissue during CR, many of which are also reported targets of adiponectin. Peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC1, encoded by Pcg1a) is 
a transcriptional co-activator able to regulate mitochondrial function, and is often 
induced by CR. Mitochondrial transcription factor A (Tfam) is a downstream target of 
PGC1 that can regulates mitochondrial function and replication. Acyl-coenzyme A 
dehydrogenase, C-4 to C-12 straight chain (Acadm) is another downstream target of 
PGC1 that also has important mitochondrial functions. Despite previous studies 
showing an induction of Pgc1a121 in this study we saw no significant differences between 
AL and CR in the gastrocnemius muscle. Both male and female mice also showed no 
significant differences between AL and CR mice in Tfam expression and females did not 
exhibit any significant differences in Acadm expression. Diet did significantly affect 
Acadm expression in males;, however, the effect was for a decrease in CR mice compared 
to AL, which was not the expected result. Thus, despite robust increases in circulating 
adiponectin during CR in both males and females, expression of these reported 




Figure 5.10 – Mitochondrial biogenesis gene transcript analysis of skeletal muscle 
in male and female mice across 6 week CR diet. RNA was extracted from 
gastrocnemius muscle and reverse transcribed to cDNA. Transcript concentration of 
mitochondrial biogenesis genes was quantified by qPCR relative to a standard curve. (A) 
Male Pgc1a gastrocnemius transcript concentrations. (B) Female Pgc1a gastrocnemius 
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transcript concentrations. (C) Male Tfam gastrocnemius transcript concentrations. (D) 
Female Tfam gastrocnemius transcript concentrations. (E) Male Acadm gastrocnemius 
transcript concentrations. (F) Female Acadm gastrocnemius transcript concentrations. 
All data points shown with median, interquartile range and range shown by box and 
whisker plot. Statistical significance was determined by 2-way ANOVA, source of 
variance significance is shown above the data. No multiple comparisons determined 
using Sidak’s correction were found to be significant. Numbers used male AL 2w – 5, all 




5.3.1. Adiponectin as a mediator of metabolic benefits of CR 
The contribution of this chapter to the overall hypothesis and aims of the thesis was to 
investigate the timing of adiponectin increases in relation to the beneficial metabolic 
effects of CR, namely improved glucose homeostasis and mitochondrial biogenesis. The 
rationale being that if metabolic changes are preceding increases in adiponectin, then 
adiponectin may not be a crucial hormone in conveying these benefits of CR. On the 
other hand, if the metabolic changes were occurring at or after the point at which 
adiponectin increased, or in a manner proportional to adiponectin increases, we could 
conclude that adiponectin may be a causal factor. In both male and female mice, we 
observed a maximal increase in adiponectin after 4 weeks of CR with a maintenance in 
concentration from 4 weeks to 6 weeks. In the female mice, between the start of the diet 
and 4-weeks post-diet, the increases in adiponectin were gradual and continuous 
whereas the male mice showed a more dramatic and sudden increase between 2 and 3 
weeks post-commencement of CR. The improvements in male glucose tolerance were 
first apparent after 1 week of CR and were statistically significant after 2 week of CR, 
which is before the increases in circulating adiponectin. This suggests that 
hyperadiponectinaemia is not a pre-requisite for improvements in glucose tolerance. 
Furthermore, whilst the female mice showed robust increases in adiponectin, few 
metabolic adaptions were seen, giving more indication that adiponectin increases are 
not required. This is a surprising conclusion, because during CR energy is scarce and to 
invest resources into robust induction of hyperadiponectinaemia suggests that this 
response must yield an evolutionary benefit that confers a survival advantage in a low-
calorie environment.  
Decreases in mitochondrial number, function, and enzyme activity in skeletal muscle 
have been shown to contribute to insulin resistance and worsening of glucose 
homeostasis244. Additionally, genes involved in mitochondrial biogenesis have been 
shown to be increased during CR121. We hypothesised that the CR-induced 
improvements in glucose tolerance could be caused by improvements in mitochondrial 
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biogenesis and function. The gastrocnemius was chosen for analysis as a large and 
readily isolated skeletal muscle. As shown above, we saw very few significant differences 
in the transcripts evaluated. This was in opposition to previously published data and 
could have occurred for two reasons. Firstly, the muscle used in previous research was 
the quadriceps121 as opposed to the gastrocnemius here, however it seems unlikely that 
this would cause such a big difference in results. Another contributing factor could be 
the pre-cull fasting procedure because, in the previously mentioned study, the AL mice 
were not fasted before the cull121 and so differences in muscle transcript expression may 
be caused by differences in fasting duration, rather than longer-term CR effects. To 
further evaluate mitochondrial number and function, confocal microscopy could be used 
to examine cross-sections of muscle tissue stained with fluorescent probes, such as 
mitotracker245. Given the lack of changes it is difficult to examine the hypothesis that 
adiponectin is driving the metabolic benefits of CR given that in this experiment it 
appeared not to be any benefits imparted. 
 
5.3.2. Sex differences in the metabolic effects of CR 
One of the most striking findings of this chapter was the vast differences between male 
and female mice in their response to CR. Male mice preferentially metabolised adipose 
tissue and displayed large improvements in glucose tolerance whilst female mice 
showed a preference to maintain fat mass and metabolise lean mass instead and did not 
exhibit any improvements in glucose tolerance aside from improvements in fasting 
glucose. Some CR studies have shown that female mice do show reduced fat mass in 
response to CR246,247, whilst some, in concordance with the results presented here, show 
that female’s fat mass is unaltered or can even increase in response to CR248,249.  One 
potential reason for some studies showing reduced fat mass in females is diet duration, 
in the above cited studies mice underwent CR for 20 weeks246 or 3 months247 indicating 
that females may lose fat mass after longer durations of CR. Mouse strain may also be an 
important determinant with some strains showing large decreases in female fat mass 
whilst others showed no change or even increases in fat mass247. The picture in humans 
is also complicated, with females showing reduced fat mass in response to CR in some 
studies but not in others233,234. No consensus has been reached regarding the nature of 
fat loss discrepancies between male and females in mice, humans or indeed other 
species. Future work could focus on ovariectomised mice to evaluate the contribution of 
female sex hormones on these differences with the hypothesis being that female mice 
without ovaries would react to CR with a more male-like phenotype. 
The dissected adipose tissue masses mirror the lipid mass changes observed by TD-
NMR, with male mice showing a decrease in both lipid mass and adipose tissue mass, 
whilst females did not show reductions in either lipid mass by TD-NMR nor less massive 
adipose depots by dissection. This indicates that the changes seen in fat mass by TD-
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NMR are indicative of gross changes in adipose depots rather than more generic changes 
in total body lipids and can be trusted to recapitulate the effects of CR on adipose depots. 
Here we chose to measure the inguinal WAT as a representative depot of subcutaneous 
adipose and gonadal and mesenteric WAT was representative of visceral depots. Whilst 
we saw effects in these depots there are also other WAT depots present in mice which 
could also have been used to quantify WAT mass and may have shown different results. 
These include perirenal WAT250 and perivascular WAT251. 
The lean mass GTT in females was performed given the hypothesis that the lack of 
response in glucose homeostasis induced by CR may be caused by a reduction in lean 
mass rather than fat mass as observed from the TD-NMR and WAT dissection data. Given 
that skeletal muscle, a type of lean tissue, is a very large source of peripheral glucose 
uptake252,253, it seemed likely that if females had less lean mass relative to their total 
body mass then the glucose dose they were receiving relative to their body mass may be 
too high. By administering glucose relative to the lean mass of the mice we sought to give 
the female mice an appropriate glucose dose relative to the major site of uptake. We 
expected that if this hypothesis was correct the GTT plots and AUC analysis in the female 
mice would appear more male-like. We did not see this, the female mice continued to 
exhibit the same response to the glucose tolerance test irrespective to the glucose dose 
being calculated relative to total body mass or lean mass. This indicates that the sex 
differences observed between males and females are not a result of inappropriate 
glucose doses and instead reflect an underlying biological difference between males and 
females. 
5.3.3. Are the metabolic effects of CR concordant with previous studies 
Body mass reduction is well established as a result of CR, it has been observed in 
humans254, rats255, rhesus monkey256, rabbits129 and, importantly, mice257. Reductions in 
body mass seen in these mice indicates that the CR intervention is working as 
anticipated and further analysis can be performed. Both male and female mice were 
showing reductions in body mass and the contribution of various tissue types was 
elucidated by TD-NMR body composition and post-cull tissue dissection. 
5.3.4. Technical considerations and limitations 
The TD-NMR measurements were performed fortnightly, this duration was chosen in 
order to reduce the stress caused to the mice that might be caused by more regular 
measurement, given that the procedure involves placing the mouse in a confined space 
for approximately 40 seconds. Despite these concerns the mice appeared to habituate to 
the procedure rapidly and therefore for future experiments, weekly measures by TD-
NMR were performed. A major advantage of using TD-NMR for body composition is the 
non-invasive nature of the procedure, this allows longitudinal measures to be made and 
changes in composition of individual mice to be tracked. This provides more insight into 
the overall effect of CR as well as enhancing the statistical analysis performed by 
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allowing for paired analysis. One small disadvantage of using TD-NMR is the inability to 
attribute changes to specific tissues. The local environment of protons is measured but 
these protons cannot be located to a specific tissue type. For example, we see a reduction 
in fat mass in male mice induced by CR, but this change cannot be attributed to a 
reduction in adipose tissue by TD-NMR alone, merely that fewer protons are in a lipid 
microenvironment, which may be a reduction in lipid in other tissues such as the liver. 
For this reason, tissue dissection was also performed to gain an understanding of 
changes in specific tissues. This, however, is a terminal procedure and therefore cannot 
be performed longitudinally. 
A potential confounding factor during the dissection of adipose depots and other tissues 
post-mortem is variability in the dissection technique. For well-defined organs, such as 
the liver, dissection is easy as the tissues are separated and adjoined to the surrounding 
tissue at few locations. However, in more diffuse tissues, such as BAT, the edges of the 
tissue are not clearly defined and the boundary is more subjective. In order to control for 
variation in dissection technique, the number of people performing the dissection across 
the multiple cohorts was kept to a minimum. In this case two different people dissected 
tissues and organs but no differences were seen in tissue masses between these people 
(data not shown). Additionally, the dietary group of the mouse was blinded in the people 
involved in the dissection as best as possible to prevent unconscious bias when the 
tissues were removed. This was difficult given the AL diet and CR diet were different 
colours, to prevent confusion when feeding, and could be seen in the digestive tract of 
the mice upon opening of the peritoneum. Another issue to overcome in the dissection 
procedure of the mice is the feeding regimen prior to cull. The nature of administration 
of the CR diet meant that the CR mice were receiving their food once per day and were 
effectively short-term fasting between daily feeds. In contrast, the AL mice had 24-hour 
free access to their food and so experienced very little fasting. If these mice were culled 
in a free-fed state it is likely that the CR mice would be in a fasted state whilst the AL 
mice would be in a fed state. This would confound the results of the experiment as the 
aims were to investigate the longer-term effects of CR and not the effects of short term 
fasting. Therefore, it was required that both groups of mice were in fasted states, such 
that any differences observed would not be influenced by an alteration in fed state. The 
pre-cull feeding regimen is described in the methods and allowed both groups of mice be 
fasted to a similar degree. Unfortunately, it was not possible to match the fasting 
duration perfectly and so many have added to some of the variation in the data between 
CR and AL groups.  
When quantifying the concentrations of adiponectin in the circulation an ELISA was 
used, this is a well-established and reliable method for quantifying adiponectin and has 
been widely used in the past12,258-260. A potentially confounding element of the 
adiponectin quantification is the collection of plasma samples that were used in the 
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ELISA. Blood sampling was performed in the morning, prior to administration of diet to 
the CR mice. This means that the CR mice were in their maximally fasted state whilst the 
AL mice had had free access to food during the night and therefore were likely more fed 
than the CR mice. Additionally, the plasma taken from the endpoint of the experiment 
was taken from mice fasted in both CR and AL groups as described previously. Despite 
this, it was not expected that this affected the results in a significant manner. Fasting or 
leptin administration (a molecular mimic of fasting) have been shown to not cause 
significant variation in circulating adiponectin concentrations261. The plasma isolated 
from the mice was frozen which can have a negative effect on proteins, particularly 
storage time in the freezer262. Despite this, adiponectin has been shown to be stable 
across multiple freeze-thaw cycles10 whilst the plasma used in this experiment only 
experienced one freeze-thaw cycle. Additionally, adiponectin in fresh frozen plasma 
samples, used clinically, has been shown to exert a specific beneficial effect in trauma 
patients263 further indicating the stability of adiponectin during freeze-thawing. 
 
A surprising observation from the adiponectin quantification was the higher 
concentration of high molecular weight adiponectin multimers than total adiponectin 
concentrations. This indicates a technical issue in the quantification given that the total 
adiponectin ELISA should measure the high molecular weight multimers in addition to 
the medium and low weight multimers. One explanation for these findings could be that 
ELISAs from different manufacturers were used for total and high molecular weight, as 
therefore, different antibodies were used in the detection of the protein. This means a 
different affinity which could result in different relative concentration. Despite this, the 
relative differences between total and HMW adiponectin are still valid given that all 
samples for either total or HMW were analysed with the same kit and thus whilst the 
absolute concentrations may not be comparable, the relationship between the multimers 
is still valid. 
 
Whilst the GTT plots and AUC in the male mice were all fairly similar across the differing 
durations of CR, the 4-week time-point appeared to show a slightly different pattern to 
the 1-, 2- and 6-week points. The reduction in fasting glucose was still present in the CR 
mice at 4 weeks but the initial increase in blood glucose was greater in the CR mice 
compared to the AL group and increased to nearly the same point 15 minutes after 
glucose administration. When this was analysed in the AUC the typical pattern was seen 
relative to 0 mM glucose, indicative of an improvement in fasting glucose, which was also 
seen in the glucose-over-time plots. However, when looking at the AUC relative to fasting 
glucose concentrations the 4-week dietary groups do not mirror the other time points. 
The 2- and 6-week time points show a reduction in AUC in the CR mice with a similar 
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(yet non-significant) trend after 1 week. In the 4-week group, no significant differences 
are observed yet the mean of the CR group is higher than the mean in the AL group, the 
opposite of what is seen in the other time points. There are two potential explanations 
for this observation: firstly, there may be metabolic changes that occur after 2 weeks of 
CR and then revert between 4 and 6 weeks, but this seems fairly unlikely given the short 
time frame and the lack of rationale for a transient abolition of glucose tolerance 
improvements induced by CR. The alternative explanation is that this is a technical issue. 
The glucose gavage can be a difficult technique and the potential for slightly incorrect 
administration is not insignificant, and whilst there were no signs of technical variation 
during the GTT this does not discount the possibility of it occurring and influencing the 
result. 
 
As mentioned previously the fasting of CR and AL mice is problematic and required some 
compromise, therefore it was deemed necessary to confirm that the effect from the 
fasting regime was not causing the differences seen between AL and CR mice. In order to 
test this, the CR mice were fed the AL ration before the fast and the AL mice were fed a 
CR ration. If the pre-GTT diet was causing the differences seen, we would have expected 
to see either a reversal in difference between AL and CR or the abrogation in difference. 
When the GTT was performed the reverse-fed mice performed in an equivalent manner 
to the normally fed mice, we therefore concluded that the short-term diet before the GTT 
was not a causative factor in the differences between AL and CR and that the long-term 
diet was the influencing factor. 
 
 
When differences in glucose tolerance are seen, insulin is the most likely cause of these 
effects and has been previously reported to show significant differences across a glucose 
tolerance test264. Yet when we evaluated plasma insulin concentrations across the 
glucose tolerance test we saw very little difference between AL and CR groups, which 
was not necessarily expected, but also no differences across the duration of the glucose 
tolerance test which was not in concordance with previous literature. One reason for this 
may be that the 15-minute time point was not rapid enough to be able to catch the rapid 
increase in insulin caused by the bolus of glucose, especially given that these mice were 
lean and therefore likely to have a far more rapid insulin response compared to obese 
mice or humans undergoing glucose tolerance tests. In order to confirm or rectify this in 
future tests, a 5-minute and/or 10-minute plasma sample could be taken to confirm if 
insulin was increasing or staying constant as indicated here. This would also allow more 
accurate blood glucose concentrations to be measured and may allow further 
conclusions to be drawn regarding the glucose homeostasis during CR.  
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5.3.5. Future directions 
Future directions for this chapter, not included in subsequent chapters, will primarily 
focus on the sex differences between males and females in their response to CR. The 
primary goal would be to ascertain if the results seen in mice are recapitulated in 
humans. Whilst human CR experiments are more complex and expensive to perform, a 
large amount of historical data exists and it would be possible to evaluate previously 
taken whole-body scans of humans undergoing CR to examine any sex differences in 
regards to fat and lean mass changes. Glucose tolerance data may be harder to come by 
in calorie restricted humans; however, fasting glucose and insulin concentrations can 
provide a rough measure of glucose and insulin tolerance. For more murine 
experimentation, female mice could be ovariectomised and calorie restricted to evaluate 
the hypothesis that female sex hormones are contributing to the phenotype seen. If this 
hypothesis is correct, we would expect female mice that have undergone ovariectomy to 
respond to CR in a more male-like manner. To further evaluate the hypothesis that 
adiponectin is driving some of the metabolic adaptions to CR we used an adiponectin 
knockout mouse model to examine how lack of this hormone affects response to CR, this 




6. Mice lacking adiponectin show altered 
responses to caloric restriction 
6.1. Introduction 
Adiponectin  inversely correlates with BMI12 as well as subcutaneous and intra-
abdominal fat265, waist circumference13 and blood pressure13. This inverse relationship 
with adiposity has been dubbed the ‘adiponectin paradox’, given that adiponectin is 
secreted exclusively by adipose tissue12 yet when adipose tissue is at the highest levels 
hypoadiponectinaemia is observed. Conversely, leanness is associated with 
hyperadiponectinaemia. Understanding the mechanisms behind hypoadiponectinaemia is 
important, because this has implications for metabolic disease. For example, circulating 
concentrations of adiponectin are also reduced in patients with type 2 diabetes compared to 
BMI-matched non-diabetics17. In addition, people with higher circulating  adiponectin 
concentrations are at a significantly reduced risk of developing type 2 diabetes in later life266. 
6.1.1. Past adiponectin studies 
Much of the previous work on adiponectin knockout mice has focussed on conditions of 
high-fat diet. While this makes sense in terms of addressing the role of adiponectin in 
obesity and diabetes, it is also perplexing considering that obesity is the condition in 
which adiponectin is at its lowest. Despite this, mice lacking adiponectin on a high-fat 
diet develop more rapid glucose intolerance compared to wild-type mice267. Additionally, 
the effects of insulin-sensitising PPARγ agonists such as thiazolidines (TZD) are 
ameliorated in adiponectin knockout mice, supporting a role for adiponectin in glucose 
sensitivity268. One study of particular note aimed to examine the role of adiponectin 
during CR but focussed on outcomes relating to ischemia-reperfusion injury. CR is 
known to restore the hearts ability to resist ischemia reperfusion injury107 indicating 
that CR has the ability to enhance the hearts defence mechanism against ischemic stress. 
Given this, the role of adiponectin during ischemic stress was examined using Ad-As 
mice which over express an anti-sense oligonucleotide against adiponectin108. They 
found that the Ad-As mice resisted the CR-induced hyperadiponectinaemia, especially 
the HMW multimers108 and they also showed a corresponding resistance to positive 
recovery from ischemia-reperfusion injury and reduced myocardial glycogen content in 
the Ad-As mice108. Interestingly, they also showed that administration of recombinant 
adiponectin to the Ad-As mice via an osmotic minipump restored the CR-induced 
improved recovery response to ischemia reperfusion injury including a reduced infarct 
size108. In addition, they also showed that treatment with an AMPK inhibitor abrogates 
the cardioprotective effect of CR108. Overall this indicates that adiponectin contributes to 
the cardioprotective effects of CR and it may be mediated through stimulating AMPK 
activity in the myocardium. This effect has also been reproduced in a model of hind limb 
ischemia, with CR enhancing the revascularisation of ischemia hind limbs in WT mice but 
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not in adiponectin KO mice109. This is important for this thesis because it shows that 
adiponectin plays an important role during calorie restriction and therefore it seems 
likely that adiponectin will also exert other CR-induced effects, especially given the 
previously described metabolic effects of adiponectin. 
Treatment with adiponectin causes a decrease in plasma glucose in wild-type mice, but 
not in mice with a double knockout of both adiponectin receptors30. Additionally, these 
double knockout mice showed markedly higher plasma insulin concentrations, 
indicating insulin resistance30. Glucose tolerance tests in these mice, when fed a high-fat 
diet, showed impaired glucose tolerance and increased plasma insulin compared to wild 
type mice30. Additionally, euglycaemia-hyperinsulinaemic clamp studies have 
demonstrated that mice lacking adiponectin have significantly impaired suppression of 
insulin-stimulated hepatic glucose production268. Treatment of mice with globular 
adiponectin decreased plasma free fatty acid concentrations8 indicating a role for 
adiponectin in lipid metabolism as well as insulin sensitivity. 
Body fat may not be the ultimate determinant of adiponectin concentrations during CR. 
Studies examining the effect of genetically low insulin during calorie restriction on mice 
showed that CR caused paradoxical increases in fat mass, yet adiponectin was still 
elevated as normal241. This could be reflective of previously discussed studies showing a 
role for BMAT in CR-induced hyperadiponectinaemeia. 
Indirect calorimetry was used gain a better understanding of the adaptions in energy 
expenditure, basal metabolism and substrate utilisation during CR. Rats on CR diet had 
decreased O2 usage and reduced resting metabolic rate269. The ratio between O2 usage 
and CO2 production is termed the respiratory exchange ratio (RER) was increased269. 
With regards to energy expenditure and resting metabolic rate alterations during calorie 
restriction, the literature shows a variety of conclusions with some showing that resting 
metabolic rate is not altered during calorie restriction when taking into account the body 
size of the animals81,270. Whereas others have shown that the tissue calorie restricted 
animals reduce their energy expenditure even when taking into account reduced 
size227,271. An additional parameter is the energy expended by activity. Mice exhibited 
decreased physical activity in response to CR as a strategy to conserve energy272. Mice 
also displayed increased activity in the hours immediately preceding feeding in a 
phenomenon known as food anticipatory activity. 
6.1.2. Aims of the chapter 
This present chapter aims to address the impact of adiponectin on imparting the 
metabolic benefits of CR. The first aim is to generate and maintain a stock of adiponectin 
knockout mice. We will then place these mice on AL or CR and characterise the basic 
physical parameters of the mice including body mass, composition and specific tissue 
masses. We will then aim to evaluate both the glucose and lipid metabolic phenotype of 
these mice. The glucose homeostasis phenotyping will comprise oral glucose tolerance 
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tests whilst the lipid homeostasis phenotyping will comprise liver and plasma lipid 
analysis. Finally, both glucose and lipid homeostasis will be evaluated on a whole 
organism scale via indirect calorimetry. If adiponectin is mediating at least some of the 
effects of calorie restriction, we will expect to see differences in response CR between 
the AL and CR diet mice in any of the above parameters. This will answer important 
questions about the physiological benefit of investing resources to increasing 
concentrations of adiponectin during times of calorie scarcity. 
6.2. Results 
6.2.1. Confirmation of genotype 
It was essential to show that the adiponectin knockout was successful. Immunoblotting 
was performed on mouse plasma in order to detect the presence of the hormone in the 
blood. The resulting Western blot confirms that the wild-type mice had detectable 
plasma adiponectin whereas the KO mice did not (Figure 6.1). A total protein stain was 
used to confirm that the poly-acrylamide gel was loaded correctly and that all lanes 
contained protein. This showed that the absence of adiponectin in the knockout mice 
was not a result of lack of protein loaded. This procedure was performed on all 




Figure 6.1 – Immunoblot for adiponectin and total protein stain from mouse 
plasma. Mouse plasma was denatured in loading buffer containing SDS. Electrophoresis 
was performed through a polyacrylamide gel then the protein transferred to a 
nitrocellulose membrane. The total protein was stained and visualised using LiCor total 
protein stain. After washing this stain, anti-adiponectin antibody was used to detect the 
absence or presence of adiponectin in the samples. 
 
6.2.2. Basic measures of whole-body composition 
As with the CR time course, one method to confirm that the dietary intervention was 
successful was to measure the body composition of the animals. CR induced weight loss 
in males and females (Figure 6.2). Given that this data in wild type mice has already been 
presented, the only statistical test performed was to detect differences between wild 
type and knockout mice within each dietary group. No differences were detected in body 
mass between WT and KO mice. However, visual inspection on the data reveals that 




Figure 6.2 –Adiponectin deficiency does not affect body mass  
Male (A) and female (B) mice were weighed weekly. Mean body mass is shown with 
error bars indicating ± SD. Statistical significance was determined by 2-way ANOVA, 
multiple comparisons between wild type and knockout mice were determined using 
Sidak’s correction and p values are shown above the data. Numbers used Male WT AL – 
10; male WT CR – 9; male KO AL – 6; male KO CR – 9. Female WT AL – 7; female WT CR – 
8; female KO AL – 9; female KO CR – 8. 
 
TD-NMR was performed to quantify their lean and fat masses. Male mice showed 
decreased fat and lean mass, whilst the females exclusively lost lean mass in response to 
CR (Figure 6.3). KO mice showed significantly different lean mass compared to WTs on 
the AL diet. This effect was present before commencing the diet, and so may not be 
related to the diet. Furthermore, the effect is not seen in the CR mice prior to beginning 





Figure 6.3 – The effects of adiponectin deficiency on body composition determined 
by TD-NMR Male and female mice underwent TD-NMR every week. (A) Male fat mass 
expressed in grams. (B) Female fat mass expressed in grams. (C) Male lean mass 
expressed in grams. (D) Female lean mass in grams. Mean measurement is shown with 
error bars indicating ± SD. Statistical significance was determined by 2-way ANOVA, 
multiple comparisons between wild type and knockout mice were determined using 
Sidak’s correction and p values are shown above the data. Numbers used as described in 
figure 6.2. 
6.2.3. Necropsy masses 
Given our hypothesis that adiponectin mediates metabolic benefits of CR, we 
investigated the possibility that adiponectin was involved in adipose tissue distribution 
and metabolism during CR. To further assess fat distribution, WAT depots were 
dissected from subcutaneous and visceral locations during necropsy of the mice (figure 
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6.4). As previously observed by TD-NMR and preceding experiments, the male mice 
showed significantly lower WAT masses caused by CR diet, whilst female mice did not. In 
terms of genotypic differences, nothing was detected in the male mice. In the female 
mice, those lacking adiponectin had significantly higher iWAT when looking across both 
AL and CR groups however this effect was not seen in the gWAT or mWAT. In the gWAT 
a significant interaction was observed in the female mice, with the gWAT mass higher in 
KO mice in the AL group but lower in KO mice in the CR group; a similar trend was also 
observed for mWAT.  
 
Figure 6.4 – Dissected adipose in males do not show any differences in mice 
lacking adiponectin, female mice may have altered iWAT mass when lacking 
adiponectin. Male and female mice were culled by cervical dislocation and tissues were 
dissected and weighed. (A) iWAT, gWAT and mWAT depot masses in male mice. (B) 
iWAT, gWAT and mWAT depot masses in female mice. All data points shown with 
median, interquartile range and range shown by box and whisker plot. Statistical 
significance was determined by 2-way ANOVA, source of variance significance is shown 
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above the data and multiple comparisons between wild type and knockout determined 
using Sidak’s correction are indicated on the data. Number used as in figure 6.2. 
 
As previously seen during the time course experiment, there were significant effects on 
BAT, liver and spleen masses during CR. To test if the absence of adiponectin alters these 
CR effects, these tissues were weighed during necropsy (figure 6.5). Additionally, no 
genotypic effects were detected for BAT mass in either sex. This indicates that BAT is 
unaffected by CR or the absence of adiponectin. The masses of liver and spleen were, 
once again, significantly reduced by CR but there was no effect caused by lack of 
adiponectin, further indicating that adiponectin does not influence the reduced mass of 




Figure 6.5 – The effects of adiponectin deficiency on BAT, liver and spleen masses. 
Male and female mice were culled by cervical dislocation and tissues were dissected and 
weighed. (A) Male BAT. (B) Female BAT. (C) Male liver. (D) Female liver. (E) Male 
spleen. (F) Female spleen. All data points shown with median, interquartile range and 
range shown by box and whisker plot. Statistical significance was determined by 2-way 
ANOVA, source of variance significance is shown above the data and multiple 
comparisons between wild type and knockout determined using Sidak’s correction are 




6.2.4. Glucose tolerance greater in Adipoq KO male mice than WT on a CR 
diet 
Previous studies have reported that adiponectin KO results in impaired glucose 
tolerance and insulin sensitivity. Therefore, we hypothesised that adiponectin 
contributes to CR-induced improvements in glucose tolerance. On this basis, we 
predicted that adiponectin KO mice would resist the improved glucose tolerance 
associated with CR. The same GTT procedure was used as described previously; briefly, 
mice were fasted for ~6-8 hours and given an oral dose of glucose relative to their whole 
body mass. Blood glucose was quantified before the glucose bolus and at multiple time 
points across the experiment. 
Blood glucose was significantly higher in ad libitum-fed male KO mice at the 15-minute 
time point of the GTT (Figure 6.6). In contrast, blood glucose was significantly lower in 
CR male AdKO mice at the 15-minute time point of the GTT. This result indicated that 
adiponectin may be a negative factor in CR-induced improvements in glucose 
homeostasis. 
When analysing glucose tolerance by AUC analysis, males and females showed a 
significant  reduction caused by CR for AUC calculated relative to 0 mM, (6.6 E & F) but 
not when relative to the fasting glucose of each animal (6.6 C & D). Thus, as in Chapter 5, 
this indicates that fasting glucose improvements are a major driving force for CR-
associated improvements in glucose tolerance. There were no genotypic effects present 
when looking at the overall performance in the test, indicating that the time-point-




Figure 6.6 – The effects of adiponectin deficiency on glucose tolerance of male and 
female mice. Male and female mice were fasted then given an oral dose of glucose 
relative to their body mass. Blood glucose concentrations were measured before glucose 
administration and 15, 30, 60 and 120 minutes after. AUC analysis was performed on the 
resulting glucose concentration plots relative to the fasting glucose of individual mice 
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and to 0 mM glucose. (A) Male blood glucose concentrations. (B) Female blood glucose 
concentrations. Mean measurement is shown, with error bars indicating ± SD. Statistical 
significance was determined by 2-way ANOVA, multiple comparisons between wild type 
and knockout mice were determined using Sidak’s correction, *: p < 0.05, **: p < 0.01. (C) 
Male AUC relative to fasting glucose. (D) Female AUC relative to fasting glucose. (E) Male 
AUC relative to 0 mM glucose. (F) Female AUC relative to 0 mM glucose. All data points 
shown with median, interquartile range and range shown by box and whisker plot. 
Statistical significance was determined by 2-way ANOVA, source of variance significance 
is shown above the data and multiple comparisons between wild type and knockout 
determined using Sidak’s correction are indicated on the data. Numbers used as 
described in figure 6.2. 
 
6.2.5. Liver and plasma lipid concentration 
Given the greater improvements in glucose tolerance observed in adiponectin KO mice 
there is a possibility that the mice lacking adiponectin have a reduced ability to 
metabolise fats and therefore are more reliant on glucose as an energy source; if so, this 
may account for the improved glucose tolerance of KO mice during CR. To test this, I first 
quantified the concentrations non-esterified fatty acids (NEFA) in the plasma of the mice, 
after the full 4 weeks of dietary intervention. Male CR mice showed elevated plasma 
NEFA concentrations. Within the CR group the adiponectin KO mice showed an elevation 
in NEFA concentrations. In contrast, the females did not show any significant differences 
in plasma NEFA concentrations. 
 
Given the lipid accumulation in the plasma we then examined the triacylglycerol 
concentration in the liver, a major site of lipid metabolism273. In contrast to plasma 
NEFA, hepatic TG concentrations were not influenced by diet or genotype in males or 
females. This indicates that, in our cohorts, adiponectin KO or CR does not influence lipid 
accumulation in the liver, despite the anecdotal evidence of observing some livers to be 





Figure 6.7 – The effects of adiponectin deficiency on plasma NEFA and liver 
triglycerides. Plasma from male and female mice was analysed for NEFA and liver for 
triacylglycerides, both by colorimetric assay. (A) Male plasma NEFA. (B) Female plasma 
NEFA. (C) Male liver TG. (D) Female liver TG. All data points shown with median, 
interquartile range and range shown by box and whisker plot. Statistical significance was 
determined by 2-way ANOVA, source of variance significance is shown above the data 
and multiple comparisons between wild type and KO determined using Sidak’s 
correction are indicated on the data. *: p < 0.05. Numbers used as described in figure 6.2. 
 
Another class of lipids present in the liver and with a link to adiponectin signalling are 
the sphingolipids, including ceramide species. Adiponectin decreased hepatic ceramides 
perhaps explaining why adiponectin improves insulin sensitivity274. Therefore, it was 
hypothesised that mice lacking adiponectin have altered ceramide profiles and that this 
may be a causal factor in their altered glucose tolerance. To address this, ceramides and 
their precursors, dihydroceramides, were quantified from frozen liver tissue by mass 
spectrometry I analysed male livers only, reasoning that males showed greater diet and 
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genotype effects on glucose homeostasis and therefore would be more likely to reveal 
effects on hepatic ceramides. The total ceramide concentrations were not altered by diet 
or genotype. However, many specific ceramide species were changed. Shorter-chain 
ceramides, 14:0, 16:0, 18:0, 18:1 and 20:1, and the long chain ceramide 23:0 were all 
increased in CR mice (Figure 6.8); ceramide 20:0 was unaffected. In contrast, medium-
length ceramide 22:0 and 22:1 were lower in CR mice. There was no effect of adiponectin 
deficiency on short or medium or the 23:0 ceramides. Adiponectin deficiency had a 
specific effect on ceramide 23:1, whereby, CR increased 23:1 in WT mice but tended to 
decrease this species in KO mice (Figure 6.8). Both 24:0 and 24:1 ceramides were 
unaffected by diet and genotype whilst long-chain ceramides 26:0 and 26:1 were 





Figure 6.8 –. The effects of adiponectin deficiency on ceramide species in liver of 
AL and CR fed males. Liver from male mice was quantified for ceramide concentration 
-137- 
 
by mass spectrometry. (A) Total ceramides. (B) Ceramide 14:0. (C) Ceramide 16:0. (D) 
Ceramide 18:0 (E) Ceramide 18:1 (F) Ceramide 20:0 (G) Ceramide 20:1 (H) Ceramide 
22:0 (I) Ceramide 22:1 (J) Ceramide 23:0 (K) Ceramide 23:1 (L) Ceramide 24:0 (M) 
Ceramide 24:1 (N) Ceramide 26:0 (O) Ceramide 26:1. All data points shown with 
median, interquartile range and range shown by box and whisker plot. Statistical 
significance was determined by 2-way ANOVA, source of variance significance is shown 
above the data and multiple comparisons between wild type and KO determined using 
Sidak’s correction are indicated on the data. Numbers used male WT AL – 9; WT CR – 9; 
KO AL – 6; KO CR – 9. 
 
To further assess the impact of CR and adiponectin on ceramide biosynthesis and 
function, I next quantified hepatic dihydroceramide content. The dishydroceramids are 
the immediate precursors to the corresponding chain length ceramides275; hence, 
measuring their concentrations may further reveal if altered biosynthesis was 
contributing to the effects of CR on ceramide concentration. In a very similar fashion to 
the ceramides, the short-chain dihydroceramides were mostly upregulated by CR, with 
14:0, 16:0, 18:0 and 18:1 each elevated (Figure 6.9). This indicates a strong association 
between ceramides and their dihydro-precursors, at least at these chain lengths. Unlike 
its 20:1 its ceramide counterpart, dihydroceramide 20:1 was not affected by diet or 
genotype. Dihydroceramides 20:0 and 24:1 were also unaltered, although this was also 
observed for the 20:0 and 24:1 ceramide counterparts. The 22-carbon dihydroceramides 
also mirrored their ceramide analogues, with CR downregulating 22:0 and 22:1, but 
upregulating 23:0 species (Figure 6.9). The 23:1, 26:0 and 26:1 species were all 
undetectable as dihydroceramides (Figure 6.9). In contrast, 24:0 dihydroceramide was 
upregulated by CR despite being unchanged at the ceramide level. Generally, the 
dihydroceramides and ceramides showed parallel regulation, Notably, Adiponectin KO 
generally had no effect on hepatic dihydroceramide content. 
The ratio of DHC:Cermide concentration is also a useful measure of ceramide 
metabolism. When analysed, these ratios showed no differences between WT and KO 




Figure 6.9 – The effects of adiponectin deficiency on dihydroceramide species in 
liver of AL and CR fed males. Liver from male mice was quantified for dihydroceramide 
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concentration by mass spectrometry. (A) Total dihydroceramides. (B) Dihydroceramide 
14:0. (C) Dihydroceramide 16:0. (D) Dihydroceramide 18:0 (E) Dihydroceramide 18:1 
(F) Dihydroceramide 20:0 (G) Dihydroceramide 20:1 (H) Dihydroceramide 22:0 (I) 
Dihydroceramide 22:1 (J) Dihydroceramide 23:0 (K) Dihydroceramide 24:0 (L) 
Dihydroceramide 24:1 (M) Dihydroceramide 23:1 (N) Dihydroceramide 26:0 (O) 
Dihydroceramide 26:1. All data points shown with median, interquartile range and range 
shown by box and whisker plot. Statistical significance was determined by 2-way 
ANOVA, source of variance significance is shown above the data and multiple 
comparisons between wild type and KO determined using Sidak’s correction are 
indicated on the data. Number used as described inn figure 6.8. 
 
6.2.6. Metabolic cages and indirect calorimetry 
A technique for assessing whole body lipid metabolism is indirect calorimetry. 
Measurement of oxygen consumption and carbon dioxide production in a defined space 
allows determination of total energy expenditure and preferential fuel utilisation, 
specifically the ratio of carbohydrate to fat catabolism. If an altered lipid metabolism 
phenotype is responsible for the altered glucose tolerance response, then we would 
expect to see a differential response to CR in the adiponectin KO mice in respiratory 
quotient.  
Figure 6.10A shows male oxygen consumption, to adjust for individual variation, mean 
oxygen consumption was calculated across the entire 24-hour period and split into the 
light and dark phases which delimit the feeding and torpor cycles of mice. Note that the 
dark phase of mice, which are nocturnal, is normally accompanied by a robust increase 
in feeding behaviour, increased activity and energy expenditure and a switch to 
carbohydrate utilisation with ingestion of a normal chow diet.  Across the entire 24-hour 
period, CR caused a significant decrease in oxygen consumption. Notably, decreased 
oxygen consumption is observed selectively over the dark phase. Adiponectin deficiency 
did not affect male oxygen consumption. 
In females, shown in figure 6.11, we observed the same phenomenon. They had lower 
oxygen consumption caused by CR and this was driven by a reduction during the night, 
but not during the day. 
As for oxygen, carbon dioxide in male mice is decreased across 24 hours with this effect 
being solely down to a difference during the night. There was also a significant 
interaction between diet and genotype during the night, with CR-induced decreases in 
carbon dioxide being more pronounced in WT mice (Figure 6.12). However, given the 
low numbers of mice studied, additional experiments should be done before firm 
conclusions can be drawn. 
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Female carbon dioxide exhalation was also decreased with CR and this was caused by 
effects during the night and not during the day (Figure 6.13). However, unlike the males, 
females did not show a significant interaction over night between diet and genotype. 
We then combined the oxygen consumption and carbon dioxide production to give the 
respiratory quotient (RER), a ratio between the two gasses which give information on 
the energy substrate utilisation of the animals. A ratio of 1 is indicative of glucose 
metabolism, a ratio of 0.8 represents protein or a mixed diet metabolism and 0.7 
indicates that lipids are being metabolised. This change in ratio is caused by additional 
oxygen being required for metabolising fats and proteins prior to them entering 
glycolysis or the TCA cycle. 
The male RER 24-hour plot shows an easily recognisable pattern, with the RER elevated 
during the day phase in the CR mice (Figure 6.14). When this was averaged out across 
the entire 24-hour period we saw a significant elevation caused by CR. When broken into 
day and night we saw that the 24-hour increase in RER was caused solely by an increase 
during the day; at night CR tended to decrease RER and this effect appeared to be greater 
in the WT than in the KO mice. This tentatively would support the possibility that CR-
mediated enhancement of fat catabolism is impaired in the KO males; however, this is 
highly speculative, underscoring the need for additional mice to be studied. 
In females the same is observed, with RER elevated in CR mice across a 24-hour period 
as a result of significant increases during the day; however, unlike in males, there was no 
trend in females for CR to decrease RER nocturnally. 
 These results for male and female mice were surprising considering that all the 
differences we had observed in oxygen and carbon dioxide had been observed during the 
night, yet the differences in RER were observed purely during the day. No genotypic 
differences in RER were observed in males or females, indicating that, generally, lack of 
adiponectin does not influence these metabolic effects of CR. 
The final metabolic measurement available from the metabolic cage measurement is 
energy expenditure. Male energy expenditure was significantly reduced by CR, no 
differences were detected during the day and all differences were accounted for by a 
reduction during the night. This pattern was mirrored in females with a reduction in 






Figure 6.10 – The effects of adiponectin deficiency on male oxygen consumption. 
Oxygen consumption was measured by quantifying differences between reference air 
and exhaled air from metabolic cages over 24 hours. All data was normalised to lean 
body mass measurement by TD-NMR. (A) Male oxygen consumption measured every 15 
minutes over 24 hours. Mean rate for each group plotted every 15 minutes with error 
bars indicating ± SD (B) Average oxygen consumption rate over 24 hours. (C) Average 
oxygen consumption rate during the day. (D) Average oxygen consumption rate during 
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the night. All data points shown with median, interquartile range and range shown by 
box and whisker plot. Statistical significance was determined by 2-way ANOVA, source of 
variance significance is shown above the data and multiple comparisons between wild 
type and KO determined using Sidak’s correction are indicated on the data. Numbers 
used male WT AL – 4; WT CR – 3; KO AL – 3; KO CR – 5. 
 
 
Figure 6.11 – The effects of adiponectin deficiency on female oxygen consumption. 
Oxygen consumption was measured by quantifying differences between reference air 
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and exhaled air from metabolic cages over 24 hours. All data was normalised to lean 
body mass measurement by TD-NMR. (A) Female oxygen consumption measured every 
15 minutes over 24 hours. Mean rate for each group plotted every 15 minutes with error 
bars indicating ± SD (B) Average oxygen consumption rate over 24 hours. (C) Average 
oxygen consumption rate during the day. (D) Average oxygen consumption rate during 
the night. All data points shown with median, interquartile range and range shown by 
box and whisker plot. Statistical significance was determined by 2-way ANOVA, source of 
variance significance is shown above the data and multiple comparisons between wild 
type and KO determined using Sidak’s correction are indicated on the data. Numbers 





Figure 6.12 – – The effects of adiponectin deficiency on male carbon dioxide 
exhalation. Carbon dioxide exhalation was measured by quantifying differences 
between reference air and exhaled air from metabolic cages over 24 hours. All data was 
normalised to lean body mass measurement by TD-NMR. (A) Male carbon dioxide 
production measured every 15 minutes over 24 hours. Mean rate for each group plotted 
every 15 minutes with error bars indicating ± SD (B) Average carbon dioxide production 
rate over 24 hours. (C) Average carbon dioxide production rate during the day. (D) 
Average carbon dioxide production rate during the night. All data points shown with 
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median, interquartile range and range shown by box and whisker plot. Statistical 
significance was determined by 2-way ANOVA, source of variance significance is shown 
above the data and multiple comparisons between wild type and KO determined using 
Sidak’s correction are indicated on the data. Numbers used as described in figure 6.10. 
 
 
Figure 6.13 – – The effects of adiponectin deficiency on female carbon dioxide 
exhalation. Carbon dioxide exhalation was measured by quantifying differences 
between reference air and exhaled air from metabolic cages over 24 hours. All data was 
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normalised to lean body mass measurement by TD-NMR. (A) Female carbon dioxide 
production measured every 15 minutes over 24 hours. Mean rate for each group plotted 
every 15 minutes with error bars indicating ± SD (B) Average carbon dioxide production 
rate over 24 hours. (C) Average carbon dioxide production rate during the day. (D) 
Average carbon dioxide production rate during the night. All data points shown with 
median, interquartile range and range shown by box and whisker plot. Statistical 
significance was determined by 2-way ANOVA, source of variance significance is shown 
above the data and multiple comparisons between wild type and KO determined using 





Figure 6.14 – – The effects of adiponectin deficiency on male respiratory exchange 
ratio. The ratio of oxygen consumed and carbon dioxide produced was calculated over 
24 hours. All data was normalised to lean body mass measurement by TD-NMR. (A) Male 
respiratory exchange ratio measured every 15 minutes over 24 hours. Mean ratio for 
each group plotted every 15 minutes with error bars indicating ± SD (B) Average 
respiratory exchange ratio over 24 hours. (C) Average respiratory exchange ratio during 
the day. (D) Average respiratory exchange ratio during the night. All data points shown 
with median, interquartile range and range shown by box and whisker plot. Statistical 
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significance was determined by 2-way ANOVA, source of variance significance is shown 
above the data and multiple comparisons between wild type and KO determined using 
Sidak’s correction are indicated on the data. Numbers used as described in figure 6.10. 
 
Figure 6.15 – The effects of adiponectin deficiency on female respiratory exchange 
ratio. The ratio of oxygen consumed and carbon dioxide produced was calculated over 
24 hours. All data was normalised to lean body mass measurement by TD-NMR. (A) 
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Female respiratory exchange ratio measured every 15 minutes over 24 hours. Mean 
ratio for each group plotted every 15 minutes with error bars indicating ± SD (B) 
Average respiratory exchange ratio over 24 hours. (C) Average respiratory exchange 
ratio during the day. (D) Average respiratory exchange ratio during the night. All data 
points shown with median, interquartile range and range shown by box and whisker 
plot. Statistical significance was determined by 2-way ANOVA, source of variance 
significance is shown above the data and multiple comparisons between wild type and 
KO determined using Sidak’s correction are indicated on the data. Numbers used as 





Figure 6.16 – The effects of adiponectin deficiency on male energy expenditure. 
The energy expenditure was calculated over 24 hours. All data was normalised to lean 
body mass measurement by TD-NMR. (A) Male energy expenditure measured every 15 
minutes over 24 hours. Mean ratio for each group plotted every 15 minutes with error 
bars indicating ± SD (B) Average energy expenditure over 24 hours. (C) Average energy 
expenditure during the day. (D) Average energy expenditure during the night. All data 
points shown with median, interquartile range and range shown by box and whisker 
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plot. Statistical significance was determined by 2-way ANOVA, source of variance 
significance is shown above the data and multiple comparisons between wild type and 
KO determined using Sidak’s correction are indicated on the data. Numbers used as 
described in figure 6.10. 
 
Figure 6.17 – The effects of adiponectin deficiency on female energy expenditure. 
The energy expenditure was calculated over 24 hours. All data was normalised to lean 
body mass measurement by TD-NMR. (A) Female energy expenditure measured every 
15 minutes over 24 hours. Mean ratio for each group plotted every 15 minutes with 
error bars indicating ± SD (B) Average energy expenditure over 24 hours. (C) Average 
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energy expenditure during the day. (D) Average energy expenditure during the night. All 
data points shown with median, interquartile range and range shown by box and 
whisker plot. Statistical significance was determined by 2-way ANOVA, source of 
variance significance is shown above the data and multiple comparisons between wild 
type and KO determined using Sidak’s correction are indicated on the data. Numbers 
used as described in figure 6.11. 
The cages used during the indirect calorimetry are equipped with light beam sensors 
that can detect movement of the mice within the cages. They exist on both the x and y 
axis of the cage and the number of times the beams are broken is used as a measure of 
physical activity of the mice. Here, I present the number of beam breaks across a 24-hour 
period as well as this same period broken into the day (lights on) phase and night (lights 
off) phase. A strong diet effect was present in both males and females across the 24-hour 
measurement period, but this was strongly sexually dimorphic: the male CR mice were 
more active than their AL counterparts whilst the female CR mice were significantly less 
active than AL females (Figure 6.18). When we break this down into the day and night 
phase, we observed that the male CR mice were more active during the day than the AL 
mice but showed the same activity levels as the AL mice during the night. Conversely, in 
females, the CR group showed the same amount of activity as AL controls during the day 
phase and less activity during the night phase (Figure 6.18). Overall, CR increased 
physical activity in males and this was due to an increase during the day, whereas CR 
decreased activity in females and this was due to a decrease during the night. These 
activity differences could provide some rationale for the sexual dimorphisms in glucose 
tolerance observed in this chapter and chapter 5. No genotypic differences were 
observed in males or females, indicating no contribution of adiponectin to activity 




Figure 6.18 – Male CR mice are more active during the day and female CR mice are 
less active during the night than their AL counterparts. Light beam breaks in the x 
and y axis were counted over a 24 hour period and summed over this entire period as 
well as for the day and night phase. (A) Male 24 hour activity. (B) Female 24 hour 
activity. (C) Male day activity. (D) Female day activity (E) Male night activity (F) Female 
night activity. All data points shown with median, interquartile range and range shown 
by box and whisker plot. Statistical significance was determined by 2-way ANOVA, 
source of variance significance is shown above the data and multiple comparisons 
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between wild type and KO determined using Sidak’s correction are indicated on the data. 
Numbers used as described in figure 6.10 and 6.11. 
 
6.3. Discussion 
Four weeks of CR was chosen for the adiponectin KO study given previously acquired 
results from the time-course study (Chapters 4-5). We observed that 4 weeks of CR 
induced the maximal increases in adiponectin and that after this point adiponectin 
plasma concentrations remained fairly constant in CR mice. Therefore, to minimise the 
amount of time animals were required to be in the experiment, we chose to restrict the 
animals to the point of maximal hyperadiponectinaemia, but no further. One 
disadvantage of this is that we saw smaller changes in glucose tolerance in the time 
course after 4 weeks when compared to both 2-week and 6-week restrictions. Despite 
this, we still saw improvements in glucose tolerance between AL and CR WT males and, 
unexpectedly, this CR effect was even greater in KO mice of each sex, indicating that the 
4-week time point was sufficient to observe differences between the diets and 
genotypes. 
Given that adiponectin has been shown to act in the liver to reduce gluconeogenesis57, it 
was expected that mice lacking adiponectin would not be able to reduce their hepatic 
glucose production as well as the WT mice in response to the glucose bolus received 
during the glucose tolerance test. As we see here, the glucose tolerance response of the 
adiponectin KO mice was better, indicating that the mice are better at reducing their 
gluconeogenesis and/or at increasing their peripheral glucose uptake. This is counter 
intuitive to the previously cited literature showing that adiponectin inhibits 
gluconeogenesis and that adiponectin can increase peripheral glucose uptake44. Unlike 
on the CR diet, KO males fed an AL diet displayed impaired glucose tolerance compared 
to WT AL males, which is consistent with previous studies reporting impaired glucose 
tolerance with adiponectin KO. Thus, it may be that CR alters the mechanism for action 
of adiponectin which causes the opposite effects of adiponectin KO on glucose tolerance. 
Unlike previous chapters the data for lean and fat mass by TD-NMR and tissue necropsy 
masses were not plotted as percentages of total body mass and were only expressed in 
absolute terms. This decision was taken given that no great differences were observed 
between absolute and percentage previously and given that there were no changes 
caused by genotype in absolute tissue masses no differences were seen for percentages 
and so the data was not shown. 
We saw large increases in plasma NEFA in response to CR, which is a phenomenon that 
has been previously reported276. However, it should be noted that this effect was 
reversed after longer term CR276. It has been previously observed that adiponectin KO 
causes an increase in plasma triglyceride concentrations but not in plasma free fatty 
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acids267, and the impact of adiponectin on CR-induced changes in plasma lipids has never 
previously been determined. My findings show that, in males, adiponectin KO increases 
plasma NEFA during CR, suggesting that adiponectin promotes NEFA clearance and/or 
impairs lipolytic NEFA production during CR. Future studies should explore these 
possibilities, for example through fatty acid tolerance tests and analysis of rates of 
lipolysis in vivo. 
The triacylglyceride assay used to quantify TG concentrations in the liver works by 
lysing the fatty acids from the glycerol backbone and then using the glycerol to produce a 
quantifiable colour change. A disadvantage of this procedure is that it does not take into 
account any constitutive glycerol in the liver prior to TG cleavage. A more robust method 
for TG quantification would be to quantify constitutive glycerol present in the liver, not 
bound to fatty acids, then to quantify the total cleaved and constitutive glycerol and 
calculate the contribution of TG incorporated glycerol as a measure of TG concentration. 
The results of the ceramide analysis indicate that despite the cytotoxic effects of some 
ceramides, many species are increased in CR, suggesting potential beneficial effects on 
cellular and physiological function. The lack of genotypic differences was also surprising 
given the reported role of adiponectin signalling on ceramide synthesis, and suggest that 
adiponectin is not a major mediator of the effects of CR on ceramide metabolism 
The observed increase daytime activity induced by CR has been previously observed, a 
previous study involved looking at feeding time on CR experiments saw that CR mice fed 
during the day or overnight on a restricted diet were more active during the day277. 
However, this was only performed in male mice so does not corroborate the behaviour 
we observed in females. Male CR mice have also been observed to be more active during 
the day in another study, which found that this effect occurred after one month of CR 278. 
This further validates our finding, yet this previous study also showed that the effect 
does not persist after 6 months of CR278. An explanation for the increase in male CR mice 
activity may be food anticipatory activity (FAA), whereby organisms react to circadian 
rhythms associated with feeding279. Far less research has been performed on female 
mice to verify our findings of reduced activity during the night. However, these sex 
differences might contribute to the other sexually dimorphic effects of CR, such as on fat 
mass and glucose tolerance (Chapter 5). Thus, future studies should further explore if 
the effects of CR on energy homoestasis differ between males and females, as this may 
have widespread implications for the use of CR as a therapeutic strategy against chronic 
diseases. 
The feeding regimen was likely to have confounded the above results, given that the AL 
mice had 24 hour free access to food, which they ate gradually over the dark phase, and 
that the CR mice were fed a once daily diet ration at around 9:00am which they ate over 
approximately 2 hours. A potential improvement to this feeding regimen that would 
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more faithfully recapitulate normal feeding behaviour in CR mice would be to administer 
small doses of food overnight, allowing them to eat gradually during the dark phase in a 
similar fashion to the AL group. Whist manual administration of food in this manner 
would not be possible, a mechanical feeding device could solve the problem. Such a 
device is disclosed by a research group from The University of Texas Southwestern 
Medical Centre, this device allows single pellets of diet at a defined weight to be 
administered with removal time recorded and a programmed delay before a new pellet 
is dispensed277. This allows for very precise feeding regimens to be implemented and 
additional feeding data to be collected. 
The lack of differences between KO and WT mice was surprising. This is because during 
times of calorie scarcity it is beneficial to the organism to conserve as much energy as 
possible to increase the chances of survival. Therefore, during mammalian evolution 
(and potentially even earlier) the increased adiponectin concentrations during CR must 
have imparted a survival benefit considering the energy investment in synthesising the 
additional protein. Given the mild phenotype of adiponectin knockout in vivo it seems 
likely that adiponectin is not playing a major role during times of calorie sufficiency, 
excess or mild deficiency. However, the effects of adiponectin on glucose and lipid 
homeostasis in vitro are well known showing that adiponectin does exert a strong 
signalling effect. Therefore, it may be that adiponectin acts most strongly during times of 
extreme calorie deficiency, at times of near starvation. This would explain why we do not 
see a large phenotype caused by adiponectin knockout during moderate CR. 
Unfortunately, this hypothesis is not easily testable given the ethical issues with severe 
CR. One potential way to test this would be to use drosophila which are not protected by 
law and have some conserved adiponectin signalling280. 
Future directions for further elucidating the role of adiponectin in mediating some of the 
benefits of CR will primarily focus on the glucose tolerance result and how and if this 
relates to the increased plasma NEFA concentrations. In order to determine the 
contribution of insulin to the improved glucose tolerance in adiponectin KO mice when 
exposed to CR, clamp studies could be used. A hyperglycaemic clamp in which glucose is 
perfused into the blood to reach a steady state concentration can be used to measure the 
insulin secretion and glucose uptake capacity of the mice. Based on our findings, we 
would expect the adiponectin KO mice to have elevated insulin secretion and/or 
increased glucose uptake during CR, given my finding that the KO mice have improved 
glucose tolerance during CR.  A hyperinsulinemic-euglycemic clamp could also be used, 
in which insulin is perfused at a concentration above basal levels whilst glucose is 
infused to maintain blood glucose concentration at basal level. The rate of glucose 
infusion can give a measure of the insulin-induced glucose uptake in the body, and 
therefore the sensitivity to insulin; under these clamp conditions, the glucose infusion 
rate is generally considered a mark of how insulin resistant the mice are. The literature 
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reports adiponectin to play an insulin-sensitising role so we may expect the KOs to be 
less insulin sensitive, at least on an AL diet; however, no previous studies have applied 
such in-depth metabolic phenotyping to adiponectin KO mice during CR. Based on the 
present findings, I would expect glucose infusion rate to increase in the CR-fed KO mice, 
relative to WT counterparts, as a result of improved insulin sensitivity in the KO mice. 
 
To further examine the impact and source of the increased NEFAs  in the blood of the CR 
mice, and the augmentation of this effect in the adiponectin KO mice, mass spectrometry 
could be used to determine which lipid species are specifically increased or if the effect is 
generic across all species. Long-term aims could evaluate the effect of tissue specific 
adiponectin KO receptors during CR to further elucidate the role adiponectin plays 
during this dietary intervention. A liver specific KO for both adiponectin receptors could 
tell us if this increase in plasma lipid is derived from the liver, additionally an adipose 
tissue KO could answer the same question for this organ.  
 
A fundamental issue with the indirect calorimetry data is the low number of mice per 
group: due to time constraints, fewer mice than would be ideal had been processed 
through the system and so it was hard to draw strong conclusions from the data. In the 
future, more cohorts will be analysed to further elucidate any genotypic differences here. 
Our results show an RER greater than one, which is fairly uncommon but can be 
explained by a variety of reasons. One reason could be metabolism of a highly oxygen-
rich energy source, such as malic or tartaric acid281; however, given that the diet 
consumed by the mice is highly controlled and the formulation known, this does not 
seem likely. Additionally, these acids are generally only present in trace amounts in food 
and are toxic in large quantities282 so could not contribute to the overall RER of the 
animals; hence, we can rule this out as a contributing factor. An alternative reason is that 
the CR mice are converting the ingested carbohydrates into fats, i.e. de novo fatty acid 
biosynthesis. This process requires oxygen and so more oxygen must be used from the 
air, resulting in a RER greater than one283.  
The values for energy expenditure and O2 and CO2 flow rates are expressed relative to 
lean mass. This is to mitigate the effects caused by varying body size of the mice, 
particularly due to the effects of CR. Whilst the calculation could have been performed 
using body mass, adipose tissue has a far lower metabolic rate than lean tissues, 
therefore lean mass is a more accurate scaling factor for the above mentioned 
parameters. One problem with this is that whilst adipose tissue has been shown to be 
fairly metabolically inert in vitro this may not be representative of adipose tissue in 
vivo284. Additionally, using lean mass also make the assumption that the adipose tissue is 
completely metabolically inert which is obviously not the case. Despite this, expressing 
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the values relative to lean mass remains a well-used measurement and can still provide 
useful conclusions. 
Given that the main differences in oxygen and carbon dioxide utilisation rates were 
during the night in the CR mice, it was surprising that the differences in RER were 
observed during the day, with no changes during the night compared to the AL mice. 
This means the change in RER is likely caused by a more subtle change in ratio between 
oxygen and carbon dioxide and that the nocturnal decreases in both are proportional, 
bringing the CR mice onto the same level as the AL mice. A topic touched on in previous 
discussion chapters is the feeding regimen for the CR mice, with the mice receiving all 
their food in one dose in the morning. This causes variation compared to the AL mice, 
which eat their food gradually across the night. This is the likely cause of the large 
increase in RER in the day, immediately after the CR mice have been fed and are 
digesting and metabolising their diet. 
The lack of genotypic differences observed in the metabolic cages experiment indicates 
that there are no organism-wide differences in lipid metabolism in opposition to our 
hypothesis. However, speculatively, it seems that there is a trend in males for the CR to 
decrease nocturnal RER in the WT mice, but not in the KO mice (Figure 6.14D). If so, this 
would support the possibility that adiponectin is required for CR-induced increases in 
lipid oxidation. As mentioned above, the low numbers per group mean that firm 
conclusions cannot yet be drawn. What is clear, from the results herein, is that lack of 
adiponectin does influence at least some of the metabolic effects of CR, but in a manner 
that goes directly against our original hypothesis. Therefore, these studies highlight 
unexpected roles of adiponectin in conditions of CR, which might relate to the 







One of the fundamental aims of this thesis was to further test the contribution of BMAT 
to hyperadiponectinaemia, both in CR and in other contexts. The other fundamental aim 
was to discover to what extent adiponectin contributes to the metabolic adaptions 
induced by CR, given the large overlap in the effects of CR and hyperadiponectinaemia. 
7.1. BMAT as a source of adiponectin 
With regard to examining BMAT as a secretory source of adiponectin, I was only able to 
draw limited conclusions from the TZD study given the lack of resistance to TZD-induced 
BMAT expansion in the Ocn-Wnt10b mice. I still observed TZD-induced increases in 
WAT adiponectin production, which indicates that adiponectin is secreted from both 
WAT and BMAT in response to TZD, as previously shown in CR121. Further tests of this 
hypothesis can be drawn from the CR time-course experiment. I see that adiponectin 
increases occur moderately rapidly, with maximal increases observed around 4 weeks of 
CR. This does not correspond to a mutual rise in tibial BMAT volume, which may indicate 
that the BMAT is not a major contributor to circulating adiponectin. This, however, is 
based on the assumption that BMAT volume increase is required for it to be able to 
increase adiponectin. It may be that increased transcription and/or translation of 
adiponectin is able to occur from a constant volume of BMAT. Importantly, I saw some 
increases in tibial Adipoq transcript expression, particularly around 4 weeks of CR, 
indicating a potential contribution from BMAT.  
There is some evidence that BMAT is acting as a contributory source of adiponectin 
during CR. We observed that in female mice, adiponectin is increased by CR after 2 
weeks whereas in males it is increased after 3 weeks. Similarly, femoral BMAT in female 
mice was increased after 2 weeks but not in males. Additionally, female mice tended to 
have increased tibial BMAT after 2 weeks whereas males did not. Based on this there 
appears to be an association between the timing of increased BMAT and increased 
circulating adiponectin. 
To further test this hypothesis, femoral BMAT volume could be quantified in the 4-week 
group of mice to examine if this bone is a more important contributor to overall CR-
induced hyperadiponectinaemia. Additionally, the transcript and/or protein expression 
of Adipoq/adiponectin in WAT could be assessed. If a large increase in expression is 
observed around 4 weeks into CR, it could be concluded that the WAT may be providing 
a greater contribution to hyperadiponectinaemia. However, previous studies have 
shown that CR generally does not increase adiponectin expression or secretion in 
WAT110, supporting the conclusion that BMAT makes a greater contribution to 
hyperadiponectinaemia in this context. Another limitation is that transcript expression 
of adipoq and other adipose markers was done for whole bones, but not for isolated 
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bone marrow or BMAds. In part this is because, when I began these studies, methods for 
isolation of mouse BMAds had not yet been optimised, and such methods only started to 
be published after my whole-bone transcript analyses had been completed285. Thus, 
future studies could better resolve the effects of CR on BM adiposity, and on adiponectin 
production from BMAT, by specifically measuring transcript expression in isolated BM 
and BMAds. Ideally, both the CR and TZD experiments could be performed in genetically 
altered mice that completely lack BMAT, to further test if they would have blunted 
hyperadiponectinaemia in response to these stimuli. Unfortunately, despite efforts from 
our lab and others, a transgenic mouse model that specifically lacks BMAT has yet to be 
established. 
7.2. Adiponectin as a mediator of the effects of CR 
The second hypothesis that adiponectin contributes to CR-induced metabolic adaptions 
was tested both via the CR timecourse studies and through CR studies in the adiponectin 
KO mice. I aimed to evaluate the coincidence of hyperadiponectinaemia and the 
metabolic adaptions to CR. If we saw the adaptions occur at the same time or after the 
rise in adiponectin, this would give evidence that adiponectin may be driving some of 
these benefits. However, if the benefits preceded hyperadiponectinaemia it would 
suggest that adiponectin is not playing a significant role. We saw very rapid 
improvements in glucose tolerance following CR, prior to any significant increases in 
adiponectin in males or females. This indicates that hyperadiponectinaemia is not 
required for the improvements in glucose tolerance induced by CR. This is consistent 
with data from the adiponectin KO mice. Looking at AL mice only, we see an effect 
consistent with previous studies, whereby adiponectin KO males show a higher blood 
glucose concentration following glucose administration. This could be caused by an 
impairment in peripheral glucose uptake and/or a reduced ability for insulin to supress 
hepatic glucose production, with the latter being more likely given previous literature268. 
Yet, when these mice are calorie restricted, we see a lower glucose peak following 
glucose administration in the adiponectin KO mice and greater effect of CR in decreasing 
the AUC. This is indicative of more rapid uptake of glucose peripherally and/or a more 
rapid or effective suppression of hepatic gluconeogenesis. From these data we can see 
that glucose homeostasis improvements in response to CR are not dependent on 
adiponectin. To the contrary, the results of these studies suggest that 
hyperadiponectinaemia impairs CR-induced improvements in glucose tolerance, such 
that this CR effect is enhanced in the absence of adiponectin. Insulin tolerance tests 
would be one way to determine if these GTT differences reflect corresponding 
differences in insulin responsiveness. As previously mentioned, a hyperinsulinaemic-
euglycaemic clamp study would give a further, more precise determination of the nature 
of these changes.  
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An interesting future direction for this work would be to characterise the BMAT volumes 
and skeletal microarchitecture of adiponectin KO mice. It may be that BMAT expansion is 
halted once adiponectin concentrations reach a certain maximal amount. If true, this 
would manifest as larger increases in BMAT volume in calorie-restricted adiponectin KO 
mice compared to wild-type controls. On the other hand, increases in adiponectin could 
help to drive the expansion of BMAT and so, without adiponectin, BMAT may not 
increase in response to CR. Some research does exist on the effects of adiponectin on 
BMAT. It has been demonstrated in vivo that adiponectin is able to block adipocyte 
formation286 and this may represent a paracrine mechanism of limiting excessive BMAT 
expansion. Additional bone research in adiponectin knockout mice could also focus on 
the cortical bone loss caused by CR. Given that adiponectin is implicated in improving 
bone mineral density213 it could be the case that CR-induced bone loss is even more 
severe in adiponectin KO mice. 
7.3. Sexual differences in the response to CR 
None of the experiments in this thesis were designed to specifically test the differences 
between males and females. In many cases, males and females in the same cohort were 
analysed on different days given the scale of mice involved. Therefore, drawing 
conclusions on the differences between males and females should be done cautiously. 
The reason for this was that our focal hypothesis related to the response to CR and what 
differences existed between either the duration of CR or the difference between WT and 
adiponectin KO mice. Therefore, when designing the methodology for the experiments, 
the cohorts were designed such that there were equal numbers of AL and CR, and WT 
and KO mice to allow accurate comparisons to be made. If sex of the mice was also 
included in this matching, it would have reduced the number of mice used in each cohort. 
This would result in an increase in the total number of mice used and greater numbers of 
mice unused given they were in excess of the strict matching criteria. Work succeeding 
this thesis will focus on designing and implementing CR experiments to directly compare 
the differences between male and female mice in greater detail. 
Regardless the above considerations, there appears to be many differences in the 
response to CR between males and females. Fundamentally, female mice appear to lose 
less weight in response to CR than males. This is a well-known phenomenon in 
humans65. We also see large sexual dimorphisms in body composition with males 
showing large reductions in fat mass with no differences in females. A further difference 
between males and females appeared to be the response to glucose tolerance tests with 
greater improvements in males compared to females. These differences need further 
research and could have implications in the far future regarding the use of adiponectin 
agonists or antagonists. Whilst much research has been performed on adiponectin 
agonists287 little has been performed on adiponectin antagonists. Based on the glucose 
tolerance results in the adiponectin knockout mice it could be possible that adiponectin 
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antagonism could improve glucose tolerance although more research is required to 
establish the mechanism behind this effect. 
7.4. Concluding Remarks 
In conclusion, we cannot say that any of our initial hypotheses can be confidently 
confirmed. However, these studies have provided valuable insights into the temporal 
dynamics of CR that were previously unknown. In addition to the data here, large 
amounts of tissue are still frozen and fixed for future analysis allowing further 
hypotheses to be tested from these experiments. We also gained valuable information 
regarding the response to CR in both the presence and absence of circulating 
adiponectin. We revealed no situations in which adiponectin is required for a beneficial 
response to CR, yet, given the large resource commitment to increase this hormone in a 
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